The role of humoral mediators in immunological reactions to streptokinase by Afshari, Afshin
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The role of humoral mediators in immunological reactions to streptokinase
Afshin Afghan
(MD)
For the degree of PhD
(August 1995)
Department of Immunology 
Glasgow University
ProQuest Number: 10391154
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391154
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOWONR?T^SITY I
Contents
Acknowledgement 1
Declaration 2
Publication 3
Abbreviations 4
List of tables 6
List of figures 8
Summary 15
Chapter 1 
Introduction
1“ 1 Streptokinase isolation and structure 18
1-2 Coagulation system 20
1-3 Streptokinase and coagulation system 22
1-4 Clinical indications for streptokinase administration 23
1-5 Adverse reactions to streptokinase administration 24
1-6 Anti-streptokinase antibodies 27
1-7 Complement system 29
1-8 Immune complexes and complement system 36
1-9 Fc receptors and immune complexes 38
1-10 Streptokinase and complement system 41
Chapter 2
Materials and general methods
Introduction 46
2-1 Materials 46
2-2 Buffers 50
2-3 Measurement of pH 52
2-4 Measurement of protein concentration 53
2-5 Preparation of agarose 53
2-6 Preparation of plates for methods employing agarose 53
2-7 Double immunodiffusion 53
2-8 Single radial immunodiffusion 54
2-9 Immunoelectrophoresis (lEP) 54
2-10 Fixing and staining of agarose gels 56
2-11 SDS PAGE electrophoresis 56
2-12 Western blotting 60
2-13 Immunisation of rabbit with streptokinase 60
2-14 Separation of serum from rabbit blood 61
2-15 Separation of normal human serum 61
2-16 Preparation of red blood cells 61
2-17 Standardisation of red blood cells 63
2-18 Quantitative precipitin test 63
2-19 Preparation of IgG by caprylic acid 65
2-20 Affinity chromatographic purification of IgM ' 65
2-21 Affinity chromatographic purification of IgA 66
2-22 Biotin N-hydroxy-succinimide labelling of IgG 67
2-23 Pepsin digestion of IgG 67
Chapter 3
Measurement of isotype specific response to streptokinase in a normal 
population and patients with acute myocardial infarction.
Introduction 69
Materials and methods
3-1 Quantitation of neutralising anti-streptokinase antibodies. 70
3-2 Determination of molecular weight and purity of streptokinase. 71
3-3 Crude screening ELISA procedure for collecting positive samples with anti- 
streptokinase antibody activity. 72
3-4 Purification of human anti-streptokinase antibodies. 74
3-5 Development of ELISA's for measuring isotype specific anti-streptokinase 
antibodies. 76
3-6 Intra-assay and inter-assay variations of techniques used for measuring anti­
streptokinase antibodies. 78
3-7 Normal control group. 78
3-8 Acute myocardial infarction patients treated with thrombolytic agents. 78
3-9 Measuring serum albumin levels by single radial immunodiffusion. 79
3-10 In vitro effect of recombinant tissue plasminogen activator on quantitation of 
neutralising anti-streptokinase antibodies. 80
3-11 Statistical analysis. 80
Results 80
Discussion 111
Chapter 4
The levels of anti-streptokinase antibodies and anti-mycobacterial heat shock 
protein in patients with auto-immune diseases.
Introduction 118
Materials and methods
4-1 Rheumatoid arthritis patients. 120
4-2 Affinity chromatography elution of rheumatoid factor. 120
4-3 Systemic lupus erythematosus patients. 121
4-4 Thyroiditis patients. 122
4-5 Henoch Schonlein Purpura patients. 122
4-6 Measuring IgG anti-heat shock protein (HSP65) in patient groups. 122
4-7 Statistical analysis. 123
Results 124
Discussion 140
Chapter 5
Streptokinase and Complement System Recruitment
Introduction 145
Materials and methods 148
5-1 Ion exchange chromatography for purification of human anti-streptokinase 
IgG. 148
5-2 Preparation of immune complexes. 150
5-3 Measurement of complement activation products (Cls:Cl-INH, C3b-P and 
C5b-9). 150
5-4 Measurement of serum C3d levels. 154
5-5 Validity of ELISA used for measuring serum C3d levels. 155
5-6 Detection of erythrocytes bound complement components by a modified 
ELISA technique. 157
5-7 The effect of thrombolytic therapy on complement activation in patients with 
AMI. 158
5-8 Effects of dose and kinetics of streptokinase on the complement activation.
158
5-9 The effect of streptokinase and thyroglobulin immune complexes on 
complement activation. 160
5-10 The effect of erythrocytes on complement activation. 162
5-11 The effect of plasmin on the levels of complement activation products. 164
5-12 Statistical analysis. 165
Results 166
Discussion 205
Chapter 6
Immune complexes and erythrocytes interactions.
Introduction 212
Materials and methods
6-1 Preparation of erythrocytes. 213
6-2 Preparation of NHS. 213
6-3 Preparation of immune complexes. 213
6-4 Flow cytometry assays (FACscan, fluorescence-activated cell sorting) 214
6-5 Dose response of rabbit streptokinase and thyroglobulin immune complexes
binding to erythrocytes. 216
6-6 Kinetics of rabbit streptokinase immune complexes binding to erythrocytes.
218
6-7 Detecting bound C3c on erythrocytes during complement activation by 
FACscan. 218
6-8 Detecting bound C3d on erythrocytes during complement activation by 
FACscan and modified ELISA. 220
6-9 Specificity of monoclonal anti-CRl for human erythrocytes. 222
6-10 Kinetics of human streptokinase immune complexes binding to erythrocytes 
and the effect of monoclonal anti-CRl on binding and generation of complement 
activation products. 223
6-11 Effects of antigen and antibody excess on human streptokinase immune 
complexes binding to erythrocytes. 226
6-12 In vivo study of streptokinase immune complexes binding to erythrocytes in 
patients with AMI. 228
6-13 Statistical analysis. 229
Results 230
Discussion 264
Chapter 7
I
___________
Non-complement dependent binding of immune complexes to erythrocytes
Introduction 274 7
'i::î
Discussion 302
Chapter 8
Final Discussion 307
References 319
Materials and methods
7-1 Indirect (Passive) haemagglutinin test for rabbit anti-streptokinase IgG. 275
7-2 Preparation of F(ab')2 fragment of IgG. 276
7-3 Binding of rabbit IgG anti-streptokinase and F(ab')2 fragment to human 
erythrocytes. 278
7-4 Inhibition of binding of rabbit IgG anti-streptokinase to human erythrocytes.
280
7-5 The binding of monoclonal anti-FcyR antibodies to human erythrocytes. 281
7-6 Purification of human IgG by Ion exchange chromatography. 282
7-7 Binding of human IgG to erythrocytes. 283
7-8 Specificity of human IgG subclasses for human erythrocytes. 285 'i
7-9 Specificity of mouse IgG subclasses for human erythrocytes. 286 7
7-10 Erythrocytes surface biotinylation and purification of putative erythrocyte 
IgG binding protein. ‘ 287
Results 288 I;
,
i
Î
Acknowledgements
I \Yish to acknowledge Dr. Elizabeth Holme who offered advice, help and  
encouragement and I owe much to her enthusiasm during this project.
My thank is due to Iranian Ministry of Health and Education for financing my study in 
Britain.
I also wish to thank all my colleagues in the department of Immunology, in particular 
Dr. Graham Phimister, for their advice and help in the laboratory.
I would like to thank my family, in particular my wife, for her patience and kindness.
I
?
s
7'"
..I
5I
Declaration
These studies represent original work carried out by the author, and have not been 
submitted in any form to any other university. Where use has been made of material 
provided by others, due acknowledgement has been made.
August 1995 Dr. Afshin Afshari
7:
Publication and presentations
Part of this study has been presented as following:
1) Immune response to streptokinase administration and recruitment of the complement 
system, Afshari A., Bhargava B., Whaley K., Hood S., Hillis S. and Holme E., has 
been submitted for publication to British Heart Journal (August 1995).
' | j
2) Scottish Clinical Immunology Meeting, June 1993, Perth, An examination of 
antibody levels to streptokinase in patients with acute myocardial infarction and 
controls.
3) Immunology Colloquium, November 1994, Glasgow Royal Infirmary, Immune 
response to streptokinase administration and recruitment of complement system.
4) British Society for Immunology, March 1995, University of Birmingham, a) Levels 
of anti-streptokinase and anti-mycobacterial HSP65 (mHSP65) in patients with auto­
immune diseases, b) Effects of erythrocytes on generation C3b-P and C3d, indicators 
of complement activation.
35) Seminar, May 1995, University Department of Immunology, Glasgow, The role of 
humoral mediators in immunological reactions to streptokinase.
;6) Immunology Colloquium, May 1995, Glasgow Western Infirmary, a) Levels of 
anti-streptokinase and anti-mycobacterial HSP65 (mHSP65) in patients with auto­
immune diseases, b) Effects of erythrocytes on generation C3b-P and C3d, indicators 
of complement activation.
II
Abbreviations used in tbe text
Ab antibody
Ag antigen
AMI acute myocardial infarction
ASK neutralising anti-streptokinase antibodies
BSA bovine serum albumin
C Celsius
CD cluster of differentiation
Cl-INH Cl-inhibitor
CR1(CD35) complement receptor for C3b
c v coefficient of variation
ECG electrocardiogram
EDTA ethylenediaminetetraacetic acid
EGTA 1,2-di(2-aminoethoxy)ethane-N,N,N’,N'“tetraacetic acid
ELISA enzyme-linked immunosorbent assay
E erythrocyte
E's erythrocytes
Fc crystal lisabale fragment
FcpR Fc receptor specific for IgG
Fab antigen-binding site
FACS fluorescence-activated cell sorting
HTC fluorescein isothiocyanate
HEPES N-2-hydroxyethylpiperazine-N'-2-ethaneesulfonic
HSP Henoch-Schonlein pupura
HSPs Heat shock proteins
IgA immunoglobulin A
IC immune complex
IgE immunoglobulin E
IgG immunoglobulin G
lEP Immunoelectrophoresis
IgM immunoglobulin M
I.U. international unit
mAb monoclonal antibody
MAC membrane attack complex (complement)
mg milligram
mHSP65 mycobacterial heat shock protein (65kDa)
min minutes
ml millilitre
|xg microgram
pi microlitre
MW molecular weight
NIP 5-iodo-4-hydroxy 3-nitrophenacetyl
nm nanometer
N.S. not significant
OD optical density
PBS phosphate-buffered saline
PE phycoerythrin
RA rheumatoid arthritis
RF rheumatoid factor
RBC red blood cell
RIA radioimmunoassay
RT room temperature
r-tPA recombinant tissue plasminogen activator
SD standard deviation
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SK streptokinase
SEE systemic lupus erythematosus
UV ultraviolet
List of Tables
Table 1-1 Amino acids composition of the streptokinase molecule.
Table 1-2: Affinity of human and mouse IgG subclasses for binding to human FcyR,
Table 3-1: Intra- and inter- assay variations of methods employed for measuring anti­
streptokinase antibodies.
Table 3-2: Mean, median, normal ranges of anti-streptokinase antibodies and percentage of the 
individuals with elevated levels of antibodies in normal controls and patients treated with 
streptokinase or r-tPA.
Table 3-3: Correlation between the levels of anti-streptokinase antibodies prior to 
administration of thrombolytic agents in 20 AMI patients.
Table 3-4: Pre-and post-treatment mean values of anti-streptokinase antibodies in 10 patients 
treated with r-tPA.
Table 3-5: Mean values of serum albumin levels fluctuations in ten patients with AMI treated 
with streptokinase.
Table 3-6: The levels of anti-streptokinase antibodies in AMI patients treated with streptokinase 
that had early reperfusion, late reperfusion and or did not reperfuse.
Table 4-1: The mean, median and normal ranges of rheumatoid factor (RF) in 15 patients with 
rheumatoid arthritis measured by ELISA's and nephelometry (a). The mean levels of anti­
streptokinase antibodies in 20 patients with Systemic Lupus Erythematosus, 15 patients with 
rheumatoid arthritis, 20 patients with thyroiditis and 12 patients with Henoch Schonlein 
Purpura (b).
Table 4-2: Correlation between levels of anti-streptokinase antibodies (IgG, IgA, IgM, IgE) 
and streptokinase neutralising antibodies in 15 patients with rheumatoid arthritis.
Table 4-3: The levels of rheumatoid factor (RF) measured by nephelometry and IgG, IgA and 
IgM anti-streptokinase antibodies in patients with rheumatoid arthritis pre- and post-affinity 
chromatographic elution of RF.
7Table 5-1: ELISA conditions for measuring complement activation products (Cls:Cl-INH, ;3f
C3b-P. C5b-9 and C3d).
Table 5-2: Intra-assay and inter-assay variations of methods employed for measuring 
complement activation products.
Table 5-3: Correlation between the levels of anti-streptokinase antibodies and generated levels 
of C ls:Cl-iN H  in 10 AMI patients treated with streptokinase.
Table 5-4: The significance of generated levels of CIs:Cl-INH and C3b-P by different 
concentrations of streptokinase compared to control at different time points incubation at 37°C 
in 10 normal individuals.
Table 5-5: Correlation between the levels of anti-streptokinase antibodies and generated 
C ls:C l-IN H , C3b-P by different concentrations of streptokinase at different time points 
incubation at 37°C with NHS of the 10 normal individuals.
Table 6-1: Correlation between the levels of erythrocyte (E's) bound immune complexes (ICs),
E's bound C3d and free complement activation products, C ls:Cl-INH,C3b-P, free C3d
■M
generated by preformed human streptokinase ICs at equivalence.
Table 6-2: Correlation between the pre-treatment levels of anti-streptokinase antibodies and the ■Ilevels of complement activation products generated at 5 and 30 minutes after streptokinase 
infusion in 4 patients with AMI,
Table 7-1: The proportion of IgG subclasses in 3 sources of IgG, prepared by ion exchange 7
chromatography, by caprylic acid precipitation and the serum of a patient with myeloma.
Table 7-2: Affinity of human and mouse IgG subclasses for binding to human erythrocytes 
using FITC rabbit F(ab')2 anti-mouse immunoglobulin and FACscan analysis.
?
8List of figures
Figure 1-1: Schematic diagram of coagulation system pathways.
Figure 1-2: Schematic diagram of the classical pathway activation.
Figure 1- 3: Schematic diagram of the alternative pathway activation.
Figure 1-4: Schematic diagram of activation of complement system by streptokinase.
Figure 2-1: Standard curve for measuring human serum albumin by single 
immunodiffusion.
Figure 2-2: Standard curve for Sigma high molecular weights.
Figure 2-3: Quantitation precipitin curve of rabbit IgG anti-thyroglobulin and 
thyroglobulin.
Figure 2-4: Double immunodiffusion performed on rabbit anti-streptokinase serum. 7
Figure 3-1: SDS-PAGE gel of streptokinase at non-reduced and reduced conditions. 2
Figure 3-2: Immunoblot of streptokinase using human anti-streptokinase serum and 
HR? conjugated anti-human IgG to visualise the protein bands.
Figure 3-3: lEP on purified human IgG anti-streptokinase using anti-whole human 
serum, anti-IgA, anti-IgM and anti-IgG sera.
Figure 3-4: lEP on purified human anti-streptokinase IgA using anti-human IgA, anti- 7
human IgG and anti-human IgM sera.
Figure 3-5: Standard curves for measuring IgG anti-streptokinase antibody using 
5p,g/ml or 10p.g/ml streptokinase in PBS (pH 7.0).
Figure 3-6: Standard curves for measuring IgG anti-streptokinase antibody using 
5fxg/ml or lOfxg/ml streptokinase in carbonate bicarbonate buffer (pH 9.6).
Figure 3-7: Standard curves for measuring IgA and IgM anti-streptokinase antibodies 
by ELISA.
Figure 3-8: The levels of isotype specific and neutralising anti-streptokinase antibodies 
in normals and patients with AMI.
'.i
Figure 3-9: In vitro effect of r-tPA on the titre of neutralising anti-streptokinase 
antibody assay.
Figure 3-10: Fluctuations of anti-streptokinase antibodies in 10 AMI patients treated 
with streptokinase.
Figure 3-11: Fluctuations of IgG and IgA anti-streptokinase antibodies in 10 AMI 
patients treated with streptokinase during the first 2 hours treatment with streptokinase. 
Figure 3-12: Fluctuations of IgM and neutralising anti-streptokinase antibodies in 10 
AMI patients treated with streptokinase during the first 2 hours treatment with 
streptokinase.
Figure 3-13: The levels of serum albumin during streptokinase treatment in 10 patients 
with AMI.
Figure 3-14: The effect of pre-existing IgG anti-streptokinase antibodies on reperfusion 
in 10 patients with AMI.
Figure 4-1: The levels of IgG and IgA anti-streptokinase antibodies in patients with 
RA, SLE, thyroiditis and HSP.
Figure 4-2: The levels of IgM and neutralising anti-streptokinase antibodies in patients 
with RA, SLE, thyroiditis and HSP.
Figure 4-3: The levels of IgE anti-streptokinase antibodies in patients with RA, SLE, 
thyroiditis and HSP.
Figure 4-4: The levels of rheumatoid factor (RF) and IgM anti-streptokinase antibodies 
in patients with RA pre- and post affinity chromatographic elution of RF.
Figure 4-5: The levels of IgG and IgA anti-streptokinase antibodies in patients with RA 
pre- and post affinity chromatographic elution of RF.
Figure 4-6: Levels of IgG anti-mHSP65 in RA, SLE, HSP, thyroiditis patients and a 
group of normal individuals.
Figure 4-7: Correlation between the levels of IgG, neutralising anti-streptokinase 
antibodies and IgG anti-HSP65 in patients with Henoch Schonlein purpura.
,v -
Figure 4-8; Correlation between the levels of IgM, IgA anti-streptokinase antibodies 
and IgG anti-HSP65 in patients with Henoch Schonlein purpura.
Figure 5-1: Schematic diagram of the formation of, Cls:Cl-INH, C3b-P and C5b-9, 
studied as indicators of complement pathways activation.
'Figure 5-2: Elution profile of fractions collected by a DE52 column from pooled sera 
with elevated levels of anti-streptokinase antibodies.
Figure 5-3: Quantitative precipitin curves for rabbit and human anti-streptokinase IgG 
anti-streptoki nase.
Figure 5-4: Standard curves for measuring CIs:Cl-INH and C3b-P.
Figure 5-5: Standard cuiwes for measuring C5b-9 and C3d.
Figure 5-6: Effects of changing antibodies condition on measurement of free C3d.
Figure 5-7: The effect of dilution on the levels of free C3d detected by ELISA.
Figure 5-8: Kinetics of C3d and C3 during complement activation.
Figure 5-9: Detecting erythrocyte bound C3, properdin and Factor B by modified 
ELISA.
Figure 5-10: Detecting erythrocyte bound C3d by modified ELISA with increasing anti- 
C3d coating concentration.
Figure 5-11: Fluctuations of C ls:C l-IN H  in 10 patients with AMI treated with 
streptokinase.
Figure 5-12: Fluctuations of Cls:Cl-INH compared to anti-streptokinase antibodies in 
10 AMI patients treated with streptokinase.
Figure 5-13: The levels of complement activation products during streptokinase 
treatment (Patient FM).
Figure 5-14: Study of dose response and kinetics of streptokinase on generation of 
C ls:Cl-IN H  and C3b-P.
Figure 5-15: The levels of Cls:Cl-INH and C3b-P generated by streptokinase at doses 
beyond the therapeutic dose.
10
ÿ
Figure 5-16: Kinetics of complement classical pathway activation by preformed and 
nascent rabbit streptokinase immune complexes at antigen excess, equivalence and 
antibody excess.
Figure 5-17: Kinetics of complement alternative pathway activation by preformed and 
nascent rabbit streptokinase immune complexes at antigen excess, equivalence and 
antibody excess.
Figure 5-18: The effect of preformed human streptokinase immune complexes on the 
classical and alternative pathways activation at 5 minutes incubation at 37°C.
Figure 5-19: Kinetics of preformed and nascent rabbit thyroglobulin immune 
complexes on classical pathway activation at antigen excess, equivalence and antibody 
excess.
Figure 5-20: Kinetics of preformed and nascent rabbit thyroglobulin immune 
complexes on alternative pathway activation at antigen excess, equivalence and 
antibody excess.
Figure 5-21: The effect of EDTA and EGTA on the levels of Cls:Cl-INH and C3b-P 
generated by human streptokinase immune complexes.
Figure 5-22: The effect of EDTA and EGTA on the complement activation products 
generated by streptokinase (Human and rabbit) and rabbit thyroglobulin immune 
complexes.
Figure 5-23: The effect of erythrocytes and anti-CRl on the levels of Cls:Cl-IN H  and 
C3b-P generated by preformed rabbit streptokinase immune complexes at equivalence. 
Figure 5-24: The effect of erythrocytes on the levels of free C3d and the effects of anti- 
CRl on the levels of erythrocyte bound C3d and free C3d generated by preformed 
rabbit streptokinase immune complexes at equivalence.
Figure 5-25: The effect of erythrocytes on the levels of C ls;C l-IN H  and C3b-P 
generated by nascent rabbit thyroglobulin immune complexes at equivalence.
11
Figure 5-26: The effect of increasing amount of plasmin on the levels of CIs:Cl-INH 
and C3b-P generated by nascent rabbit thyroglobulin immune complexes at 
equivalence.
Figure 5-27: The effect of increasing amount of streptokinase on the levels of CIs:Cl- 
INH and C3b-P generated by nascent rabbit thyroglobulin immune complexes at 
eqifivalence.
Figure 6-1: Quantitative precipitin curve for streptokinase immune complexes using 
patient positive serum.
Figure 6-2: Dose response of erythrocyte binding and complement activation by nascent
'Ïthyroglobulin immune complexes at equivalence.
Figure 6-3: Dose response of erythrocyte binding and complement activation by 7
preformed rabbit streptokinase immune complexes at equivalence. ’ j:
Figure 6-4: Dose response of erythrocyte binding and complement activation by rabbit 
IgG anti-streptokinase at doses equal used for immune complexes.
■7'
Figure 6-5: Dose response and kinetics of erythrocyte binding and CIs:Cl-IN H  
generation by preformed rabbit immune complexes at equivalence.
Figure 6-6: Dose response and kinetics of C3b-P generation by preformed rabbit 7
immune complexes at equivalence. ' 7;
Figure 6-7: Kinetics of erythrocyte bound C3c and free CIs:Cl-INH, C3b-P by rabbit 
thyroglobulin and streptokinase immune complexes.
Figure 6-8: Kinetics of erythrocyte bound C3d generated by preformed rabbit
7:'streptokinase immune complexes at equivalence, detected by flow cytometry and 
modified ELISA.
Figure 6-9: Kinetics of C ls:C l-IN H  and C3b-P generated by preformed rabbit
streptokinase at equivalence in presence and absence of erythrocytes.
12
Figure 6-10: The levels of erythrocyte bound C3d generated by preformed rabbit 
streptokinase immune complexes at 10 minutes incubation at 37°C, detected by flow 
cytometry and modified ELISA.
Figure 6-11: The levels of complement activation products generated by preformed 
rabbit streptokinase immune complexes at 10 minutes incubation at 37°C.
Figure 6-12: Histograms of fluorescence intensity channels for human erythrocytes 
incubated with monoclonal mouse anti-hum an CRl IgG and detected by FITC 
conjugated sheep anti-mouse IgG.
Figure 6-13: Kinetics of erythrocyte bound human IgG and IgA incorporated in 
streptokinase immune complexes.
Figure 6-14: Kinetics of erythrocyte bound human IgM incorporated in streptokinase 
immune complexes and erythrocyte bound C3d.
13
:
Figure 6-15: Kinetics of Cls:Cl-INH and C3b-P generated by human streptokinase
. 1;immune complexes in presence of naive E’s or E's treated with anti-CRl.
Figure 6-16: Kinetics of free C3d generated by human streptokinase immune 
complexes in presence of naive E's or E's treated with anti-CRl.
Figure 6-17: The levels of CIs:Cl-INH and C3b-P generated by human streptokinase 
immune complexes at equivalence, 4 times antigen excess, and 4 time antibody excess. 
Figure 6-18: The levels of free C3d and erythrocyte bound C3d generated by human 
streptokinase immune complexes at equivalence, 4 times antigen excess, and 4 time 
antibody excess.
Figure 6-19: The levels of erythrocyte bound C3d and human streptokinase immune 
complexes at equivalence, 4 times antigen excess, and 4 time antibody excess.
Figure 6-20: The levels of IgG and IgA anti-streptokinase antibodies in 4 AMI patients 
treated with streptokinase.
Figure 6-21: The levels of IgM anti-streptokinase antibodies and Cls:Cl-INH in 4 AMI 
patients treated with streptokinase.
!I13
-3
7
Figure 6-22: The levels of C3b-P and free C3d in 4 AMI patients treated with 
streptokinase.
Figure 6-23: Fluctuations of anti-streptokinase IgG and erythrocyte bound  
streptokinase immune complexes during streptokinase treatment in patient TB.
Figure 7-1: Indirect haemagglutinin test for rabbit IgG anti-streptokinase.
Figure 7-2: Elution profile of IgG purified by ion exchange chromatography on DE52 
from pooled NHS.
■■Figure 7-3: Reciprocal titres of indirect haemagglutinin test for rabbit IgG anti­
streptokinase binding to human erythrocytes in different groups.
Figure 7-4: Immunoelectrophoresis of rabbit IgG anti-streptokinase and F(ab')2 
fragment prepared by pepsin digestion.
Figure 7-5: Kinetics of complement activation products by rabbit IgG anti-streptokinase 
and F(ab')2 fragment.
Figure 7-6: Kinetics of rabbit IgG anti-streptokinase and F(ab')2 fragment binding to 
human erythrocytes in presence and absence of NHS.
Figure 7-7: Histograms of fluorescence intensity of FITC anti-rabbit IgG binding to 
human erythrocytes (E'), and inhibition effect of human Fc .then with rabbit IgG.
Figure 7-8: The binding of monoclonal anti-FcyR antibodies, FcyRI (CD64), FcyRII 
(CD32) and FcyRIII (CD16).
Figure 7-9: The binding of human IgG prepared by ion exchange chromatography, 
caprylic acid and from a patient with myeloma.
Figure 7-10: The percentage of human IgG subclasses binding to erythrocytes.
Figure 7-11: The percentage of mouse IgG subclasses binding to human erythrocytes.
Figure 7-12: Elution profile of lysed erythrocytes washed through a IgG-Sepharose 
column and then bound material eluted by Glycine-HCl pH 2.5.
14
Summary
Streptokinase is now a commonly administered thrombolytic agent in AMI patients. 
One of the main disadvantages of its administration is that as a foreign antigen it 
may provoke hypersensitivity reactions due to previous streptococcal infections, 
and pre-existing antibodies may reduce efficacy of treatment.
The aim of this study was to look at role of humoral immunity to streptokinase. To 
this end three areas were studied; 1) Specific anti-streptokinase antibodies .2) Role 
of complement and 3) Role of the immune complex removal.
ELISA's were developed to measure the levels of IgG, IgA, IgM, IgE and 
neutralising anti-streptokinase antibodies in a noimal population. Only a small 
proportion of the normal individuals had elevated levels of anti-streptokinase 
antibodies (IgG 1.68%, IgA 2.7%, IgM 9.9% and neutralising anti-streptokinase 
antibodies 0.4%).
The levels of anti-streptokinase antibodies in 20 patients with AMI (10 patients 
treated with streptokinase and 10 with r-tPA) were compared to the normals. 
Administration of streptokinase in 10 patients studied, resulted in an immediate fall 
in level of anti-streptokinase antibodies and developed a specific response.
The levels of anti-streptokinase antibodies in patients treated with streptokinase and 
reperfused early were within the normal ranges, and levels rose in the late 
reperfusion or non reperfusion groups. Of the 10 patients given streptokinase, one 
patient with elevated levels of IgG and IgA developed serum sickness.
The levels of specific IgM anti-streptokinase antibodies in patients with rheumatoid 
arthritis were significantly elevated. This did not correlate with IgG anti­
mycobacterium heat shock protein 65 (mHSP65). In patients with Henoch 
Schonlein Purpura there was a correlation between IgG anti-mHSP65 levels and 
IgG, IgA and neutralising anti-streptokinase antibodies levels.
The interactions of complement system and immune complexes was studied by 
measurement of complement activation products Cls:Cl-INH, C3b-P and C5b-9
15
using modified techniques introduced by Auda et al 1990. An indirect ELISA for 
measuring serum C3d levels and a modified ELISA for detecting erythrocyte (E) 
with bound C3d were developed to evaluate the relationship of bound C3d and the 
levels of free complement components.
Patients treated with r-tPA did not generate complement activation products. All the 
ten'patients administered streptokinase generated Cls:Cl-INH and only one patient 
had increased levels of C3b-P and C5b-9. The extent of complement activation 
correlated with the pre-treatment levels of anti-streptokinase antibodies.
In vitro effects of the ICs on complement activation showed that the presence of 
erythrocytes did not modulate significantly C3d or Cls:Cl-INH levels generated by 
the ICs, however, they exerted an influence on C3b-P through the actions of CRT 
The kinetics and dose response of streptokinase ICs, C3c and C3d binding to 
erythrocytes (E's) were studied by flow cytometry and its relationship with free 
complement activation was determined by measuring the free complement activation 
products in the accompanying supernatants. This study showed that the binding of 
ICs to E’s depended significantly on the extent of complement activation (p<0.001) 
and the dose of ICs (p<0.001).
The clearance of ICs during streptokinase treatment was studied during a period of 
30 minutes after streptokinase administration in 4 patients with AMI by detecting E 
bound ICs using FACscan analysis. Streptokinase ICs were detectable on E’s in 
one of patients. This patient generated high levels of complement activation 
products which correlated with E’s bound ICs (p<0.001), thus the clearance of 
streptokinase ICs depends on the extent of complement activation and the observed 
adverse reaction in patient CD (With elevated levels of IgA) is due to poor 
complement activation by the formed ICs.
Study of anti-streptokinase ICs and IgG interactions with E’s revealed that they also 
bound to E's in absence of NHS. A haemagglutinin test among normal individuals 
and patient groups revealed that the of binding of rabbit IgG to human erythrocytes 
is not a non-specific adsorption. In addition, F(ab')2 fragment did not bind to the
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E's as determined by FACScan analysis. Using flow cytometry human IgG (Fc 
fragment) inhibited the binding of rabbit IgG to human erythrocytes indicated that 
both rabbit IgG and Fc fragment of human IgG bind to the same sites on 
erythrocytes. Using a set of monoclonal anti-human FcyR antibodies, FcyRI 
(CD64) was detectable on erythrocytes.
Thé pattern of mouse IgG subclasses binding to human E's (IgG3 > IgG2b 
>IgG2a) was consistent with the pattern of CD 16 (isoforms A and B) and CD64 
(isoform A). These findings indicate the presence of FcyR on the erythrocytes, 
which may play an important role in handling of immune complexes.
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Chapter 1 
Introduction
1-1 Streptokinase isolation and structure. In 1933 Tillet and Gamer were the 
first to observe that cultures of haemolytic streptococci could liquefy clotted
18
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human plasma. They separated 28 strains of haemolytic streptococci from patients 
who suffered from septicaemia, erysipelas, scarlet fever, acute tonsillitis,
'cellulitis, otitis media, empyema and 18 strains from animal sources. All human 
strains of haemolytic streptococci and 3 strains of animal haemolytic streptococci 
exhibited the biological activity of liquefying clotted plasma (Tillet & Gamer 
1933). This thrombolytic activity is now known to be due to the action of 
streptokinase.
Streptokinase is released during streptococcal infections and facilitates the
Sidissolution of the clotted tissue in the streptococcal infected area, this in turn Iimproves the bacteria diffusion from the site of origin (Guyton 1986). ;S
Streptokinase was first prepared by alcoholic precipitation from extra-cellular 
products of haemolytic streptococci groups A and C (Garner & Tillet 1934,
Weinstein 1953), and later streptokinase was purified by column chromatography, 
resulting in the determination of amino acid composition and molecular weight of 7
this protein (Dillon & Wannamaker 1964, DeRenzo etal 1966). Group C 
haemolytic streptococci have been used as the preferred source of commercial 
streptokinase production since they produce the most active form of streptokinase 
and it also provide an easier preparation for purification (Christensen 1945).
Streptokinase has a molecular weight of 47-48 kD and consists of 415-440 amino 
acids (Morgan & Henschen 1969, Jackson & Tang 1982) (Table 1-1).
Unusually, in the stmcture of this single chain polypeptide, the amino acids 
cysteine and cystine are absent (DeRenzo et al 1966, Morgan & Henschen 1969,
Brockway & Castellino 1974, Jackson & Tang 1982). There are however, 4
ï;'I
Amino acid Number of amino acids 
residues
aspartic acid 41
aspargine 24
theonine 30
serine 25
glutamic acid 28
glutamine 16
proline 21
glysine 20
alanine 21
valine 23
methionine 4
isoleucine 23
leucine 40
tyrosine 22
phenylalanine 15
histidine 9
lysine 32
arginine 20
tryptophan 1
total residues 415
Table 1-1; Amino acids composition of the streptokinase molecule 
(Jackson & Tang 1982)
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methionine residues hence cyanogen bromide cleavage, results in its breakdown 
into five fragments (Morgan & Henschen 1969, Bruserad et al 1992).
There are the two large regions of internal homology in streptokinase (N-terminal 
residues 1-173 and C-terminal residues 254-415), therefore the predicted 
secondary structure of streptokinase suggests that streptokinase contains two 
domains of similar tertiary structure (Jackson & Tang 1982).
The isoelectric point of the protein is reported to be between 4.7 and 5.2 
(DeRenzo et al 1967, Einarsson et al 1979, Barth 1990) and alkaline treatment 
damages the biological activity of streptokinase by destruction of the amide 
groups of the protein (Dillon & Wannamaker 1964, Hugh et al 1965, Einarsson et 
al 1979).
1-2 Coagulation system. Several elements in blood and tissues contribute to the 
blood coagulation system. These are known as pro-coagulants and anti­
coagulants. Anti-coagulants are normally dominant but damage to the 
endothelium of vessels or tissues initiates coagulation and results in clot 
formation. This can occur by two different pathways (Figure 1-1):
a) The intrinsic pathway is triggered when surfaces i.e. damaged vascular wall or 
foreign surface like a glass tube are exposed to factor XII (is also known as glass 
factor or contact factor). Healthy endothelium usually prevents the interaction 
between factor XII and collagen fibres in the vascular wall but damaged 
endothelium provokes the activation of pro-coagulants (e.g. the release of pro­
coagulant cytokines, see 1-10).
b) The extrinsic pathway is triggered by cell injury and the release of a cell 
surface protein, tissue thromboplastin which in turn activates factor VII. 
Activation of factors XII and VII (from the intrinsic and extrinsic pathways 
respectively) results in activation of factor X (thrombokinase). The activated form 
of factor X, Xa, by interacting with factor V, calcium and platelets, catalyses the
20
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Figure 1-1; Schematic diagram of coagulation system pathways.
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protein, inactivating factors V, VIII and enhancing the activation of plasminogen 
(Ganong 1991),
..
transformation of pro-thrombin to thrombin (Guython 1986, Ganong 1991).
Calcium and phospholipids of aggregated platelets (platelet factor 3) are essential 
for the activation of coagulation pathways.
Thrombin is a serine protease and converts soluble fibrinogen (MW=340000 kD) 
to insoluble monomeric fibrin. Finally, the formation of a clot is completed when 
monomeric fibrin is polymerised and long fibrin threads are formed.
As mentioned before prevention of clot formation is to a large extent dependent 
on healthy vessels by preventing the contact of factor XII with the vascular wall 
and inhibition of intrinsic pathway activation. On the other hand, vascular 
endothelium also secretes a thrombin-binding protein (thrombomodulin) which 
converts thrombin to a protein C activator. Protein C is a natural anti-coagulant
Î
Anti-thrombin IH and heparin are anti-coagulants that work in synergy. Anti­
thrombin m , a protease inactivator, binds to thrombin and inactivates it. Heparin
■li
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itself has little anti-coagulant effect but by combining with anti-thrombin III 
shows a significant thrombolytic activity. Mast cells around the connective tissues 
of capillary walls are the major source of heparin (Guython 1986).
Lysis of clot is initiated by the activation of the plasminogen (previously called 
pro-fibrinolysin) pathway. Plasminogen is a single chain protein with a molecular 
weight of 92000 kDa. This glycoprotein is a zymogen but when a clot is formed 
and a large amount of this inactive enzyme entrapped within the clot, the 
plasminogen activators can then initiate its activation. These activators can be, 
protein C (see above), activated factor XII, tissue plasminogen activator, 
urokinase and finally a foreign protein, streptokinase (1-3).
Plasminogen activators split the arginyl^^^-valine^^ 1 bond of the plasminogen 
molecule resulting in formation of a two-chained plasmin molecule connected by 
a single disulphide bond (Bajaj & Castellino 1977, Fears & Smith 1985, Podlasek 
& McPherson 1989, Edelberg et al 1989). Plasmin is a potent serine protease and
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digests fibrin and pro-coagulants (including fibrinogen, factor V, factor VIII, pro 
thrombin and factor XII) (Haire 1992).
A small amount of plasmin is produced in 24 hours in the body to remove tiny 
clots formed in the peripheral vessels. On the other hand, the production of 
plasmin is controlled by plasminogen inactivators to maintain low levels. oc2 anti- 
plasmin is the major physiological inhibitor of plasminogen system and by 
binding to plasmin inactivates the enzyme (Guython 1986). Histidine-rich 
glycoprotein is also an inhibitor of plasminogen system, this inhibitor binds to 
plasminogen and protects it from the action of plasminogen activators (Mankuvad 
1993).
1-3 Streptokinase and coagulation system. Since the 1930's the thrombolytic 
action of streptokinase has been studied (Tillet & Gamer 1933). Milston in 1941 
reported that human semm contains a factor (lysine-plasminogen) which is 
necessary for the thrombolytic activity of streptokinase. Christensen (1945) 
studied the effects of streptokinase on the lysis of fibrin, casein and gelatine and 
he showed that plasminogen, an inactive enzyme, is activated by streptokinase.
As mentioned streptokinase has a plasminogen-dependent thrombolytic activity. 
Native plasminogen (also known as Glu-plasminogen, with N-terminal glutamic 
acid) is the predominant form of plasminogen in the circulation. Streptokinase 
binds to a small region of the Glu-plasminogen that consists of amino acids 557 to 
565 and this interaction results in formation of a one to one stoichiometric 
complex (Podlasek & McPherson 1989, Bajaj & Castellino 1977). The formed 
equimolar complex has the ability to hydrolyse the native plasminogen and to 
generate plasmin (Takada & Takada 1990). There is a high degree of homology 
between N-terminal region of streptokinase molecule (amino acids 1-253) and the 
serine proteases family (e.g. trypsin, Jackson &Tang 1982). Furthermore, the N- 
terminal region of streptokinase is an efficient binding site for the interaction of 
streptokinase and plasminogen (Reed et al 1993). On the other hand, C-terminal
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residues of the streptokinase (amino acids 384-415) are not essential for the 
thrombolytic action of streptokinase (Jackson et al 1986).
The formation of clot itself enhances the thrombolytic effect of the streptokinase 
by two mechanisms. Firstly, the presence of fibrin is shown to increase the rate of 
the streptokinase-plasminogen complex formation (Fears et al 1985, Takada 
&Takada 1990) and secondly the complex of streptokinase-plasminogen binds to 
fibrin with a greater affinity than plasminogen alone (Cassel et al 1987).
The factors that prevent the thrombolytic effect of streptokinase have not been 
clearly identified. lipoprotein-A has extensive homology with plasminogen but 
lacks the critical bond of Arg^^^-Val^^l that is required for the activity of 
plasminogen activators (see 1-2). Elevated levels of lipoprotein-a which have
of streptokinase by competing with plasminogen for binding to streptokinase 
(Edelberg et al 1989). The presence of anti-streptokinase antibodies in circulation 
as a result of previous streptococcal infections or streptokinase therapy, may also 
prevent the therapeutic effect of the streptokinase (Massel et al 1991) (see 1-6).
1-4 Clinical indications of streptokinase adm inistration. During the 1960's and 
the 1970's fibrinolytic therapy caused a 25% reduction in the mortality of patients 
with obstructed veins and arteries (Randomised trial of intravenous streptokinase
1988), subsequently fibrinolytic therapy became a common treatment for deep 
vein thrombosis (Walker et al 1973, Thayer 1981). Large-scale trials of treatment 
of acute myocardial infarction (AMI) in the 1980's, revealed the efficacy of 
thrombolytic therapy in AMI (Sharma 1982 & Sashara , GSSI-2 1990).
In the 1950's streptokinase became a known fibrinolytic agent for the treatment of 
a variety of diseases to remove clotted blood and purulent exudate. These 
included; empyema, post-operatively after pulmonary resection, constant 
pneumonia, hemothorax, suppurative extra-pulmonary tuberculosis, soft tissue 
infections, amoebic abscess, clearing the dead tissues (e.g. bums), resistant
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been shown to correlate with athrosclerotic lesions, inhibit the thrombolytic effect
Î
infections of bones and joints, decubitus ulcers, pilonidal cysts (Beckman 1958, 
Goodman & Gilman 1975),
The results of angiographic patency studies in patients with AMI treated with 
streptokinase revealed a significant promotion of heart muscle reperfusion (53 % 
Hogg et al 1990, 73% Anderson et al 1991, 77.5% Chouhan et al 1992), and the 
reduction of the mortality rate in these patients is now well known (White et al 
1990, Munkvad 1993).
Different regimes of streptokinase administration for the treatment of AMI 
patients have been tested. The optimum regime is considered to be a large single 
bolus administered intravenously (usually 1200000 units) and this large dose is 
usually given during a period of one hour.
The clinical indications for streptokinase administration are summarised as 
followings: a) Acute myocardial infarction, b) Deep venous thrombosis, c) 
Pulmonary embohsm. d) Occlusion of peripheral arteries, e) Central retinal 
venous or arterial thrombosis, f) Occlusion of shunts and intra-vascular or cavity 
catheters (Sharma & Sahara 1982).
1-5 Adverse reactions to streptokinase adm inistration. Adverse reactions to 
streptokinase have been recorded since the advent of its use in the clinical 
settings. Reports come from both large-scale trials and from individual case 
reports. A diverse range of complications have been reported.
Many reports indicate the incidence of fever following streptokinase 
administration (Toty et al 1981, White et al 1990, Siebert et al 1992). Thayer 
(1981) reported 26.8% of a group of his patients (n=82) developed fever 
following streptokinase administration. Sharma & Sashara (1982) and Anderson 
et al (1991) reported a similar incident of fever (25%) following streptokinase 
administration (n=100 and 182 respectively). From these reports it can be 
assumed that at least one in every four patients treated with streptokinase may
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experience fever, and the duration of the resulting fever can be several days 
(Beckman 1954).
Nausea and vomiting, headache, muscle pain, flushing and urticaria are mild, rare 
and usually transient complications to streptokinase administration (Thayer 1981, 
Sharma & Sashara 1982, Anderson et al 1991).
Hypotension and bradycardia are observed in over 7% of patients undergoing 
streptokinase therapy (7.2% GISSI-2 1990,10% ISSI-2 1988 and 8 % White e ta l
1991). Anderson et al 1991, reported a higher prevalence of hypotension and 
bradycardia due to streptokinase administration (46%). The discrepancy may be 
related to the unstable status of the AMI patients. The hypotension due to 
streptokinase administration usually occurs simultaneously with the peak of
(Rajadyalan et al 1992, Sharma & Sashara 1982, Hogg et al 1990, Califf et al
1992), results from large trials indicate that life-threatening bleeding is a rare 
complication (0.9% Thayer 1981, 0.3% ISSI-2 1988, 0.57% GISSI-2 1990, 
0.8% The international study group 1990).
The prevalence of stroke and cerebral haemorrhage is reported to be between
streptokinase administration are documented (Kerstein & Adinolfi 1986, Siebert
I..
anaphylatoxin generation (Agostoni et aU 1994a).
. . . .The possibility of bleeding as a complication of streptokinase administration has
always been considered (Stehle & Schettler 1986, Chesterman 1992). Although 
the reports of bleeding following streptokinase administration are abundant
%
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0.1% and 1% (ISSI-2 1988, GISSI-2 1990, The international study group 1990). 
To date, only two reports of respiratory distress syndrome (ARDS) following
et al 1992). These patients developed an immediate pulmonary dysfunction after 
.administration of streptokinase with a low arterial oxygen level and diffuse 
congestive atelectasis. Salien et al (1983) have reported a case of liver function 
impairment following streptokinase administration. The patient showed an 
elevation in temperature and liver enzymes (SGOT, alkaline phosphatase) which
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after discontinuing the administration of streptokinase returned to the normal 
levels.
Administration of streptokinase has been shown to provoke immunological 
reactions. Many descriptions of isolated allergic reactions have been described 
(Baungartner & Davis 1982, McGrath & Pattersonl984, Schweitzer et al 1991, 
Bindels & Peters 1992). Studies of large patient groups have suggested that 
between 3% (Thayer 1981) and 18% (Jarvinen 7 et al 1978) of patients treated 
with streptokinase developed allergic reactions which necessitated discontinuation 
of its use. The reports describe two types of immunological reactions, immediate 
anaphylaxis and serum sickness.
Reports of anaphylaxis to streptokinase are rare and to date less than ten cases 
have been cited (Baugrtner & Davis 1982, Me Grath & Patterson 1984, 
Bednayrzyk et al 1989, Callif et all 1992, Lee et al 1992, Hohage 1993). The 
results of large trials showed no anaphylactic reaction to streptokinase 
administration (Sharma & Sashara 1982, ISSI-2 1982).
The majority of reported allergic reactions to streptokinase administration were 
likened to serum sickness (Davies et al 1990, Siebert et al 1992, Totty et al 1981, 
Taylor et al 1984, Alexopoulos et al 1984, Murray et al 1986, Noel et al 1987, 
Dykewicz 1988, Davidson et al 1988, Schweitzer et al 1991, Siebert et al 1992, 
Bindies & Peters 1992, Lee et al 1992). These patients usually develop fever, 
arthralgia, maculopapular rash and renal function impairment (Alexopoulos et al 
1984, Murray et al 1986, Schweitzer et al 1991, Bindles & Peters 1992). The 
nature of skin lesions has been investigated in many of the cases and reported to 
be like those observed in Henoch-Schonlein purpura (Siebert et al 1992, Zilliox et 
al 1988). The skin lesions exhibit an acute vasculitis and infiltration of 
neutrophils, mononuclear cells, and necrosis (Taylor et al 1984, Noel et al 1987, 
Ong et al 1988, Davidson et al 1988, Bindles & Peters 1992, Yvorra 1993).
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A renal biopsy report from a patient who developed renal function impairment 
following streptokinase administration showed proliferative glomerulo-nephritis 
with polymorphonuclear infiltration (Murray et al 1986).
As described the current literature indicates that inflammatory reactions to 
immune complexes formed between streptokinase and pre-existing antibodies is 
more prevalent than anaphylaxis, following administration of streptokinase.
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1-6 Anti-streptokinase antibodies. Tillet & Gamer (1933) were the first to 
observe that plasma of patients who suffered from haemolytic streptococci 
infections when added to streptococcal cultures inhibited the lytic effect of these 
cultures. Since then there has been much interest in immune mediated reactions to 
streptokinase.
Streptokinase as described is a foreign protein released during haemolytic 
streptococci infections. Streptococcal infections has been shown to increase the 
levels of anti-streptokinase antibodies in patients sera (Anderson et al 1948, Flute 
1973, Buchalter et al 1992). Furthermore, the streptokinases released from
'
haemolytic streptococci exhibit different antigenic properties (Weinstein 1953,
'Dillon &Wannamaker 1965).
Elevated levels of anti-streptokinase antibodies is an important issue, as patients 
with high levels of anti-streptokinase antibodies could be at risk of developing 
hypersensitivity reactions when given streptokinase therapy (Lee & et al 1992). In 
spite of this fact, the role of anti-streptokinase antibodies in patients administered 
streptokinase is unclear (Moran et al 1984, McGrath et al 1985b, Dykewicz et al 
1986, Sanjeev & Morris 1990, Lynch et al 1991, Rosenschein et al 1991).
It has been shown that elevated anti-streptokinase antibodies can prevent the 
thrombolytic effect of streptokinase (Gmer & Tillet 1934, Lew et al 1984, Massel 
et al 1991, Bom et al 1993) but this elevation is not always necessarily 
accompanied by immunological reactions to streptokinase (Lew et al 1984), and
in contrast allergic reaction to streptokinase is not always associated with the 
failure of streptokinase treatment (White et al 1990).
Low levels of anti-streptokinase antibodies are presented in the normal population 
(Spottl & Mosumi 1974a, Moran et al 1984) and studies to date document varying 
levels of these pre-existing antibodies. James (1973) in an early study using a 
streptokinase resistance assay, showed that 15,6% of patients admitted for 
myocardial infarction or ischemic heart disease had a level of reactivity to 
streptokinase greater than the amount needed to neutralise completely 250 000 
units of streptokinase. Moran et al (1984) quote a positively rate of 80% and 
Lynch et al (1991) 75% . However, their is no detaüs of individuals who may be 
at risk when given streptokinase due to presence of high titres of specific 
antibodies.
During thrombolytic therapy the levels of anti-streptokinase antibodies are shown 
to decrease after streptokinase administration. Lynch et al (1991) showed IgG 
anti-streptokinase antibody levels drop at day 1 of administration and increase to 
pre-treatment levels by day 4 with no change in IgM levels. Fears et al (1992b) 
also showed that IgG anti-streptokinase levels dropped after streptokinase 
administration and by the day 4 of administration there was an elevation in 
specific antibodies to streptokinase, corresponding to an immune response to the 
streptokinase. Elevated levels of streptokinase antibodies persist for at least 6 
month in patients treated with streptokinase (Sanjeev & Morris 1990, Lynch et al 
1991, Massel et al 1991, Lee et al 1992, Buchalter et al 1992, Fears et al 1992b, 
Lee et al 1993, Elliot et al 1993).
There are a variety of methods for measuring anti-streptokinase antibodies: 
Kaplan (1944) presented the first quantitative method for measuring anti- 
streptokinase antibodies. This method is a neutralisation test, assessing the abiUty 
of the anti-streptokinase antibodies to prevent the lytic effect of streptokinase. In 
this method a constant amount of streptokinase is incubated with serial dilutions 
of serum and subsequently coagulation proteins (fibrinogen, plasminogen and
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thrombin) are added. The last dilution of serum which prevents lysis of clot is 
considered as the serum titre of anti-streptokinase antibodies (Kaplan 1944, 
Anderson et al 1948, James 1973). This method has been commonly used to 
detect anti-streptokinase antibodies. Streptokinase resistance test has the same 
principles as neutralising anti-streptokinase assay but serial dilutions of 
streptokinase are added to the same sample and the lowest concentration of 
streptokinase that provides complete lysis is expressed as streptokinase resistance 
titre (Moran et al 1984).
In counter electrophoresis streptokinase is placed in the cathodic wells of an 
agarose plate (pH=8.6) and the serum is placed in the anodic wells and 
electrophoresis is performed for about 30 minutes to allow the formation of a 
precipitate line between antigen and antibody (Spottl & Kaiser 1974, Lew et al 
1984).
Radial immunodiffusion is modified from that described by Mancini (1965), 
briefly agarose plates are prepared by mixing agarose and streptokinase 100 u/ml, 
serum to be tested for the presence of anti-streptokinase antibodies is loaded into 
wells and antibodies are allowed to diffuse for 24-36 hours (Spottl & Kaiser 
1974).
Radio immunoassays have been used for measuring IgG and IgE anti- 
streptokinase antibodies using streptokinase radio-labelled with I25j (Moran et al 
1984, McGrath & Patterson 1984, Hoffmann et al 1988, Fear et al 1992a) and 
finally, enzyme linked immunoassay (ELISA) have been used. Indirect ELISA’s 
have been employed by many investigators to measure different anti-streptokinase 
isotypes (McGrath & Patterson 1984, Dykewicz et al 1986, Rosenschein et al 
1991, Buchalter et al 1992, Fears et al 1992b, Lee et al 1993, Elliot et al 1993 , 
Lynch et al 1994).
1-7 Complement system. The biological activity of the complement system in 
humoral immunity is now well established. These activities encompass promoting
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phagocytosis, chemotaxis of neutrophils to sites of complement activation, 
anaphylatoxin generation, processing of immune complexes and regulation of 
antibody production. Some of these activities will be discussed in detail later.
The complement system consists of at least 30 serum and membrane 
glycoproteins which contribute about 10 % of the total serum proteins. Most of 
the serum proteins of this system are produced in the liver. The generation of 
biological activities of this system is achieved by a complex cascade reaction. The 
system can be divided into two early pathways (Classical and alternative 
pathways) and a late pathway (membrane attack complex MAC or terminal 
pathway).
Complement components of the classical and terminal patliways are designated 
with C (i.e. C l, C2 etc.). Components of alternative pathway are referred to by 
their individual names (i.e. Factor B, Factor P and Factor D). These are often 
abbreviated to letters (i.e. B, P, and D).
Cleaved fragments of complement components are showed by suffixed lower case 
letter (i.e. C3a, C4b). Activated Cl and its subcomponents have a bar over their 
name. Complement receptors are designated as CRl to CR4 or as abbreviations of 
their trivial names.
The Classical pathway consists of C l, C4 and C2 (Figure 1-2). The first 
component, C l is a macromolecule consisting of three proteins; one C lq  
molecule, two C lr and two C ls molecules. The complex of C lq :C lr:C ls is 
calcium dependent (Loos & Colombo 1993). C lq  molecule is composed of 18 
polypeptide chains (6A, 6B and 6C) each containsing a collagen-like N-terminus 
and a non-collagen C-terminus. The polypeptides (one A, one B and one C) are 
associated at their N-terminal region, the association of the 6 triple chains forms 
the common stem of C lq. The non-collagen region forms the six globular heads 
o f the C lq  molecule.
The globular heads of the C lq  molecule impart specificity to the classical 
pathway by binding to the Fc regions of antibodies. The binding of at least two of
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Figure 1-2: Schematic diagram of the classical pathway activation. Classical pathway activation is 
initiated by binding immune complexes and C l, this interaction activates C ls and activated C ls 
in turn cleaves C4 and C2 to form classical pathway C3 convertase (C4b 2a).
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the globular heads of C lq  to the Fc regions of antibodies (i.e. antibodies bound to 
antigens) is required for the conformational change within the C lq  molecule and 
activation of the pro-enzyme C lr and Cls. Monomeric IgG has a weak affinity for 
C lq  and can not activate C l.
In human the classical pathway is efficiently activated by IgGl, XgG3 and IgM. 
IgG2, IgG4 and IgA are poor activators of the classical pathway (Law & Reed 
1988, Holme & Whaley 1989, Lucisano & Lanchmann 1991).
Activated c “ls has the enzymatic activity to cleave C2 and C4. The cleavage of 
C4 results in the formation of a small fragment C4a and a large fragment C4b. 
C4b does not contain an enzymatic site but through a newly exposed thiolester 
bond can bind to amino or hydroxyl groups on immune complexes or cell 
surfaces, C4b which does not bind to targets becomes inactivated through the 
interaction with H2O (Holme & Whaley 1989).
If C2 binds to C4b in the presence of activated C"is then C2 is split to C2a which 
is enzymaticaly active and C2b, The C4b2a complex is the classical pathway C3 
convertase and cleaves C3 to C3a and C3b. C3 constitutes 1-2% of the total serum 
proteins and contains alpha (118 kD) and beta (75 kD) chains. The alpha chain 
contains the cleavage and binding sites for interaction of Ç3 with membranes and 
receptors. By the cleavage of C3, C3a is released into the fluid phase. C3b has a 
newly exposed thiolester bond (externalised) and Hke C4b, this allows the binding 
of the molecule to the cell surface or immune complexes, otherwise it becomes 
inactivated through the interaction with H2O. The labile thiolester bond is located 
in the C3d region on the alpha chain of C3.
The alternative pathway consist of Factors B, P, D and C3b (Figure 1-3). 
Activation of this pathway depends upon the structure of cell surfaces (i.e. micro­
organisms) rather than antibodies. The pathway therefore has no immune 
specificity in its action. C3b is generated at a low rate in the fluid phase through 
nucleophilic attack and is called C3i or C3(H20). C3b and C3i have a similar 
molecular conformation, when deposited on an activating surface, bind factor B in
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Figure 1-3: Schematic diagram of the alternative pathway activation. Activating surfaces 
protect C3i (C3b) from the regulatory effects of factors I and H, and alternative pathway is 
initiated by theinteraction of C3i and factor B.
34
the presence of magnesium ions. Factor D cleaves bound factor B to 
enzymatically active Bb and releases Ba to the fluid phase (Holme & Whaley 
1989).
The C3bBb complex which is formed in this way is very unstable and stabilised 
by the addition of properdin. This complex C3bBbP is the alternative pathway C3 
convertase. As described the low rate production of C3i is amplified by activating 
surfaces forming a positive feed back cycle. The addition of an extra molecule of 
C3b to either C3 convertases changes their specificity from C3 to C5 convertases 
and allows the mitiation of the terminal pathway. The cleavage of C5 molecule by 
C4b2a3b or C3bBbP3b results in formation C5a and C5b. C5a is released into the 
fluid phase and C5b remains attached to the C5 convertase via C3b. Cleavage of 
C5 is the last enzymatic step in the pathway.
C5b which is weakly attached to C3b in the C5 convertases, binds C6 and forms a 
stable C5b-6 complex. C5b-6 complex remains attached to the convertase until 
the binding of C l and formation of C5b6~7 complex. The C5b6-7 complex is 
released into the fluid phases. If the C5b6-7 complex after release from C5 
convertase is exposed to a membrane then it can bind to the membrane otherwise 
rapid inactivation occurs. The bound C5b6-7 complex to lipid bilayer is extremely 
stable and upon binding of C8, results in formation of small pores in the bilayer. 
Finally binding of 1 to 28 molecules of C9 to the C5b-8 complex enhances the 
lytic effect of the complex on the target cell (Whaley et al 1993).
The complement system has the potential to inflict cellular damage and is 
therefore controlled by groups of inhibitors, these are both serum and cellular in 
origin.
Cl-inhibitor (Cl-INH) is a glycoprotein and binds covalently to activated C lr and 
C ls, and dissociates them fiom the Clq. This binding results in C lr:C l- 
lNH:Cls:Cl-INH complexes and C lq  which remains attached to the 
immunoglobulin (Loos & Colombo 1993). This controls initial activation of the 
classical pathway by preventing the enzymatic action of C lr and Cls.
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Factor I degrades free or bound C3b to iC3b, therefore controls the amount of 
generated C3b, the formation of the alternative C3 convertase (C3bBbP) and C5 
convertases. The further degradation of iC3b to C3c and C3dg is also through the 
function of Factor I and possibly plasmin (Law & Reed 1988).
Factor H binds to C3b and prevents the interaction of C3b and Factor B, 
accelerates the decay of the alternative pathway C3 convertase, the C5 convertase 
and also acts a as cofactor to Factor I. Factor H also shown to bind to C l but the 
biological importance of this interaction is not clear (Holme et al 1992a). 
Membrane cofactor protein (MCP) and CRl (CD35) act as cofactors to Factor I to 
cleave C3b.
C4 binding protein (C4bp) and decay-accelerating factor (DAF, membrane bound) 
compete with C2a for binding to C4b and prevent the formation of the classical 
pathway C3 convertase. C4bp also act as a cofactor for Factor I to degrade C4b to 
C4c and C4d.
As mentioned, in the fluid phase the production of C4b and C3b which are 
important in the formation of C3 and C5 convertases, is controlled by the 
interaction of their thiolester bond with H^O.
The host cells are protected from the potential damage of MAC formation by 
many plasma and membrane proteins. Lipoproteins, anti-thrombin XU and C8 
regulate the formation of MAC. CD59 (protectin) and homologous restriction 
factor (HRF) are expressed on the surface of many cells, and bind to C8 and C9 
preventing membrane insertion. S-protein binds to the C5b6-7 complex to prevent 
the binding of the complex to ceU surface.
The biological activities of the complement system integrate with other aspects of 
the immune system to maintain homeostasis. The binding of C3b to tlie surface of 
a pathogen which initiated the activation of complement system is a major effect 
of complement activation and is called opsonization. Opsonised foreign particles 
can trigger phagocytosis. As described the lytic effect of complement is by the 
formation of MAC and is effective against the gram negative infections.
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Anaphylatoxins C3a, C4a and C5a are released to the fluid phase after the 
cleavage of C5, C4 and C5 respectively and participate in the inflammation 
process. The anaphylatoxins trigger mast cells degranulation, increase vascular 
permeability and result in smooth muscle contraction. C5a is a powerful 
chemotactic factor and also enhances cell adherence, oxygen radical production 
and degranulation of neutrophils and monocytes. Anaphylatoxins are inactivated 
by carboxy peptidase N (Law & Reed 1988). The complement system has also a 
major role in prevention of immune complexes deposition in tissues.
1“8 Imm une complexes and complement system. Interaction of antigen and 
antibody to form immune complexes is an important humoral defence mechanism, 
resulting in neutrahsing and elimination of the foreign substance. Complement 
plays an important role in the processing of these immune complexes.
When the reaction between antigen and antibody takes place, immune complexes 
of various sizes are formed and initial precipitation due to Fc-Fc reaction occurs 
(Shifferli & Taylor 1986). This reaction (immediate aggregation) together with 
F(ab')2 : antigen reaction initiates lattice formation. Large immune complexes are 
less soluble and can aggregate, and therefore tend to deposit in tissues. Immune 
complexes when deposited in tissue outside the reticuloendothelial system can 
provoke inflammatory reactions and damage to the tissues. The structure of 
immune complexes can influence their destination and this is determined by 
several factors. The size of immune complexes depends on the nature and amount 
of antigen, the antibody response, the ratio of antigen and antibody and finally the 
effect of complement on the processing the immune complexes.
The complement system protects the host from immune complex deposition, by 
preventing immune complex precipitation and promoting clearance of immune 
complexes.
Inhibition of immune precipitation (IIP) through binding of C l, C4b and C3b to 
the immune complex is an essential step for the processing the immune
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complexes (ICs). The initial binding of C l, delays the immune aggregation 
during the initial minutes of immune complex formation. Cl reduces the 
immediate interaction of Fc-Fc of the immune complexes. The classical pathway 
activation by immune complexes results in C4b and C3b formation. C3b binds 
covalently to the immune complexes and inhibits their precipitation. C3b 
incorporation is the critical step of IIP. Activation of the alternative and terminal 
pathways are not vital in IIP mechanisms (Naama et al 1985, Holme et al 1992b). 
The isotype of antibody incorporated into the immune complex is important in 
initiating the activation of complement and HP mechanisms (Johnson et al 1987). 
As described immune complexes formed with IgA cannot activate the 
complement system (Lucisano & Lanchmann 1991). IgM rheumatoid factor 
interferes with the IIP since it can interact with the Fc of different IgG (Whaley et 
al 1993).
If the IIP mechanisms fail to process the immune complexes appropriately, 
insoluble immune complexes are formed and precipitated. Precipitated immune 
aggregates can be solubilised by the complement system. Solubilization (SOL) of 
these complexes is by the incorporation of C3b into the preformed lattice, this 
reduces the forces between antigen and antibody rendering the complex more 
soluble. The classical pathway has importance role in accelerating deposition of 
C3b on ICs during the early step of solubilization (Naama et al 1985, Schifferli et 
al 1986c, Holme et al 1992b). Furthermore, it shown that the extent of 
solubilization mechanisms depend on the affinity of antibody incorporated into 
the immune complex (Johnson et al 1987) and even may fail due to covalent 
binding of antigen and antibody through the antigen binding site (Whaley et al
1989).
Immune complexes coated with C3b and its breakdown fragments have the 
capacity to bind to complement receptors. Predominant in the circulation are CRl 
receptors on the erythrocytes. The binding of immune complexes to erythrocytes
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is through C3b-CR1 interactions and influenced by the size, nature of immune 
complexes, and isotype of antibodies.
CRl is a membrane glycoprotein which has 4 allotypes with molecular weights of 
160kD, 190kD, 220kD and 250 kD. The number of receptor sites per erythrocyte 
is 200-1200, and is influenced by genetic and environment factors (Holme et al 
1986, Fyfe et al 1987). The binding of the immune complexes to erythrocytes 
coirelates with number of CRl on the erythrocytes. The predominant ligand for 
CRl is polymeric C3b, however, monomeric C3b or C4b and iC3b can also bind 
to CRl with a lower affinity.
CRl on erythrocytes is distributed in small clusters (approximately 8-20 clusters / 
erythrocyte), the clusters allow a better binding to multivalent opsonised immune 
complexes than other cells which possess CRl.
Incorporation of complement components in the immune complexes prevents the 
immune complexes from deposition in tissues and most of the immune complexes 
bound to the erythrocytes can be removed from circulation and disposed in the 
liver and spleen. The mechanisms involved in the removal of immune complexes 
from the circulation is not fully understood. In vitro studies show that by blocking 
Fc receptor in the reticuloendothelial cells, the immune complexes remain 
attached to the erythrocytes (Halma et al 1992). The presence of CR3 receptor on 
the Kupffer cells with a high affinity for binding to iC3b may also facilitate the 
release of immune complexes fi*om the erythrocytes. Factor I accelerates the 
release immune complexes from erythrocytes by degradation of C3b to C3dg 
which has no affinity for CRl (Yokoyama & Waxman 1994).
1-9 Fc Receptors and immune complexes. The Fc domain of antibody has an 
important role in the immune system either by activating classical pathway of 
complement system or by binding to cell surface receptors and triggering variety 
of cells activation (Reviliard 1981). The CH2 domain near the hinge in IgG is the 
binding site for C lq and Fc receptors, furthermore, the differences between IgG
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subclasses in triggering biological functions is related to difference of this region 
(Brekke & Sandile 1995).
Fc receptors are a family of glycoproteins with specificity for different 
immunoglobulin isotypes, they are expressed on various subsets of white blood 
cells and bind to native immunoglobulins or complexed immunoglobulins 
(imiqune complexes, aggregated antibodies).
Three distinct Fc gamma receptors (FcyR) with extra-cellular immunoglobulin­
like domain, can interact with IgG. The affinity of IgG subclasses for binding to 
these receptors is not the same (Table 1-2).
Fey RI (CD 64) is a high affinity receptor for monomeric IgG and it is expressed 
on monocytes and naive macrophages. FcyRI is effective in killing the IgG- 
opsonised cells, it also regulates the IgG catabolism by endocytosis and 
degradation of the IgG molecule (Ravetch 1994).
FcyRII (CD 32) is a low affinity receptor for IgG and is expressed in two 
isoforms: FcyRIIA is presented on neutrophils, FcyRIIB is presented on B cells. 
The two isoforms of FcyRH have different cytoplasmic domains and this results in 
differences in signal transduction. Binding the cross-linked Fc of immune 
complexes or aggregated IgG to phagocytes bearing FcyRIIA results in 
internalisation but the binding the cross-linked Fc to B cells bearing FcyRIIB 
down regulates the antibodies production (Ravetch 1994).
FcyRIII (CD 16) is also a low affinity receptor for IgG and is expressed on the 
macrophages, polymorphonuclear leucocytes (neutrophils and eosinophils) and 
NK cells and is responsible for mediating ADCC and the clearance of immune 
complexes from circulation.
Although activation of complement is essential for binding of immune complexes 
to the erythrocytes, there is evidence that aggregated IgG and immune complexes 
bind to human erythrocytes in the absence of complement mediated mechanisms 
(Hajos et al 1978, Virella & Sherwood 1983). The mechanism of non-complement 
mediated adherence of ICs to erythrocytes has not been fully investigated. Two
40
i
"'.:î
Receptor Human IgG subclass Mouse IgG subclass
FcyRI (CD64) Isoform A XgG3>IgGl>IgG4>»lgG2 TgG2a=IgG3> »IgGl,IgG2b
FcyRH (CD32) isofoim A IgG3>IgG 1 >IgG2> >IgG4 IgG 2a= IgG 2b»IgG l
FcYRn(CD32) isoform B IgG3>IgGl>IgG4>IgG2 IgG 2a= IgG 2b»IgG l
FcyRH (CD32) isoform C ND ND
FcyRHI (CD 16) isoform B IgG3=IgG 1 > » IgG 2 ,IgG 4 IgG2a=IgG3> >IgG2b,IgGi
Table 1-2: Affinity of human and mouse IgG subclasses for binding to human Fc gamma
receptors (FcyR).
I
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mechanisms have been suggested for this binding; Firstly, the presence of Fc 
receptor on erythrocytes may be responsible for the non-complement binding of 
ICs (Virella & Sherwood 1983) since treating the erythrocytes with Fc fragment 
inhibits this binding (Hajos et al 1978). Secondly, the IgG binds to erythrocytes 
after alterations in their membrane by oxygen radicals or proteolytic enzymes 
(Weiss & Mutaaugh 1992).
1-10 Streptokinase and complement system. Before the 1990's the majority of 
studies on immune mediated reactions to streptokinase were related to anti­
streptokinase antibodies. SpotU (1974)a in an early study showed the complement 
system involvement during the administration of streptokinase. In the 1990's, as 
the administration of streptokinase has become a common clinical procedure, 
these studies have improved to the extent of assessing the complement system 
fluctuations during streptokinase treatment (Davies et al 1990, Hargreaves et al 
1992, Freydottir et al 1993, Lynch et al 1993, Frangi et al 1994, Agostoni 1994). 
Streptokinase activates complement through two mechanisms: a) Immune 
complex mediated complement activation is initiated by interaction of pre­
existing antibodies and administered streptokinase which results in formation of 
immune complexes and classical pathway activation. By studying the extent of 
this activation, the highest levels of complement activation were observed in 
individuals who had elevated levels of anti-streptokinase antibodies (Freydottir et 
al 1993, Lynch e ta l 1993),
b) Activation of complement pathways can occur by plasmin. As described 
streptokinase activates plasminogen to generate plasmin which in turn dissolves 
fibrin (Takada &Takada 1990). On the other hand, plasmin, like trypsin, can 
activate the classical pathway in absence of antibodies (or independent of Clq) 
through the direct activation of C ls (Gewurz et al 1993, Munkvad 1993). It has 
also been shown that alternative pathway is activated by plasmin, since plasmin 
can replace Factor D to degrade Factor B and generate the alternative pathway C3
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convertase (Munkvad 1993, Yamouchi et al 1994). Administration of 
streptokinase in patients with acute myocardial infarction may also result in 
formation of membrane attack complexes (Agostoni et all 1994b).
Complement system itself can have direct effects on the coagulation system. 
Complement activation provokes the release of pro-coagulant cytokines 
(interleukin-1 and tumour necrosis factor) from the leukocytes and influences the 
endothelial dependent coagulation (Munkvad 1993). C l inhibitor like a l  anti- 
plasmin, by binding to plasmin can inhibit the proteolytic activity of plasmin 
(Levi et al 1993, Cugno et al 1993). Activated Factor B is able to convert the 
plasminogen to plasmin (Munkvad 1993) (Figure 1-4). C7 the component of 
terminal pathway, binds to plasmin and accelerates the activation of plasmingen 
by t-PA and also protects the plasmin from the inhibitory effect of a 2 anti- 
plasmin (Reinartz et al 1995).
Streptokinase is a potent thrombolytic agent and is used in a variety of diseases in 
particular patients with acute myocardial infarction (AMI). The administration of 
streptokinase in patients suffering from AMI results in heart muscle reperfusion 
and reduces the mortality rate in these patients. The presence of serum anti­
streptokinase antibodies may reduce the effrcacy of streptokinase and provoke the 
immunological reactions, the mechanisms of which have not fully investigated 
(Lew et al 1984, Gemmil et al 1990, Hoffmann et al 1988, Fears et al 1992a). As 
reviewed from the literature it is difficult to predict the role of these antibodies in 
the clinical out-come of streptokinase administration. However, to ensure that the 
circulating anti-streptokinase antibodies would not prevent the effect of the 
administered streptokinase, a large single dose is given intravenously (usually 
1200000 units) during a period of one hour (Crossland 1980),
The cost of alternative thrombolytic agents (r-tPA) and the efficacy of 
streptokinase have made this foreign protein a commonly used thrombolytic 
agent. However, there are associated problems with the administration of
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Streptokinase
Plasm in generation Im m une complex form ation
A Cl-INH
t
B Cls
Figure 1- 4: Schematic diagram of activation of complement system by streptokinase. The 
activation of complement system by streptokinase is through immune complex formation and 
plasminogen activation.
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.streptokinase, firstly the factors that are responsible for the ftiilure of streptokinase 
treatment are not fully understood, secondly the recognition of individuals who 
are at risk of developing hypersensitivity reactions when given streptokinase is 
difficult. Susceptibility to immunological adverse reactions to administered 
streptokinase is whether high streptokinase antibodies levels and other factors 
such as isotype specific response to streptokinase in association with appropriate 
complement activation and recruitment of other biological effector systems. The 
aim of this study was to look at role of humoral immunity to streptokinase 
administration. To this end three areas were studied; 1) Anti-streptokinase levels,
2) Effects of complement. 3) Role of the immune complex removal.
Ï
Chapter 2
Materials and General Methods
In trod u ction . This chapter details materials and general methods used. 
Subsequent chapters describe where appropriate more specific materials and 
methods.
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2-1 Materials. With the exception of those chemicals listed below chemicals were 
of Analar quality from Merck Ltd., Hunter Boulevard, Magna Park, Lutterworth,
Leics.
Materials obtained from Sigma chemical Co. Ltd., Fancy Road, Poole, were:
Agarose (fraction V)
Ammonium per-sulphate 
a-D (+) Melibiose 
Biotin N-hydroxy-succinimide ester 
Bovine semm albumin (type II)
Bovine thyroglobulin 
Bromophenyl blue 
Caprylic acid (octanoic acid)
Coomassie brilliant blue R 
Horseradish peroxidase (HRP) conjugated goat anti-human IgA 
HRP conjugated goat anti-human IgE 
HRP conjugated goat anti-human IgG 
HRP conjugated goat anti-human IgM
High molecular weight markers for gel electrophoresis (contains: carbonic 
anhydrase, egg albumin, bovine albumin, phosphorylase, ^-galactosidase,
■1molecular weights between 29 and 116 kD)
■'S
I
:
Human serum albumin
Human IgG subclasses (IgGl, IgG2, IgG3 and IgG4)
Isopropanol
Mouse IgG subclasses (IgGl, IgG2a, IgG2b and IgGB)
N'N-dimethyl formamide
N-Hydroxysuccinimidobiotin
N,N,N',N'-Tetramethylenediamine (TEMED)
O-phenylenediamine (OPD)
Pepsin (from procine stomach mucosa)
Plasmin (from human plasma)
Polyoxenthylen sorbitan monolaurate (Tween 20)
Protamine conjugated to Sepharose (4 % beaded agarose)
Sodium azide
Sodium dodecyl (lauryl) sulphate (SDS)
Materials obtained from the Scottish Antibody Production Unit, Law Hospital, 
Carluke, Lanarkshire, were:
Sheep anti-human whole serum
Sheep anti-human IgA
Sheep anti-human IgG
Sheep anti-human IgM
Mouse monoclonal anti-human AFP
Huorescein isothiocyanate (FITC) conjugated sheep anti-human IgG
Donkey anti-rabbit IgG
FITC conjugated donkey anti-rabbit IgG
HRP conjugated donkey anti-rabbit IgG
FITC conjugated sheep anti-mouse IgG
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Materials obtained from Atlantic Antibodies (INCSTAR), P.O. Box 285, 1951, 
North Western Avenue, Stillwater, USA, were:
Goat anti-human C3 (IgG fraction)
Goat anti-human Properdin (IgG fraction)
Goat anti-human Properdin factor B (IgG fraction)
Goat anti-human C l (esterase) inhibitor (IgG fraction)
Goat anti-human C ls (IgG fraction)
Goat anti-human serum albumin (IgG fraction)
FITC conjugated goat anti-human properdin (IgG fraction)
FITC conjugated goat anti-human IgG (Fc fragment specific)
Materials obtained from Dako Ltd., 22 The Arcade, The Octagon, High 
Wycombe, Bucks, were:
Mouse monoclonal anti-human CRl (IgGl, kappa)
Rabbit anti-human complement C3d 
FITC conjugated rabbit anti-human complement C3d 
FITC conjugated F(ab')2 fragment of rabbit anti-mouse immunoglobulin
Materials obtained from Cappel Laboratories, Cochramville PA 19330, USA 
were:
Sheep anti-rabbit IgG (Fab')2 fragment 
Human IgG Fc fragment 
Rabbit IgG Fc fragment
Materials obtained from Behring-Hoechst, Salisbury Road, Hounslow, were:
FITC conjugated rabbit anti-Human C3c 
Streptase (Streptokinase)
Materials obtained from Difco Laboratories Ltd., P.O.Box 14B, Central Avenue, 
East Molesey, Surrey, were:
Freund's complete adjuvant
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Freund's incomplete adjuvant
Materials obtained from Pharmacia LKB Biotechnology, Davy Avenue, Milton 
Keynes, were;
Protein G conjugated to Sepharose-B4 fast flow 
Sepharose-4B-cyanogen bromide activated (CNBr)
Cellophane membranes
Materials obtained from The Binding Site Ltd., Birmingham Research Park, 
Vincent Drive, Birmingham, were:
Sheep anti-rabbit IgG (Fab')2 fragment
Materials obtained from Whatman Ltd, Maidstone, were:
Diethylaminoethyl celloluse (DE52) 
pH indicator paper
Monoclonal anti-human FcyR antibodies and aggregated human IgGl and IgG3 
were kind gifts from Dr.G.Sandilands, Department of Pathology, Western 
Infirmary, Glasgow. The antibodies anti-human FcyR are available from Serotec 
Ltd, 22 Bankside, Station Approach, Kidlington, Oxford,OX5 IJE.
Mouse monoclonal anti-human CD64 (FcyRI) (10.1)
Mouse monoclonal anti-human CD32 (FcyRII) (AT 10)
Mouse monoclonal anti-human CD 16 (FcyRIII) (Leu-11a)
Sources of following materials were:
Actilyse (recombinant tissue plasminogen activator, r-tPA): Boehringer Ingelheim 
Ltd., Bracknell, Berkshire.
Donkey anti-rabbit IgG: Wellcome Reagents Ltd, Beckman, England.
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ASK titration kit (Anti-Streptokinase): Bio-Merieux Ltd., Graften House, 
Graftenway, Basingstoke, Hampshire.
Rabbit anti-bovine thyroglobulin serum: was a kind gift of Dr.E.Holme, 
Department of Immunology, Western Infirmary, Glasgow.
Membrane peroxidase substrate tetramethylene blue (TMB), phosphatase 
substrate (BCIP/NBT): Kirkegaard & Perry Laboratories Inc., 2 Cessna, 
Gaitherburg, Maryland, USA.
Dialysis tubing: Medical International Ltd. 239 Liverpool Road, London.
Ethanol: James Burrrough, 60 Montford Place, London.
Falcon round-bottomed tubes (5ml): Becton Dickson, 2 Bridge Water lane, 
Lincoln Park.
Horse radish peroxidase Avidin-D, Alkaline phosphatase Avidin-D: Vector 
Laboratories Inc., 30 Ingold Road, Burlingame, USA.
Heparin sodium: Pharmacy, Western Infirmary, Glasgow.
Immulon type 4 ELISA plates: Dynatech Laboratories Inc. 14340, Sullyfield 
Circle, Chanlilly, Virginia.
Jacalin conjugated to agarose: Pierce, Rockford, Illinois, P.O.Box 117, USA. 
Methanol: May and Baker Ltd., Liverpool Road, Bator Moss, Eccles, Manchester. 
Nitro-cellulose transfer membrane: Amersham International Pic, Little Chalfont, 
Buckinghamshire.
Round-bottomed microplates: Greiner Labs Ltd., Station Road, Cambridge. 
Recombinant mycobacterial mHSP65 (mycobacterial bovis BCG): Dr.J.D.A.Van 
Embden, National Institute of Public Health and Environment, Biltohoven, 
Netherlands.
2-2 Buffers. De-ionised water was used to make up all buffers and for methods 
employing water.
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Phosphate buffered saline (PBS) 0.15M
8 g sodium chloride (NaCl), 1.2g dipotassium hydrogen orthophosphate 
(K2HPO4), 0.34g potassium dihydrogen orthophosphate (KH2PO4), were 
dissolved in 800 ml of water and made up to a total volume of one litre.
Twenty times strength phosphate buffered saline (PBS X201
160g NaCl, 24.2g K 2HPO4 and 6.8g KH2PO4 were dissolved in 800ml water and
final volume was made up to one litre.
10 % Gelatin
Ten grams of gelatin was dissolved in SOmis of boiling water and the final volume 
was made up to 100ml, after being autoclaved the gelatin was aliquoted and 
stored at 4°C.
ELISA coating buffer fpH 9.601
1.58g sodium carbonate (Na2C0 3 ) and 2.92g sodium hydrogen carbonate 
(NaHCOs) were dissolved in 800ml water and total volume was made up to one 
litre.
ELISA blocking buffer
To 500ml of PBS, 5ml of 10 % gelatin was added to give a final concentration of 
0.01% of gelatin.
ELISA wash buffer
1ml of Tween 20 was added to 2 litres of PBS to give a 0.05% solution.
0.2M citric acid
0.2M citric acid was made by dissolving 42g of citric acid in 800 mis of water and 
total volume was made up to 1 litre with water.
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ELISA enzyme substrate
To 25 ml of 0.2M citric acid, concentrated KOH was added till the pH reached 
4.5-5.0. The total volume was then made up to 50 ml with water, 0.025g 0- 
phenylenediamine (OPD) and 0.025ml hydrogen peroxide (H2O2) were added. 
The substrate was used within the 15 minutes of adding the H2O2.
4N H^SOd was made by adding lOOmL of concentrated sulphuric acid gradually 
and cautiously to 800 mis of water and the total volume was made up to 1 litre
Q.086M isotonic EDTA
197.7ml of 0.3M NaOH (12g of NaOH/lL water) was added to 500 ml of 0.12M 
EDTA (44.67g of EDTA/IL water) to give a final pH of between 7.2 and 7.6.
0.02M isotonic EDTA
23ml 0.086 isotonic EDTA was diluted to a final volume of 100ml. 
Q.lMMg-EGTA
38.04g of EOT A was dissolved in 500ml water and concentrated NaOH was 
added to give a pH of 7.4. The final volume then was made up to one litre with 
water. To 10 ml of O.IM EGTA, 7ml of 0. IM MgC12 (20.33g of Magnesium 
chloride/IL water) was added before use.
2-3 Measurement of p H and conductivity;
pH: pH was measured using a Russell pH meter model 640 or Whatman pH 
indicator papers.
Conductivity: The conductivity of samples were measured at 0°C using a 
conductivity meter model CD M3, Radiometer, Copenhagen.
52
2-4 Measurement of protein concentration:
The absorbency of samples at 280 nm was measured using a Beckman 
spectrophotometer (model DU-64). The buffers in which the samples were 
suspended was used to zero the spectrophotometer,
2-5. Preparation of agarose se l:
5g agarose was added to 400ml hot barbitone buffer (2-9) and the final volume 
was made up to 500ml (1%). 15g polyethylene glycol (PEG, molecular weight 
4000) was then added. When dissolved, the agarose was aliquoted and stored at 
4°C until required.
2-6 Preparation of plates for methods employing agarose:
Gel-bond was used as a mount for agarose. Films were cut approximately to 8.5 X 
8.5 cm and supported on a glass plate on a levelling table before application of 
agarose. Ten ml of agarose (see 2-5) was poured on the hydrophilic surface of the 
gel-bond and allowed to cool for half an hour before the wells or troughs were cut.
2-7 Double immunodiffusion (Ouchterlonv technique, Ouchterlonv 1958);
This technique is employed to identify antiserum specificity to antigen. Holes 
were punched in agarose gel plates (see 2-6) in a pattern consisting of central well 
surrounded by at least 5 equally spaced peripheral wells.
The inner well was filled with antigen and the outer wells were filled with 
doubling dilutions of antiserum. The plates were left a few minutes to allow the 
diffusion of antigen and antibody into the agarose and then they were left 
overnight at room temperature in a humidified chamber to allow the antibody and 
antigen to diffuse towards each other. When diffusion was complete the presence 
or absence of precipitation lines between antigen and antibody was recorded or 
plates were fixed and stained as described in 2-10 (Figure 2-3).
53
2-8 Single radial immunodifFusion (Mancini technique, Mancini 1965):
In this technique antigen is loaded in wells of an agarose gel pre-mixed with 
antibody. Antigen diffuses into the gel and combines with the antibody in the gel 
and at equivalence point an immunoprecipitin ring is formed around the well. This 
technique was used to measure the concentration of serum albumin. To three mis 
of agarose (see 2-5) at 56°C, 0.15ml of rabbit IgG anti-human albumin (47 
mg/ml) was added. After mixing, the agarose was poured into 5cm petri dishes 
and allowed to cool. Ten wells were punched in each plate, which were filled with 
normal human serum (NHS) double diluted from 1/32 to 1/256 to allow the 
construction of a standard curve. Samples were pre-diluted 1/60, before 
application to individual wells of the plate. The plates were left overnight at room 
temperature in a humidified chamber. The diameters of precipitin rings were 
measured and recorded. A standard curve was constructed and from this the 
albumin concentrations in the unknown samples were determined (Figure 2-1).
I
2-9 Immunoelectrophoresis (lEP):
lE P is a com bination of electrophoretic separation, diffusion and 
immunoprécipitation of proteins.
Barbitone buffer (for electrophoresis, pH 8.60): Barbitone buffer was made by 
dissolving 9.21 g barbitone and 51.54g sodium barbitone separately in 500ml 
water then mixed in a final volume of 5 litres with water, 5g Sodium azide was 
added to this solution.
Agar plate:(size 8.5 X 8.5 cm, see 2-6)
Using a template a series of wells were cut in agar plate near to the anode and 
troughs were cut between the wells. The wells were filled with the test antigen on 
a levelling table and allowed to diffuse into the agarose for a few minutes.
Approximately 150 mis barbitone buffer pH 8.6 was poured in each side of the 
electrophoresis apparatus and the plate was put on wicks (pre-soaked in barbitone 
buffer) and subjected to electrophoresis for 2 to 3 hours at 40 mA. The extent of
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Figure 2-1: Standard curve for measuring human serum albumin by single immunodiffusion.
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electrophoresis was monitored by the movement of a bromophenyl blue marker 
(placed in the top well) across the plate. After electrophoresis, the appropriate 
antisera were placed in the troughs on a levelling table. Both antigen and antibody 
were allowed to diffuse at room temperature in humidified chamber overnight. 
The resultant precipitin arcs between antigen and antibody were recorded and the 
gel.was stained (2- 10).
2-10 Fixing and staining of agarose plates:
The agarose attached to gel-bond was soaked in PBS (diluted 1:1 with water) for 
two hours to remove unbound proteins. The plate was then dried at room 
temperature by pressing between layers of Whatman filter paper. When 
completely dried the gel was stained with 0.5 % coomassie brilliant blue in 
ethanol : water : acetic acid (50ml : 45ml : 5ml respectively) until precipitin arcs 
were well coloured. The plate was then destained in water : acetic acid : methanol 
(87ml : 8ml : 5ml respectively) and changed several times until background 
staining was removed. The plate was then air dried at room temperature.
2-11 Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis:
This technique was employed to assess the purity and molecular weight of 
streptokinase used in the ELISA assays.
Buffers: 10% SDS: lOg of SDS was dissolved in 80ml water and the final volume 
was made up to 100 ml water.
0.75M Tris (hydroxyl methyl amino methane): 90.8g of Tris was dissolved in 
800ml water and the final volume was made up to 1 litre by water.
0.75M Tris-HCl pH 6.80: was made by adding concentrated HCI to 0.75M Tris to 
adjust the pH 6.80 .
0.75M Tris-HCl pH 8.80: was made by adding concentrated HCI to 0.75M Tris to 
adjust the pH 8.80 .
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0.86M Glycine: 64.4g of glycine was dissolved in 800ml water and the final 
volume was made up to 1 litre by water.
30 % acrylamide: 30g acrylamide and 0.8g bisacrylamide was dissolved in 80ml 
water and final volume was made up to 100ml. The solution then stored in dark 
container at 4°C.
Tank buffer: The followings were mixed together , 10ml SDS 10%, 33ml Tris 
0.75 M and 220ml glycine. The final volume was then made up to 1 litre with 
water.
Sample buffer was made by mixing 30ml SDS 10% , 8.5ml 0.75M Tris-HCl pH 
6.80, 10ml glycerol and 0.1 g bromophenol blue and final volume was made up to 
100ml with water. For samples using reduced condition 5ml mercaptoethanol 
was added to the sample buffer.
Staining buffer contained 0.1% Coomassie brilliant blue in methanol : acetic acid : 
water (5ml : 1ml : 4ml respectively).
Destaining buffer contained methanol: acetic acid : water (1ml : 1ml : 8ml 
respectively).
The following stock solutions were made up as shown for separating gel and 
stacking gels (10% SDS gel according to the method of Lammeli 1970) using a 
Raven vertical slab gel apparatus:
Stock solution Separating gel Stacking gel
Acrylamide, bisacrylamide 10ml 1.8ml
0.75M Tris (pH 6.8) 6ml
0.75M Tris (pH 8.8) 15ml
SDS 0.30ml 0.18ml
Ammonium per sulphate 30mg 18mg
TEMED 15pL 9^L
Water 4.7ml 13ml
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The separating gel was mixed and poured immediately between two plates 
separated by spacers and overlaid with water saturated isopropanol until 
polymerised. Isopropanol then was removed and the residue was washed away 
with water and the stacking gel poured. A comb forming lanes was inserted and 
the gel allowed to set. Samples were mixed with an equal volume of sample 
buffer (see above). For reducing conditions samples were mixed with an equal 
volume of sample buffer containing mercaptoethanol (see above) and boiled for 
two minutes. The samples were carefully layered in the wells and electrophoresis 
was performed for approximately 3 hours at 40mA, until the tracking dye had 
reached the bottom of the gel. The gel was stained with staining buffer overnight 
at room temperature and destained with destain buffer (see above). The respective 
electrophoretic mobility (RF) for each sample was calculated by measuring the 
distance migrated from the bottom of the well, compared to the distance migrated 
by the tacking dye. The system was calibrated using reduced high molecular 
weight markers to form a standard curve (Figure 2-2).
Drying the gel: The gel was soaked in 5% glycerol for one hour to make it pliable 
and then placed between two layers of cellophane membrane (soaked in water) 
and d ried  w ith  a gel d ry e r at 60° C for 3 hours.
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Figure 2-2: Standard curve for Sigma molecular weights markers.
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2-12 Western blotting:
Buffers:
Transfer buffer: was made of 0.025M tris, 0.192M glycine and 20% methanol 
( 12. i Ig of Tris, 51.61% of glycine and 800 ml of methanol was made up to a final 
volume of 4 litres by water).
Tris-buffered saline pH 7.50 (TBS); was made of 0.02M Tris and 0.5M NaCl 
(2.42g Tris and 29.22g NaCl were dissolved in 800ml of water and the final 
volume was made up to one litre with water).
Blocking buffer: 3g dried semi-skimmed milk was dissolved in 100ml TBS (3% 
Marvel).
Washing buffer; 100pi Tween 20 was added to 100ml TBS (0.1% Tween).
The specificity of antibodies to the proteins was determined by transferring the 
SDS PAGE gel to a nitro-cellulose membrane and performing a second 
electrophoresis. The electrophoresis performed at 400mA in one and half hour 
(Bio-Rad Trans-Blot TM cell). The membrane was then blocked with blocking 
buffer (see above) for one hour with constant agitation and washed with washing 
buffer (see above) 3 times each time for 5 minutes with constant agitation. The 
blot then was then incubated with anti-streptokinase antiserum (1/100 diluted with 
0.15M TBS) for one hour at room temperature and constant agitation. After 
incubation the blot was washed and coated with anti-human IgG or IgM 
conjugated with HRP (diluted 1/1000 with TBS-Tween) for half an hour. The blot 
was then washed and developed with membrane peroxidase substrate 
tetramethylene blue (TMB) and hydrogen peroxide (H2O2), until bands were 
clearly seen and reaction was stopped by washing the blot in water.
2-13 Immunisation of rabbit with streptokinase:
Two New Zealand white rabbits were immunised with streptokinase (emulsified 
in complete Freund's adjuvant) by two intramuscular injections. After two boosts 
of streptokinase Img/lml (emulsified in incomplete Freund's adjuvant) at days 10
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and 17, the rabbits were bled at day 20 to identify the specificity of the raised 
antiserum to streptokinase by employing double immune diffusion technique (2-7, 
Figure 2-3). The rabbits were then exsanguinated and the serum separated as 
described in 2-14.
2-14 Separation of serum from rabbit blood:
Rabbit blood was incubated at 37°C for 30 minutes (to allow clot formation) 
followed by 30 minutes at 4°C (to allow clot retraction). The blood was then spun 
and the serum removed and heat inactivated at 56®C for half an hour to destroy 
complement components. Serum was then aliquoted and stored at -20®C, until 
required.
2-15 Separation of normal human serum (NHS);
Normal human serum was obtained from healthy volunteers. The blood was 
incubated in glass tubes at 37°C for 30 minutes (to allow clot formation) followed 
by 30 minutes incubation at 4°C (to allow clot retraction). Aliquots were stored at 
-70°C and used within ten days.
2-16 Preparation of human erythrocytes (RBC'sl:
Ten millilitres of venous human blood was mixed with preservative free sodium 
heparin (5 units/ml). The blood was spun at 1300 rpm, at 4°C for 7 minutes. The 
buffy coat layer was completely removed and the cells were washed a further 
three times with buffer (1% bovine serum albumin in PBS) and resuspended in 
buffer.
...1
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Figure 2-3: Double immunodiffusion performed on rabbit anti-streptokinase serum. The 
inner well filled with streptokinase and the outer wells filled with double diluted rabbit anti­
streptokinase serum.
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2-17 Standardisation of human erythrocytes (E's\i
Washed erythrocytes were standardised using the following method:
0.1 millilitre of E’s from a known volume was added to 2.9 ml of water and the 
optical density of lysed cells was measured at wavelength of 541nm (OD54O or 
414 nm (OD414).
The volume of RBC suspension then adjusted to the required cell concentration 
by using the following formula:
Volume of E's required = (Initial volume X OD measured) / X 
X was one of the following values:
OD414 of 0.327 = iXlO 8 cells/ml 
OD541 of 0.185 = 5X10 8 cells/ml 
OD541 of M l  = 1X 10 9 ceils/ml
2-18 Quantitative precipitin curve:
Increasing volumes of antigen were added to a series of tubes containing a 
constant amount of antibody. The tubes were then incubated at 37°C for half an 
hour and then at 4°C overnight. The samples then spun at 3000g for 5 minutes, 
the supernatants removed and the precipitate washed twice with ice-cold PBS. 
The precipitate was re-dissolved in O.IM sodium hydroxide. The optical densities 
(OD) of re-dissolved precipitates were read at 280nm and recorded. A graph was 
plotted of OD readings against concentration (Figure 2-4). The maximum optical 
density was considered as the equivalence point of the antigen and antibody 
immune complex (when all the antigen and antibody is complexed in the 
precipitate ).
63
II
0.3
0.2
Optical Density
0.1
0.0
0 50 100 150 200 250
Thyroglobulin (ug)
Figure 2-4: Quantitative precipitin curve of rabbit IgG anti-thyroglobulin and thyroglobulin.
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2-19 Purification of IgG using Caprylic acid
Buffers; 0.1 M acetic acid: was prepared by adding 0.6ml of glacial acetic acid to 
lOOmI water.
Saturated ammonium sulphate (SAS): 75g of ammonium sulphate was dissolved 
in 80ml water and final volume was made up to 100 ml with water, then stored at 
4 °C to allow crystal formation. Only the supernatant was used.
The antiserum was initially treated with caprylic acid to precipitate the proteins of 
serum. Caprylic acid precipitates all proteins with an exception of IgG. By 
employing O.IM acetic acid (see above) the pH of antiserum was reduced to 4.5- 
5.0, Neat caprylic acid then was added to antiserum to give a 5% suspension, 
mixed vigorously and spun for 5 minutes at lOOOOg. An equal volume of SAS was 
added slowly to the supernatant, antiserum and SAS were mixed for 2 hours at 
room temperature then spun and the supernatant discarded. The pellet was 
resuspended in PBS and dialysed extensively against PBS at 4°C. Absorbance of 
the protein at 280 nm was measured and the protein concentration was determined 
using an extinction coefficient of 1.42 = Img/ml for IgG. The purity of the 
prepared antibody was tested by lEP (see 2-9) and the IgG was stored at -20°C, 
until required.
2-20 Affinity chromatographic purification of IgM:
Buffers:
0.08M phosphate buffered saline (0.077M NaCl): 0.2g potassium dihydrogen 
phosphate, 1.15g disodium hydrogen phosphate, 0.2 g potassium chloride and 
8.2g Sodium chloride were dissolved in water and final volume was made up to 2 
litres with water.
0.8M phosphate buffered saline (I.IM  NaCl): 0.2g potassium dihydrogen 
phosphate, 1.15g disodium hydrogen phosphate, 0.2 g potassium chloride and 
120g sodium chloride were dissolved in water and final volume was made up to 2 
litres with water.
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Protamine binds to IgM. Sepharose coupled to protamine was spun at lOOOOg for 
2 minutes, the supernatant discarded and the pellet was washed 3 times with 
0.08M PBS containing 0.077M NaCl (see above). Serum known to contain IgM, 
was pre-diluted with water (1:1) and added to an equal volume of Sepharose and 
stirred at 4^C for 3 hours. The sample was then washed three times with PBS 
containing 0.077M NaCl (pre-diluted 1:1 with water). To elute the bound IgM 
from protamine, PBS containing I.IM  NaCl (see above) was added to the sample 
and stirred at room temperature for one and half hours. The sample was then spun 
and the supernatant was tested for purity by lEP (2-9) and was stored at -20®C, 
until required.
Protamine Sepharose was recycled by washing with 0.08M PBS containing 
0.077M NaCl and then stored at 4®C in 0.08M PBS.
2-21 Affinity chromatographic purification of IgA;
The lectin Jacalin is obtained from the seeds of Jackfruit and when conjugated to 
agarose can be used to purify human IgAl.
Buffers:
0.175M Tris pH 7.50: Concentrated HCl was added to 250ml 0.75M Tris (see 2- 
11) till pH 7.50 was achieved, then the total volume was made up to one litre with 
water.
O.IM Melibiose: made by dissolving 0.34g Melibiose in 10 ml water.
Storage buffer of Jacalin agarose: was made by dissolving 0 .15M sodium chloride 
(4.38g), O.IM calcium chloride (5.55g), 0.02M galactose (1.8g) and O.OIM 
HEPES pH 7.50 (1.19g) in 400ml water and the final volume was made up to 
500ml with water. Sodium azide 0.4g was added to the buffer as a preservative 
(0.08% W/V).
The pH of the serum known to contain IgA was adjusted to 5.50 by the dropwise 
addition of concentrated HCl. Solid ammonium sulphate then was added slowly to 
75% saturation and the sample stirred at room temperature for one hour. The
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sample was then spun, the supernatant discarded and the pellet resuspended in 
PBS. The resuspended pellet was then added to equal volume of Jacalin-sepharose 
pre-washed in 0 .175M Tris pH 7.50 and mixed at room temperature for one hour. 
The sample was then spun and the supernatant discarded. An equal volume of 
O.IM Melibiose was then added to the pellet and stirred at room temperature for 
half an hour. The sample was then spun and the supernatant tested for purity and 
the presence of IgA by lEP (2-9). The supernatant was stored at -20°C, until 
required.
Jacalin-agarose was recycled by washing with 0.175M Tris pH 7.5 and then 
resuspending in storage buffer and kept at 4®C.
2-22 Biotin labelling of IgG:
IgG was dialysed against PBS at 4 overnight and the concentration of dialysed 
sample adjusted to 5 mg/ml. Three mg of biotin N-hydroxy-succinimide ester was 
dissolved in 100 [.iL of dimethylformamide and immediately added to 1ml of IgG 
(5mg/ml). They were allowed to mix at room temperature for 2 hours. The sample 
then dialysed extensively against PBS at 4®C and stored a t.4 until required.
2-23 Pepsin digestion of IgG:
Pepsin digestion of IgG results in a molecule which is the F (ab')2 portion 
containing the intact antigen binding site and has a molecular weight of 100000. 
The amount of pepsin needed for the digestion is 1-2 milligram per 100 mg of 
IgG. Protein G coupled to Sepharose binds to Fc portion of IgG and can be used 
to separate F (ab')2 and Fc fractions from pepsin digested IgG.
Buffers:
Sodium phosphate O.IM (pH 7.0): 3.1 g sodium dihydrogen phosphate 2 hydrate 
was dissolved in one litre water to make O.IM NaH2P04 and 2.84g disodium 
hydrogen phosphate anhydrous was dissolved in one litre to make O.IM Na2HP0 4
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separately. To 50mls of the first buffer, 70 ml of latter buffer was added to give a 
final pH of 7.0.
0.1 M sodium acetate: made by dissolving 8.2g sodium acetate in 800 ml water 
and final volume was made up to 1 litre with water.
O.IM glycine: made by dissolving 7.5g glycine in 800 mi water and final volume 
was jnade up to 1 litre with water, the pH of buffer then adjusted to 2.5-3.0 with 
concentrated HCl.
Samples known to contain IgG were dialysed against 0.1 M sodium acetate for 3 
hours at 4®C. The pH of sample was adjusted with O.IM acetic acid (2-19) to 
4.50. The required amount of pepsin was added to sample and incubated at 37°C 
overnight. The digested sample was then spun and any precipitate discarded and 
the pH was adjusted to 7.40 by addition of solid Tris. The sample was then 
dialysed against PBS for 3 hours at 4°C to inactivate the enzyme. Sepharose 
(coupled to protein G) was pre-washed with 0.02M sodium phosphate buffer (see 
above) and resuspended in buffer to give a ratio of 25% 0.02M sodium phosphate 
buffer and 75% Sepharose. The sample IgG was then added to resuspended 
Sepharose and mixed at room temperature for one and half hour. The sample was 
then spun and the supernatant containing F(ab')2 was kept. The purity of F(ab')2 
was tested by IE? (2-9) and sample was kept at -20^C, until required.
The Sepharose was recycled by washing 3 times in O.IM glycine and resuspended 
in ethanol as a preservative to give a ratio of 20% ethanol and 80% Sepharose.
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Chapter 3
Measurement of isotype specific response to streptokinase in a 
normal population and patients with acute myocardial infarction
Introduction
The presence of anti-streptokinase antibodies in patients sera is a result of previous 
streptococcal infections (Anderson et al 1948, Flute 1973, Buchalter et al 1992). 
However, it is not clear that to what extent these antibodies exist in the population, 
how they influence the efficacy of streptokinase treatment for acute myocardial 
infarction (AMI) or provoke hypersensitivity reactions in patients given 
streptokinase (Moran et al 1984, Dykewicz et al 1986, Sanjeev & Morris 1990, 
Rosenschein et al 1991).
Development of assays to measure serum levels of anti-streptokinase antibodies, 
has been driven by a quest to answer these questions (James 1973, McGrath & 
Patterson 1985, Lynch et al 1991). Studies to date have concentrated on the 
measurement of IgG and neutralising antibodies to streptokinase. The aim of the 
present study was to determine not only the prevalence of IgG and neutralising anti­
streptokinase antibodies but also the levels of the other isotypes of anti­
streptokinase antibodies IgM, IgA, IgE in the normal population. The levels of anti- 
streptokinase antibodies in patients with acute myocardial infarction (AMI) were 
then compared with the normals to establish if they had elevated levels of pre­
existing anti-streptokinase antibodies and whether this had any effect on clinical 
outcome.
Anti-streptokinase antibodies have been quantified by several methods (1-6). The 
classical neutralising titration assay was developed to measure anti-streptokinase 
antibodies which inhibit the biological activity of streptokinase on the breakdown of 
clots (Kaplan 1944). In this study a commercial ASK-kit was used to quantify the 
levels of neutralising anti-streptokinase antibodies in serum samples.
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Enzyme-linked immunosorbent assay (ELISA) is a sensitive and reproducible 
technique for measuring the levels anti-streptokinase antibodies and is now 
commonly used (Lynch et al 1991, Fears et all 1992a, Elliot at al 1993). The 
ELISA technique is the method of choice as it is safe and cost effective compared to 
radioimmunoassays which are also sensitive and reproducible. In addition ELISA 
technique can be used successfully to measure individual antibody isotypes. In this 
study four enzyme-linked immunosorbent assays (ELISA's) were developed to 
detect IgG, IgA, IgM and IgE anti-streptokinase antibodies levels in sera of normals 
and patients.
Materials and methods
3-1 Quantitation of neutralising anti-streptokinase antibodies. A nti­
streptokinase neutralising antibodies were quantified in serum samples by the 
classical neutralising titration assay, in this method the sera containing these 
antibodies prevents the lytic effect of streptokinase on clots.
Materials and Buffer: Sources of materials used here are described in 2-1.
ASK-kit
Round-bottomed microplates
Rabbit erythrocytes
Phosphate buffered saline (PBS) (2-2)
M ethod. The levels of neutralising antibodies in sera samples were measured 
following manufacturer's instructions. Samples were diluted 1/10 in PBS and 25 pi 
was applied to a round-bottomed microplate and double diluted across the plate up 
to 1/640 in PBS, Streptokinase (25 pi) was then added to each well and incubated 
at 37°C for half an hour. Fifty pi of a mixture of fibrinogen and plasminogen was 
then added to each well. Rabbit erythrocytes were washed in PBS and resuspended 
in PBS to give a 5 % suspension and then was added to dried bovine thrombin.
70
Twenty five pi of the rabbit erythrocytes suspension was then applied to all the 
wells of the plate and the plate was covered and incubated at 37°C for 2 hours. The 
last dilution that prevented the lytic effect of streptokinase on the formed clots and 
prevented the sedimentation of erythrocytes was considered as the end point titre of 
the sample and expressed in reciprocal titre of neutralising anti-streptokinase 
antibodies per ml.
A serum sample with known levels of the neutralising anti-streptokinase antibodies 
(80 units/ml) was used as control.
3-2 Determination of molecular weight and purity of streptokinase.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is 
widely used technique to determine molecular weight of proteins, the proteins bind 
in a constant ratio to SDS according their molecular size and allows the 
determination of their molecular weight. SDS-PAGE was employed to assess the 
purity and molecular weight of commercial streptokinase used as the antigen in the 
ELISA assays.
Materials: Sources of materials used here are described in 2-1.
Molecular weight markers for gel electrophoresis 
Streptokinase
Buffers (2-11)
10% SDS 
0.75M Tris
0.75M Tris-HCl pH 6.80 
0.75M Tris-HCl pH 8.80 
0.86M Glycine 
30 % acrylamide 
Tank buffer 
Sample buffer
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Staining and destaining buffers
M ethod. The stock solutions were made up as described for separating gel and 
stacking gels (5 to 15 % SDS gel according to the method of Laemmeli 1970) (2- 
1 1 ).
The separating gel was mixed and poured immediately between two plates separated 
by spacers and overlaid with water saturated isopropanol until polymerised. 
Isopropanol then was removed and the residue was washed away with water and 
the stacking gel poured. A comb forming lanes was inserted and the gel allowed to 
set.
Streptokinase was mixed with an equal volume of sample buffer to give 10 to 20 p,g 
streptokinase per track. For reducing conditions streptokinase was mixed with an 
equal volume of sample buffer containing mercaptoethanol and boiled for two 
minutes. Streptokinase mixtures were carefully layered in the wells and 
electrophoresis was performed for approximately 3 hours at 40mA, until the 
tracking dye had reached the bottom of the gel. The gel was stained with staining 
buffer overnight at room temperature and destained with destain buffer. The 
respective electrophoretic mobility (RF) for each track was.calculated by measuring 
the distance migrated from the bottom of the track, compared to the distance 
migrated by the tacking dye. The system was calibrated using reduced high 
molecular weight markers to form a standard curve (Figure 2-2). The gel was dried 
as described before (2-11). Under optimum conditions of electrophoresis, 
streptokinase at 5-10 p,g per track was run on a 10% gel, the molecular weight of 
precipitate bands in the gel were calculated.
3-3 Crude screening ELISA procedure for collecting positive samples 
with anti-streptokinase antibody activity. By neutralising titration assay the 
presence of anti-streptokinase in serum can be assessed. However, this technique is 
not specific for individual antibody isotypes and costs more than ELISA
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techniques. Therefore indirect ELISA's were developed to quantify specific IgG, 
IgM, IgA and IgE isotypes to streptokinase. Positive serum samples with anti­
streptokinase antibody activity were required to construct standard curves to 
measure levels of IgG, IgA, IgM and IgE streptokinase specific antibodies in 
unknown samples. Sera from normal individuals and patients treated with 
streptokinase were screened by ELISA technique as following, to select samples.
Materials: (2-1)
ELISA plates (Dynatech, Immulon 4)
Streptokinase
Horseradish peroxidase (HRP) conjugated goat anti-human IgA 
HRP conjugated goat anti-human IgE 
HRP conjugated goat anti-human IgG 
HRP conjugated goat anti-human IgM 
O-phenylenediamine (OPD)
Buffers: Prepared as described in 2-2.
Phosphate buffered saline (PBS)
10 % Gelatin
ELISA coating buffer pH 9.60 
ELISA blocking buffer (0.01% gelatin)
ELISA wash buffer (0.05% Tween in PBS)
0.2M citric acid 
ELISA enzyme substrate 
4N H2SO4
Method. For detecting antibodies ELISA plates were coated with streptokinase (5 
Hg/ml in ELISA coating buffer pH 9.60) overnight at 4°C. After extensive washing 
in PBS-Tween the plates were blocked for one hour at room temperature with 200
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jxl per well of 0.01% gelatin in PBS. The plates were washed and samples were 
applied to the plates. The plates were incubated for a period of 2 hours at room 
temperature. After washing horseradish peroxidase conjugated anti-human IgG, 
IgA, IgM or IgE (diluted l/KXX) in 0.01% gelatin in PBS, 100 p,l per well) were 
added and after a further one hour incubation the plates were washed and developed 
using o-phenylenediamine (OPD) and the reaction stopped with 4N H2SO4. Colour 
reaction was read at 490 nm on a Dynatech ELISA reader.
Samples which gave a strong positive signal were chosen for construction of 
standard curves.
3-4 Purification of human anti-streptokinase antib od ies. Following 
sources of antisera were used to construct standard curves of isotype specific anti­
streptokinase antibodies in ELISA's to measure antibody concentrations in 
unknown serum samples. Sources of materials used here are described in 2-1.
The commercial ASK-kit purchased for measurement of neutralising anti­
streptokinase antibodies (3-1) contained a positive anti-streptokinase antibody 
control serum. The specificity of the positive serum for streptokinase was 
determined by the following procedure. SDS-PAGE electrophoresis was performed 
on streptokinase (10 to 20 p,g streptokinase per track, 3-2) and the gel transferred to 
a nitro-ceilulose membrane (2-12). The membrane was then blocked with 3% 
Marvel in TBS for one hour and washed (2-12). The blot was then incubated with 
the positive control sample diluted 1/100 in 0.15M TBS for one hour at room 
temperature with constant agitation (2-12). After incubation the blot was washed 
and incubated with HRP conjugated goat anti-human IgG or IgM, diluted 1/1000 in 
TBS-Tween, for half an hour (2-12). The blot was then washed and developed 
with the peroxidase substrate tetramethylene blue (TMB) and hydrogen peroxide 
(H2O2), until bands were clearly seen, the reaction was then stopped by washing 
the blot in water.
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Human anti-streptokinase IgG was purified from this positive serum using the 
caprylic acid precipitation method (2-19). Briefly the positive sample contained 
50.8 mg/ml protein was treated with 5% caprylic acid to precipitate the majority of 
serum proteins except IgG (2-19). The supernatant was treated with an equal 
volume of SAS to precipitate IgG and the pellet resuspended with PBS and dialysed 
against PBS (2-19). The final IgG concentration was 33.4 mg/ml (46% protein 
recovery). The purified IgG was then used to construct a standard curve for 
measuring IgG anti-streptokinase antibodies in unknown samples.
To find an IgM anti-streptokinase antibody positive serum, 94 samples from normal 
individuals and patients treated with streptokinase were screened by the crude 
ELISA (3-3). IgM was initially purified from normal human serum (NHS) 
(Contained 23 mg/ml total protein) by affinity chromatography using protamine 
coupled to Sepharose (2-20). As protamine binds to IgM, Sepharose-protamine 
was added to an equal volume of NHS and stirred at 4°C for 3 hours. The 
Sepharose suspension was then washed with PBS and IgM was eluted using PBS 
containing I.IM  NaCl (2-20). Absorbency of the eluted protein at 280 nm was 5.2 
mg/ml (22.6% protein recovery). However, the availability of the serum positive 
for IgM anti-streptokinase activity (3-3) was low, therefore to construct standard 
curve for measuring IgM anti-streptokinase antibodies in unknown samples the 
positive serum was used directly and not the IgM fraction.
IgA was purified from a known positive sample (Contained 53 mg/ml total protein) 
with anti-streptokinase IgA activity (a kind gift from Dr. E. Holme) by affinity 
chromatography purification using the lectin Jacalin derived from Jackafruit 
conjugated to agarose (2-21). Solid ammonium sulphate was added slowly to 75% 
saturation to the serum known to contain IgA (at pH 5.50) and stirred at room 
temperature for one hour. The mixture was then spun, the supernatant discarded 
and the pellet resuspended in PBS, added to equal volume of Jacalin-agarose and 
mixed at room temperature for one hour (2-21). The agarose suspension was then
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spun and the supernatant removed. To elute bound IgA an equal volume of O.IM 
melibiose was added to the pellet and stirred at room temperature for half an hour. 
The suspension was again spun and the supernatant removed and retained. 
Absorbency of the supernatant at 280 nm was 8.4 mg/ml (15.8 % protein 
recovery). The purified IgA was contaminated with IgG (see results) therefore for 
constructing standard curve for measuring IgA anti-streptoldnase antibodies in 
unknown samples the positive serum was used directly and IgA was not purled 
from the positive sample.
An IgE response was not detectable in any of the normal controls, although for 
capturing IgE anti-streptokinase antibody, the concentration of streptokinase was 
increased from 5p,g/ml to 250 p,g/ml (3-3).
The purity of the antibodies was checked by immunoelectrophoresis (lEP, 2-9) 
using sheep anti-human IgG, IgA, IgM and anti-human whole antiserum (diluted 
1/5) and 8% SDS-PAGE electrophoresis, both in reduced and non-reduced 
conditions (2-11). The purified antibodies were stored at - 20^0 until required.
3-5 Development of ELISA's for measuring isotvpe specific an ti­
streptokinase antibodies. Indirect ELISA's were developed to measure the 
levels of specific IgG, IgM, IgA and IgE isotypes to streptokinase in the population 
and study their effect in patients treated with streptokinase.
Materials: (described in 3-3)
Buffers: (described in 3-3)
Method. For detecting antibodies different ELISA conditions were examined to find 
the optimum conditions for each assay. ELISA plates were coated with 
streptokinase solution overnight at 4°C. As alkaline buffers may damage the 
biological activity of streptokinase by destruction of the amide groups of the protein 
(1-1), ELISA plate were coated with 5 p,g/ml and 10 p-g/ml streptokinase diluted in 
PBS pH 7.0 or ELISA coating buffer pH 9.60 to examine the effect of the
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concentration of streptokinase and the pH of coating buffer. After extensive 
washing in PBS-Tween the plates were blocked for one hour at room temperature 
with 200 jxl per well of 0.01% gelatin in PBS.
The plates were washed and standard curves for each antibody isotype (IgG, IgA 
and IgM) were constructed and run on the plates to allow the determination of the 
concentration of the unknown sample as follows.
For the IgG, purified IgG anti-streptokinase (3-4) was double diluted from 1/100 
and applied to the plates, the first dilution was assigned an arbitrary value of 225 
units/ml.
IgA and IgM anti-streptokinase positive sera (3-4) were double diluted from 1/100 
and 1/10 respectively and applied to the plates, the first dilutions being assigned 
arbitrary values of 1000 units/ml and 100 units/ml respectively. For IgE no positive 
sample with IgE anti-streptokinase was available and no standard curve was run, 
samples were expressed as positive or negative based on the OD of the blank. 
Values were accepted as positive if the OD was 3 times the value of the blank.
To establish the dilutions of samples which corresponded to the linear part of 
standard curves, different dilutions of samples were examined and the optimum 
dilutions were 1/200 for IgG and IgA, 1/30 for IgM. For detecting IgE samples 
were diluted 1/5. After applying standard curves and samples on the plates, the 
plates were incubated for a period of 2 hours at room temperature.
After washing horseradish peroxide conjugated to human IgG(diluted from 1/1000 
to 1/8000), IgA (diluted 1/1000). IgM (diluted 1/1000) and IgE (diluted 1/500) 
were added and after a further one hour incubation the plates were washed and 
developed using o-phenylenediamine (OPD) and the reaction stopped with 4N 
H2SO4. The colour reaction was read at 490 nm on a Dynatech ELISA reader. The 
antibody concentrations in unknown serum samples were obtained by interpolation 
from standard curves and the values expressed in the arbitrary units/ml.
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3-6 Intra-assay and inter-assav variations of techniques used for 
m easuring anti-streptokinase antibodies. Intra-assay and inter-assay 
variations of the assays used was determined by following procedure.
Intra-assay variations: Known positive samples which contained 10 units/ml IgG, 
330 units/ml IgA, 16 units/ml IgM and 80 units /ml neutralising anti-streptokinase 
antibodies were studied for intra-assay and inter-assay variations. The levels of 
isotype specific anti-streptokinase antibodies, IgG, IgA and IgM, were measured 
by indirect ELISA and the levels of neutralising anti-streptokinase antibodies were 
measured by ASK-kit 12 times within the same assay as described before (3-1 and
3-5). The coefficient variations (C.V.) of the samples for each assay was then 
determined by the following formula: C.V. = Standard Deviation / Mean X 100. 
Inter-assav variation: The levels of specific isotype response to streptokinase (IgG, 
IgA and IgM) and neutralising anti-streptokinase antibodies were determined in 
samples with known levels of anti-streptokinase antibodies (IgG 2 units/ml, IgA 
330 units/ml, IgM 22 units/ml and ASK 80 units/ml) on 7 different days by 
ELISA's and ASK-kit respectively (3-1 and 3-5). The C.V. of them was calculated 
as described.
3-7 Normal control group. Two hundred and forty six normal controls were 
studied for the presence of isotype specific anti-streptokinase antibodies. These 
samples were kindly provided by Dr. Elizabeth Holme, Department of Immunology 
Western Infirmary, Glasgow and the details of these individuals have been 
documented else where (Fyfe et al 1987). Their ages ranged between 14 and 79 
years and at the time of venesection they had no known current or recent illness. 
The sample were stored at -70°C.
3-8 Acute m yocardial infarction lAMI) patients treated  with  
throm bolytic agents. This study was performed in collaboration with Dr 
Elizabeth Holme (Department of Immunology, Western Infirmary, Glasgow) and
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Dr.Stewart Hillis (Department of Cardiology, Western Infirmary, Glasgow). 
Twenty patients with AMI (13 males, 7 females, mean age 57.6, range 37-70) were 
studied. They all presented with chest pain of duration greater than 30 minutes and 
less than 6 hours. AMI was confirmed by standard ECG criteria of ST segment 
elevation >lm m  in at least two limbs leads or >2mm in at least two chest leads. 
Fourteen patients had inferior and six patients had anterior infarcts.
Ten patients received intravenous streptokinase (1,5 million units over 1 hour) and 
ten patients received r-tPA (70-100 mg over 1 hour). Blood samples were taken 
prior to administration of thrombolytic agents and at timed intervals after treatment. 
Reperfusion in the twenty patients treated for AMI was monitored by the ECG 
(changes of the ST segment) and was observed from 2 hours to 24 hours after 
thrombolytic administration. The patients were therefore categorised into 3 groups 
according to their response to thrombolytic therapy, early reperfusion group 
responded within 2 hours, late reperfusion group responded within 24 hours and 
non-reperfusion group.
3-9 M easuring serum  album in  levels by sin g le  r a d i a l  
immunodiffusion. Serum albumin levels were measured in serum samples prior 
to administration of thrombolytic agents and at timed intervals after treatment by 
single radial immunodiffusion using rabbit IgG anti-human albumin (2-8).
0.15ml of rabbit IgG anti-human albumin (47 mg/ml) was added to three mis of 
agarose (2-5) and mixed at 56°C. The agarose was poured into petri dishes and 
allowed to cool. Wells were punched in plates and were filled with normal human 
serum (NHS) double diluted from 1/32 to 1/256 to construct standard curves. 
Samples diluted 1/60 were applied to the remaining wells and the plates were left 
overnight at room temperature in a humidified chamber. The diameters of precipitin 
rings were measured and recorded. A standard curve was constructed by plotting 
the d2 (diameter) of the precipitin rings of controls versus their concentration, and 
from this the albumin concentrations in the unknown samples were determined.
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3-10 In vitro effect of recombinant tissue plasminogen activator on 
quantitation of neutralising anti-streptokinase antibodies. The presence 
of recombinant tissue plasminogen activator (r-tPA) in the sera of patients treated 
with this thrombolytic agent may interfere with neutralising anti-streptokinase assay 
(3-1). Therefore this effect was studied in vitro by following procedure.
Materials and Buffer Sources of materials used here is described in 2-1.
ASK-kit
Positive serum with anti-streptokinase activity 
r-tPA
Round-bottomed microplates 
Rabbit erythrocytes 
PBS (2-1)
Method. The levels of neutralising anti-streptokinase antibodies in a serum sample 
with known levels of the antibodies (80 units/ml) were measured in the presence 
and absence of r-tPA. The serum sample was diluted 1/10 in PBS (Total volume 
500|xl) or was diluted 1/10 in PBS containing increasing amount of r-tPA from 0.3 
jag/ml to 5000 |.ig/ml (Total volume 500fxL) (Therapeutic dose of r-tPA = 1000 
pig/ml). The titre of neutralising anti-streptokinase antibodies in the diluted serum 
samples then were measured as described in 3-1.
3-11 Statistical analysis. Statistical analysis of data was performed using 
Spearman rank correlation test, Wilcoxon signed rank test and Mann-Whitney test.
Results
D eterm ination of m olecular weight and purity of streptokinase.
Molecular weight and purity of the commercial streptokinase used as antigen in the 
ELISA assays was first determined by SDS-PAGE (3-1). The mobility of
80
streptokinase as observed by this technique showed no difference under non­
reduced and reduced conditions (Figure 3-1), Streptokinase run on a SDS-PAGE 
revealed two close bands with molecular weights of 47 and 50 kD (Figure 3-1), 
Immunoblots performed with known positive serum containing anti-streptokinase 
antibodies (3-4) confirmed that the two bands correspond to the streptokinase 
molecule at 47 and 50 kD (Figure 3-2).
Isolation of positive samples for construction of standard curves. A
crude ELISA procedure was used to select serum samples which were positive for 
IgG, IgA, IgM or IgE anti-streptokinase antibodies. Attempts were made to purify 
the specific isotypes of antibody from the positive serum samples. IgG was purified 
by caprylic acid and IgM and IgA by affinity chromatography.
IgG was purified from the positive kit control of the ASK kit. This control was IgG 
as confirmed by western blotting (3-4, Figure 3-2). After caprylic acid purification
SDS-PAGE electrophoresis (3-4) under non-reducing conditions showed a band 
with molecular weight of 150000 corresponding to the molecular weight of IgG and 
in reduced condition a band with molecular weight of approximately 55000 
corresponding to molecular weight of the heavy chain of IgG.
When IBP was performed to examine the purity of the IgG preparation a thick 
precipitation arc was observed with anti-human IgG and no precipitation arc with 
anti-human IgM (Figure 3-3). However, the lEP showed that the purified IgG was 
contaminated with IgA (Figure 3-3). To assess whether this IgA contamination 
would influence the use of the IgG in the ELISA assay system, the levels of IgA 
were determined by ELISA (3-3), using HRP conjugated anti-human IgA utilising 
the IgG ELISA protocol. The optical density of the purified sample for IgA 
(OD490nm=0-08) was close to the optical density of blank (OD490nm=0-05) thus the 
presence of IgA did not appear to interfere in the IgG ELISA.
Five of the samples screened for IgM anti-streptokinase antibodies (n=94) showed 
elevated levels of IgM when the optical densities were compared with the optical
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(a) (b)
66 kD
Figure 3-1: Streptokinase run on a 10 % SDS-PAGE gel. Track (a) shows molecular 
weight markers for constructing the standard curve and tracks (b) and (c) show 
streptokinase run non-reduced and reduced respectively.
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(b)
Figure 3-2: Immunoblot of streptokinase transformed from a 10 % SDS-PAGE gel and 
incubated with the human anti-streptokinase and HRP conjugated anti-human IgG (Tracks 
a and b non-reduced and reduced respectively).
(a)1 I
I (b)
I
(c)
4 (d )
I
(e)
0
Figure 3-3: lEP showing purified human IgG anli-streptokinasc run in wells and after 
electrophoresis, anti-whole human scrum (troughs a and e), anti-lgA (b), anti-IgM (c) and 
anti-1 gG (d) were applied to the plate.
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density of the blank (OD^gonm^ 0.06) (3-3) and one was chosen (OD490nm=l-30) 
to construct a standard curve for measuring IgM in the unknown samples sera. IgM 
was initially purified from NHS by affinity chromatography (3-4), however, the 
amount of the positive serum was not sufficient for affinity chromatography 
purification (see protein recovery 3-4) as purification procedure resulted in a low 
yield of IgM (22%), therefore to construct standard curve for IgM anti­
streptokinase the positive serum was used directly.
IgA was purified from a known positive sample with IgA anti-streptokinase activity 
by Jacalin-agarose affinity chromatography (3-4).The yield of IgA was 8.4 mg/ml 
and the purity of the sample was determined by lEP (Figure 3-4). The purified IgA 
was contaminated with IgG. To assess the amount of IgG, the level was determined 
by ELISA using HRP conjugated anti-human IgG and HRP conjugated anti-human 
IgA. The OD490nm of IgA was 0.44 and IgG was 0.40. Due to large IgG 
contamination and the limited supply of IgA positive sera for constructing standard 
curve whole serum and not the purified IgA fraction was used.
D evelop in g  E L ISA 's for m easuring isotype sp ecific  anti" 
streptokinase antibodies. For detecting anti-streptokinase antibodies different 
ELISA conditions were examined to find the optimum conditions for each assay.
As alkaline buffers may damage the biological activity of streptokinase (1-1), 
streptokinase was coated into ELISA plates at 5 pg/ml and 10 p.g/ml in PBS pH 7.0 
or in ELISA coating buffer pH 9.60 to assess the effect of concentration of 
streptokinase and the pH of coating buffer (3-5). Overnight coating of streptokinase 
in PBS (pH 7.0) resulted in more consistent standard curves than observed with 
alkaline buffer (Figures 3-5 and 3-6). In addition the sensitivity of the assay 
appeared to be greater with coating in PBS (Figures 3-5 and 3-6). The 
concentration of 5|Lig/ml streptokinase as opposed to lOpg/ml streptokinase did not 
significantly effect the standard curves (Figures 3-5 and 3-6), however, for 
economic reasons streptokinase at a concentration of 5|.ig/ml was used.
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Figure 3-4: lEP showing purified human anti-streptokinase IgA by affinity chromatography 
run in wells and after electrophoresis, anti-human IgA (troughs a and b), anti-lgG (trough 
c) and anti-human IgM (d) were applied.
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Figure 3-5: Standard curve for IgG anti-streptokinase. 
(Streptokinase 5ug/ml (a) and lOug/ml (b) coated in PBS, pH = 7)
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Figure 3-6: Standard curve for IgG anti-streptokinase. (Streptokinase 5 ug/ml (a) 
and 10 ug/ml (b) was coated in coating buffer, pH=9.6)
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The HRP conjugated anti-human IgG was titrated from 1/1000 to 1/8000, the 
curves were linear from 5 units/ml to 100 units/ml with an optimal colour reaction 
with the 1/1000 dilution (Figures 3-5 and 3-6).
For IgM and IgA more consistent standard curves and optimal colour reaction was 
observed with 1/1000 dilution of HRP conjugated anti-human IgM and IgA (Data 
not. presented). Standard curves for IgA and IgM anti-streptokinase were 
constructed with the positive sera as described (3-5) (Figure 3-7)
For IgE no standard curve was run, samples were expressed as positive or negative 
based on the OD of the blank.
As result of the preceding analysis the following ELISA conditions were chosen: 
ELISA plates were coated with 5 [Ag/ml streptokinase in PBS pH 7.0 overnight at 
4°C. After washing the plates in PBS-Tween the plates were blocked for one hour 
at room temperature with 200 pil per well of 0.01% gelatin in PBS.
The plates were washed and standard curves and samples run on the plates as 
described (3-5).and the plates were incubated for a period of 2 hours at room 
temperature. After washing horseradish peroxidase conjugated to human IgG , IgA 
(diluted 1/1000), IgM ( For all conjugates diluted 1/1000) and IgE (diluted 1/500) 
were added and after a further one hour incubation the .plates were washed and 
developed using o-phenylenediamine (OPD) as described (3-5).
Determination of intra-assay and inter-assay variations. The intra-assay 
and inter-assay variations of the methods employed for measuring anti­
streptokinase antibodies were determined to assess accuracy and reproducibility of 
the methods (3-5).
The CVs for intra-assay variation in the ELISA techniques were between 11% and 
20% and for neutralising assay (ASK-kit) the CV was 21% (Table 3-la).
The CVs for inter-assay variations in the ELISA techniques were between 11% and 
17% and for neutralising assay (ASK-kit) the CV was 20% (Table 3-lb).
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Figure 3-7: Standard curves for measring IgM (a) and IgA (b) anti-streptokinase antibodies by ELISA.
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(a)
Isotype Number of 
measurements
Mean Median S.D. C.V.
IgG 12 9.21 9.2 1.91 20%
IgA 12 361.9 373.5 40.2 11%
IgM 13 13.8 13 1.88 14%
ASK 12 73.3 80 15.6 21%
Table 3-la: Intra-assay variations in methods employed for measuring anti-streptokinase 
antibodies (The values are expressed in units/ml).
iî“; 
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(b)
Isotype Number of 
measurements
Mean Median S.D. C.V.
IgG 8 2.0 1.9 0.2 11%
IgA 7 320 320 46.2 14%
IgM 7 25 24 ' 4.3 17%
ASK 7 74.3 80 15 20%
Table 3-lb: Inter-assay variations in methods employed for measuring anti-streptokinase 
antibodies (The values are expressed in units/ml).
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Intra-assay and inter-assay variations in the ELISA techniques were generally lower 
compared to the neutralising assay (ASK-kit) (Table 3-1).
Levels of isotvpe specific anti-streptokinase antibodies in a normal 
population. IgG, IgM, IgA and IgE anti-streptokinase antibodies levels were 
determined in 246 normal individuals (3-7). The values attained for all isotypes for 
the population studied were skewed in their distributions toward the lower end of 
the range (Figure 3-8a, b and c). To normalise the distributions, the values were 
transformed to Log 10. To transform the 0 values, they were assigned a value which 
was half of the lowest value obtainable from the standard curve for each isotype. 
The normal ranges of anti-streptokinase antibodies for each isotype were then 
established using mean ± 2SD (Table 3-2a, Figure 3-8a, b and c).
Most of the normal individuals had detectable levels of IgG and IgA anti­
streptokinase antibodies (90%), however, only 1.68% and 2.7% respectively had 
levels above the normal ranges (Table 3-2, Figure 3-8a and c). In contrast 76% of 
the normal individuals did not have any detectable levels of IgM anti-streptokinase 
antibodies, 14.1% had levels within the normal ranges and 9.9% had levels above 
the normal range (Table 3-2, Figure 3-8b).The levels of the individual isotype 
responses did not correlate with one another.
None of the normal individuals tested showed any IgE anti-streptokinase activity 
(3-4).
Levels of neutralising anti-streptokinase antibodies in a normal
pop ulation . The values of neutralising anti-streptokinase antibodies in the 
normals showed a skewed distribution. To normalise the data, the values were 
transformed to LogiO- To transform the 0 values, they were assigned as value of 
half of the lowest value obtained in the assay (i.e. 5 u/ml). The normal range for
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(a)
Isotype Mean Median Normal ranges
IgG 5.7 3.8 0.24 - 45.8
IgA 31.3 15.1 0.37 - 324
IgM 1.9 0 0.06 - 10.8
ASK 29.2 20 1.7 - 166
Table 3-2a: Mean, median and normal ranges of anti-streptokinase antibodies (Values are 
expressed in units/ml).
(b)
Isotype Controls (n=240) SK (n=10) r-tPA (n=10)
IgG 1.68% 20% 0%
IgA 2,7% 10% 0%
IgM 9.9% 80% 50%
ASK 0.4% 10%' 0%
Table 3-2b: Percentage of the individuals with elevated levels of anti-streptokiase antibodies 
in normal controls and patients treated with streptokinase (SK) or recombinant tissue 
plasminogen activator (r-tPA).
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neutralising anti-streptokinase antibodies was then established using mean ± 2SD 
(Table 3-2a, Figure 3-8d).
In the population studied 39.8% of the normal individuals did not have any 
detectable levels of neutralising anti-streptokinase antibodies, 59.8% had levels 
within the normal ranges and only 0.4% had levels above the normal range (Table 
3-2b, Figure 3-8d).
The levels of neutralising anti-streptokinase antibodies in the normal individuals 
showed a statistically significant positive correlation with the levels of IgG anti­
streptokinase ( r=: 0.553, p < 0.001) but not with IgM (r = 0.005) or IgA (r = 0.04) 
levels.
Isotvpe specific response and n eu tra lisin g  a n ti-strep to k in a se  
antibodies in patients with acute myocardial infarction. Of the 20
patients studied, pre- and post-thrombolytic treatment for AMI, 10 were treated 
with r-tPA and 10 with streptokinase (Figure 3-8a, b, c and d).
The pre-treatment levels of isotype specific and neutralising anti-streptokinase 
antibodies in the 20 patients did not show statistically significant difference from the 
control population (Figure 3-8).
Based on the calculated normal ranges it was observed that 10-80 % of patients 
who were treated with streptokinase had levels of anti-streptokinase antibodies 
above the normal ranges (Table 3-2b) as following: for IgG 20% of patients had 
elevated levels of antibodies (Controls 1.68%), IgA 10% (Controls 2.7%), IgM 
80% (Controls 9.9%) and neutralising antibodies 10% (Controls 0.4%) (Figure 3- 
8a, b, c and d. Table 3-2b).
In contrast to the normal control group the levels of IgG in the 10 patients, prior to 
administration of streptokinase did not correlate with neutralising antibodies, 
however, they correlated with the levels of IgA (r=0.58 p<0.08).(Table 3-3a). The 
levels of IgA in these patients also correlated with neutralising antibodies (r=0.75
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Coirelation rvalue Significant
IgG/ASK 0.4 N.S.
IgG/IgM -0.44 N.S.
iRG/IgA 0.58 p < 0.08
IgA/IgM 0.07 N.S.
IgA/ASK 0.75 p <0 .01
IgM/ASK 0.1 N.S.
Correlation rvalue Significant
IgG/ASK 0.67 p<0.03
IgG/IgM 0.06 N.S.
IgG/IgA 0.77 p < 0.009
IgA/IgM 0.4 N.S.
IgA/ASK 0.72 p <0 .01
IgM/ASK -0.06 N.S.
Table 3-3; Correlation between the levels of anti-streptokinase antibodies prior to 
administration of thrombolytic agents in 10 AMI patients treated with streptokinase (a) 
and in 10 AMI patients treated with r-tPA (b).
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p<0.01) (Table 3-3). The levels of IgG and IgM did not correlate with neutialising 
antibodies or one another (Table 3-3a).
In the group of the patients treated with r-tPA 50% had elevated levels of IgM anti­
streptokinase antibodies (Controls 9.9%), however, none of them had elevated 
levels of IgG, IgA and neutralising anti-streptokinase antibodies (Figure 3-8 a b c 
and d. Table 3-2b).
Similar to the normal control group and in contrast to streptokinase patients group 
the levels of IgG anti-streptokinase in the 10 patients treated with r-tPA, prior to 
administration of r-tPA correlated with neutralising antibodies (r=0.67 p<0.03) 
(Table 3-3b). The levels of IgA correlated with the levels of IgG (r=0.77 p<0.009) 
and neutralising antibodies (p=0.72 p<0.01) (Table 3-3b).
An IgE response was not detectable in any of the patients treated with thrombolytic 
agents.
Out of ten patients given streptokinase two patients (Patients EM and CD) had 
elevated antibody levels of IgG anti-streptokinase antibodies (46 and 47 units/ml, 
normal range=0.24-45.8 units/ml) and had levels of IgA anti-streptokinase 
antibodies of 310 and 350 units/ml (Normal range=0.37-324), only CD's value for 
IgA levels was above the normal range. Only one patient (EM) had elevated levels 
of neutralising anti-streptokinase antibodies (160 units/ml) (Normal rangeai.7- 
166).
The effect of adm inistration of r-tPA on the levels of anti­
streptokinase antibodies. The levels of isotype specific and neutralising anti­
streptokinase antibodies in patients treated with r-tPA were studied during the time 
course of treatment till day 7. These patients did not show statistically significant 
changes in the levels of isotype specific anti-streptokinase antibodies, as measured 
by ELI SA's (Table 3-4). However, quantitation of neutralising anti-streptokinase 
by the ASK-kit (3-1) showed a significant reduction in the levels of neutralising
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Isotype Pre-treatment
(n=10)
Post-treatment
(n=10)
IgG 5.1 5.6
IgA 0.4 0.5
IgM 8.3 9.4
ASK 28 2.2
Table 3-4: Pre- and post-treatment (at 10 minutes) mean values of IgG, IgA, IgM and 
neutralising anti-streptokinase antibodies (ASK) in patients treated with r-tPA (the values 
are expressed in units/ml).
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anti-streptokinase in post-treatment samples compared to pre-treatment values at 10 
minutes (p < 0.01) (Table 3-4).
In vitro effect of r-tPA on quantitation of neutralising an ti­
streptokinase antibodies. Since administration of r-tPA to patients, reduced the 
levels ASK titre at 10 minutes, the interference of r-tPA in this assay was examined 
(3-10). When serum with known elevated levels of anti-streptokinase antibodies 
(80 units/ml) was added to serial dilutions of r-tPA a sudden reduction in the 
measurable titre of neutralising anti-streptokinase antibodies was observed (Figure 
3-9). The presence of 2.5 [Ag/ml of r-tPA (Therapeutic dose = 1000 pg/ml) dropped 
the titre from 80 units/ml to undetectable levels.
The effect of administration of streptokinase on the levels of anti­
streptokinase antibodies in ten patients with AMI. The levels of isotype 
specific and neutralising anti-streptokinase antibodies in patients treated with 
streptokinase were studied serially every 15 minutes during the first two hours of 
treatment and then every day till day 7.
Administration of streptokinase in the group as whole resulted in an immediate fall 
in the levels of IgG anti-streptokinase antibodies within 15 minutes (n=10, p < 
0.01), the levels remaining depressed until day 5 (Figure 3 -10a). The levels of IgG 
anti-streptokinase antibodies then began to rise and reached values above the pre­
treatment levels by the day 7 (Figure 3 -10a). Analysis of the individual patients 
within the group showed the same general fluctuations for IgG, as seen when the 
mean values were compared (Figure 3 -11a). Even those individuals with low levels 
of IgG showed a drop at 15 minutes after streptokinase administration (Figure 3- 
11a).
As described two patients treated with streptokinase had elevated levels of anti­
streptokinase IgG prior to treatment (patients EM and CD), these patients in 
particular showed a dramatic reduction (50%) in the levels of IgG anti-strep to kinase
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Figure 3-9 : In vitro effect of r-tPA on the titre of neutralising anti-streptokinase antibodies.
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Figure 3-10; Fluctuations of the anti-streptokinase antibodies in 
10 patients treated with streptokinase (Vertical bars represent SE).
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Figure 3-11: Ructuations of IgG (a) and IgA (b) anti-streptokinase antibodies in 10 patients 
with acute myocardial infarction (AMI) during the first 2 hours of streptokinase treatment.
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%
antibodies after streptokinase administration (Figure 3-1 la), although the levels of 
IgG anti-streptokinase antibodies in these individuals (patients CD and EM) took 
longer to drop than those with lower levels (Figure 3-1 la).
Administration of streptokinase in the group as a whole decreased the levels of IgA 
anti-streptokinase antibodies in 60 minutes and the levels remained depressed until 
day 6 (Figure 3 -10b). The levels of IgA then began to rise and reached values 
above the pre-treatment levels by the day 7 (Figure 3 -10b). Analysis of the 
individual patients within the group showed that administration of streptokinase in a 
patient with elevated levels of IgA (Patient CD) resulted in a significant fall (80% 
reduction at 30 minutes) in the levels of IgA (Figure 3-1 lb). The reduction in the 
levels of IgA in patient EM who also had high levels of IgA occurred more slowly 
and the other patients with the lower levels of IgA showed little variation over the 
time course (Figure 3-1 lb).
The levels of IgM in the 10 patients did not show any significant changes during 
and after streptokinase infusion (Figure 3-10b), nor were any significant changes 
seen when individual patients were studied (Figure 3 -12b). Only one patient 
(Patient LC) in this group showed a significant reduction in the levels of IgM (90%
at 45 minutes) after streptokinase administration (Figure 3-12b).
Administration of streptokinase resulted in an immediate fall in the levels of 
neutralising anti-streptokinase antibodies within the 30 minutes (p < 0.01), the 
levels remaining undetectable until day 2 (Figure 3-10a). The levels of neutralising 
anti-streptokinase antibodies then began to rise and reached the values above the 
pre-treatment levels by the day 7 (Figure 3-10a). Analysis of the individual patients 
within the group showed the same general fluctuations for neutralising antibodies, 
as when the means were compared (Figure 3 -10a and 3-12a).
All the patients had elevated levels of specific antibodies to streptokinase by day 5, 
corresponding to an immune response to the administered antigen (Figure 3-10a,b).
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Figure 3-12: Fluctuations of neutralising (a) and IgM (b) anti-streptokinase antibodies in 10 
acute myocardial infarction (AMI) patients during the first 2 hours treatment with streptokinase.
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The levels of serum albumin during thrombolytic therapy. To determine 
whether clinical procedure and changes in plasma volume had any effect on the 
levels of proteins in patients with AMI the levels of serum albumin during 
streptokinase treatment were measured by single radial immunodiffusion (3-9). The 
administration of streptokinase did not cause any effect on the levels of serum 
albumin when post-treatment levels were compared with pre-treatment levels 
(Mann-Whitney test, U values ~ 23-46, not significant for all time points). The 
mean values of serum albumin levels of during streptokinase treatment are 
presented in Table 3-5 and Figure 3-13.
The effect of anti-streptokinase antibodies on clinical out-com e of 
thrombolytic therapy. The patients were categorised into 3 groups according to 
their responses to thrombolytic therapy, early reperfusion group (less than 2 
hours), late reperfusion group (less than 24 hours) and a group which showed no 
reperfusion.
Of 10 patients treated with r-tPA, 4 had an early reperfusion, 5 had late reperfusion 
and 1 did not reperfuse. Of 10 patients treated with streptokinase, 5 had early 
reperfusion, 3 hW late reperfusion and 2 did not reperfuse (Table 3-6).
All of the patients (n=5) who reperfused within 2 hours of receiving streptokinase 
(early reperfusion group), had levels of IgG, IgA and neutralising anti- 
streptokinase antibodies which were within the normal ranges (Table 3-6). The 
mean values of IgG (8.2 units/ml), IgA (43 units/ml) and neutralising anti­
streptokinase (10 units/ml) in this group were lower than late reperfusion group 
(17.5, 124 and 30 units/ml respectively) and the patients group which showed no 
reperfusion (26, 180 and 80 units/ml respectively) (Table 3-6, Figure 3-14).The 
levels of IgM anti-streptokinase antibody did not differ significantly in the 3 groups 
(Mean values for the 3 group in order were 9.8, 7.6 and 11.5 units respectively).
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Figure 3-13: The levels of serum albumin during streptokinase administration in 10 patients with AMI.
106
Time (Minutes) Serum Albumin (mg/ml)
Pre-treatment 40
0 45.1
15 45.5
30 45.8
45 43.4
60 44.9
75 43.9
90 44.1
105 4.3
120 44.8
Day 1 42.1
Day 2 44.3
Day3 44.8
Day 4 43.7
Day 5 45
Day 6 43.6
Day 7 44.8
Table 3-5: Mean values of serum albumin levels fluctuations in ten patients with AMI
treated with streptokinase.
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(a)
E arly IgG __ IgA ASK
J.M. 6.4 10 20 0
M.G 2.4 11.5 36 10
M.A. 5.8 11.1 5 0
• F.M. 24 11 39 20
H.M 2.7 5.2 7 0
(b)
Late IgG IgM IgA ASK
J.S. 3.8 11 3 0
A.M. 1.72 11.8 20 10
C.D. 47 0.1 350 80
(c)
N on IgG IgM IgA ASK
E.M. 46 11.5 310 160
L.C. 5.4 11.5 49 0
Table 3-6: The levels of anti-streptokinase antibodies in AMI patients treated with 
streptokinase that had early reperfusion (a), late reperfusion (b) and or did not reperfuse 
(c).The values are expressed in units/ml.
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One of the 3 patients who reperfused late (patient CD) had elevated levels of IgG 
(47 units/ml) and IgA (350 units/ml) anti-streptokinase antibodies (Table 3-6). Two 
of the patients (patients EM and LC) did not respond to streptokinase treatment 
(Non-reperfusion group). Patient EM had elevated levels of anti-streptokinase 
antibodies (IgO=46 units/ml, XgA=310 units/ml and neutralising antibodies™ 160 
units/ml) (Table 3-6). Patient LC had levels of IgG, IgM, IgA and neutralising anti- 
streptokinase antibodies that were within the normal ranges (IgG=5.4 units/ml, 
IgM =lL5 units/ml, IgA= 49 units/ml and neutralising antibodies=0 units/ml, Table 
3-6), howevar, the levels of IgM anti-streptokinase m this patient after streptokinase 
administration reduced by 91% (Figure 3-12b).
Of the 10 patients given streptokinase, one patient (Patient CD, see above) 
developed adverse reaction to this agent She developed fever, became unconscious 
and was admitted to I.T.U. After extensive bacteriology studies diagnosis of serum 
sickness was made, she was treated with corticosteriods, her condition improved 
and she was discharged from I.T.U. Patient EM who had also elevated levels of 
IgG anti-streptokinase antibodies (IgG - 46 units/ml, IgA= 310 units/ml and 
neutralising antibodies = 160 units/ml), did not develop adverse reaction to 
streptokinase administration, however, did not reperfuse.
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Figure 3-14: The effect of pre-existing IgG anti-streptokinase antibodies 
on reperfusion in 10 patients treated with streptokinase.
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Discussion
Streptokinase is now a commonly administered thrombolytic agent in patients with 
AMI. By promoting clot lysis the mortality rate is reduced (White et al 1990, 
Anderson et al 991, Chouhan et al 1992), it has the same efficacy as r-tPA (GISSÎ- 
2, 1990, White et al 1990) but is often chosen preferentially as it is about ten times 
cheaper (Sharma & Sashara 1982). One of the main disadvantages of the 
streptokinase administration is that, as a foreign antigen it may provoke 
hypersensitivity reactions, through the presence of pre-existing anti-streptokinase 
antibodies in patients as a result of previous streptococcal infections. In addition 
pre-existing antibodies are thought to reduce the lytic effect of streptokinase (Gamer 
& Tillet 1935, Lew et al 1984, Massel et al 1991, Fears et al 1992a, Bom et al 
1993). To what extent these antibodies exist in the population and the role of 
isotype specific anti-streptokinase antibodies in triggering hypersensitivity reactions 
or reducing efficacy have not been fully studied.
Many types of methodology have been employed to measure anti-streptokinase 
responses. As described radio immunoassays have been employed to measure IgG 
and IgE anti-streptokinase antibodies, counter immuno-el'ectrophoresis and radial 
immunodiffusion have been infrequently employed for detecting neutralising anti­
streptokinase antibodies in patients sera (1-6). Enzyme-linked immunosorbent 
assay (ELISA) a sensitive and reproducible technique is now commonly used for 
antibody quantitation (Lynch et al 1991, Fears et al 1992, Elliot et al 1993), this 
technique is safe and cost effective compared to radioimmunoassays. In addition the 
ELISA technique can be adapted to measure individual antibody iso types.
In this study ELI SA's were developed to measure the levels of IgG, IgA, IgM, IgE 
and neutralising anti-streptokinase antibodies in a normal population and to find to 
what extent these antibodies exist in normal individuals. Serum samples were also 
analysed for neutralising anti-streptokinase antibodies using a commercial ASK-kit 
(3-1), as this methodology is still in common use.
I l l
The ELI SA's were developed using commercial streptokinase used for AMI 
administration. Molecular weight and purity of the commercial streptokinase used in 
the different assays was first determined by SDS-PAGE (3-2). SDS-PAGE 
revealed two close bands with molecular weights of 47 kD and 50 kD (Figure 3-1). 
This is in agreement with previous reports of 2 close bands corresponding to 
streptokinase with a molecular weight of approximately 47 kD (Lynch et al 1993). 
The mobility of streptokinase as observed by this technique showed no difference 
between non-reduced and reduced conditions, this can be ascribed to the absence of 
the amino acids cysteine and cystine in the structure of this single chain polypeptide 
(DeRenzo et al 1967, Morgan & Henschen 1969, Brockway & Castellino 1974, 
Jackson & Tang 1982) (Figure 3-1). Immunoblotting with anti-streptokinase 
antiserum confirmed that these bands correspond to the streptokinase molecule at 47 
and 50 kD (Figure 3-2). The presence of two bands has been observed by other 
investigators and reported to be due to the effect of de-ami dation of the 
streptokinase molecule by alkaline buffer (Dillon & Wannamaker 1964, Hugh et al 
1965, Einarsson et al 1979, Lynch et al 1993). ELISA coating buffers commonly 
used are alkaline in nature in particular for coating streptokinase therefore the effect 
of buffers on coating of streptokinase to the ELISA plates was examined (3-5). 
Streptokinase at pH 7.0 gave a better standard curve when compared with alkaline 
buffer(pH 9.6) (Figures 3-5 and 3-6). Therefore PBS was used for coating 
streptokinase onto ELISA plates.
The intra-assay and inter-assay variations in ELISA's techniques compared with 
quantitation neutralising assay (ASK-kit) showed a lower variations and better 
reproducibility (Table 3-1).
IgG, IgM, IgA and IgE anti-streptokinase antibodies levels were determined in 246 
normal individuals (3-7) and normal ranges for each antibody isotype were 
established (Table 3-2, Figure 3-8a, b, c and d). The majority of the normal 
individuals had detectable levels of IgG and IgA anti-streptokinase antibodies 
(90%), however, only 1.68% and 2.7% had levels above the normal ranges. 24%
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of the normal individuals had detectable levels of IgM (9.9% were above the normal 
range) and 60% had detectable levels of neutralising anti-streptokinase antibodies 
(0.4% were above the normal range) (Table 3-2).
Neutralising anti-streptokinase assay is a functional assay that measures the 
efficiency of antibodies to streptokinase to inhibit clot breakdown. In the present 
study the levels of IgG and neutralising anti-streptokinase antibodies correlated 
significantly (r=0.55 p<0.001) in normal control group. In contrast to the normal 
control group the levels of IgG in the 10 patients, prior to administration of 
streptokinase did not correlate with neutralising antibodies (Table 3-3), which may 
be explained by small population size studied. However, in 10 patients treated with 
r-tPA the correlation between IgG and neutralising antibodies was observed 
(r=0.67, p<0.03), in agreement with Hoffmann et al 1988 who demonstrated in a 
group of 61 individuals with AMI a significant correlation between the levels of 
IgG and neutralising anti-streptokinase antibodies (p= 0.43, p<0.001).
The group of normals that were studied here represent a group of European 
individuals, therefore the proportion of individuals with elevated anti-streptokinase 
antibodies in other normal population groups may vary according to the prevalence 
of streptococcal infections in their location. Therefore it does appear important that 
normal ranges are constructed which reflect the population being examined.
Studies to date document varying degrees of pre-existing anti-streptokinase 
antibodies. James (1970) in an early study using a streptokinase resistance test 
assay, showed that 8.3% of normals had a level of reactivity to streptokinase which 
fell above an arbitrary level which could completely neutralise 250000 units of 
streptokinase. As described the ubiquity of exposure to streptococcal antigen is 
demonstrated in my study by the numbers of the individuals with a detectable 
antibody response and is supported by Moran et al (1984) and Lynch et al (1991) 
who quote positivity rates of 80% and 75%.
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Analysis of AMI group as a whole showed pre-treatment levels of anti- 
streptokinase antibodies in two groups of patients treated with streptokinase and r- 
tPA did not differ significantly from the normal population (Figure 3-8).
A break down of the 2 patient groups based on the normal ranges derived from the 
normal population studied showed that 50% of the patients treated with r-tPA had 
elevated levels of IgM anti-streptokinase antibodies (9.9% of normal controls were 
above the normal range) whilst IgG, IgA and neutralising antibodies were within 
the normal ranges (Figure 3-8a, b, c and d. Table 3-4). The larger incidence of 
elevated IgM anti-streptokinase antibodies in this group compared with normal 
individuals could be explained in two ways. 1) The majority of them may had a 
recent streptococcal infection, or 2) As fibronectin and streptokinase share a similar 
epitope (Gonzalez-Gronow et al 1993), in AMI patients, the presence of tissue 
damage antibodies against fibronectin (or fibronectin combined with other body 
constituents) may show cross-reactivity with streptokinase.
The levels of isotype specific anti-streptokinase antibodies (measured by ELISA's) 
in the patients treated with r-tPA did not change by the administration of this agent 
(Table 3-4). However, quantitation of neutralising anti-streptokinase (measured by 
ASK-kit) in these patients showed a significant reduction (p < 0.01) in the levels of 
detectable antibodies in post-treatment samples at 10 minutes (Table 3-4). Study of 
the effect of r-tPA on quantitation of neutralising anti-streptokinase assay in vitro 
(3-10) revealed that the presence of administered r-tPA in the patients sera was 
responsible for this observation (Figure 3-9). The effect of r-tPA which is through 
generation of plasmin and results in a false low neutralising anti-streptokinase 
antibody titre (ASK-kit) has not been reported before. This effect implies that the 
neutralising assay is not a suitable method for clinical diagnosis of anti­
streptokinase antibodies levels in patients since any alteration to the coagulation 
system due to anticoagulant therapy i.e. heparin, r-tPA etc. may interfere with this 
assay.
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Analysis of 10 patients treated with streptokinase based on the normal ranges 
derived from the normal population studied showed a larger incidence of elevated 
anti-streptokinase antibodies in particular for IgM (80%). Similar to r-tPA group 
this can be accounted for by recent streptococcal infection or cross reaction with 
fibronectin.
Administration of streptokinase in 10 patients studied, resulted in an immediate fall 
in level of IgG (15 minutes, p<0.01) and neutralising anti-streptokinase antibodies 
(30 minutes, p<0.01) (Figure 3-10). The observed reduction in the levels of the 
antibodies could not be accounted for by changes in plasma volume during the 
clinical procedure, as no changes were observed in serum albumin levels, or 
circulating IgM (Figures 3-10 and 3-13). The reduction of anti-streptokinase 
antibodies is therefore due to sequestering of specific anti-streptokinase antibodies 
into an immune complex with the administered streptokinase.
The decrease in levels of specific antibodies after streptokinase administration has 
been observed by other workers, Lynch et al (1991) showed IgG levels to drop at 
day 1 and increase to pre-treatment levels by day 4 with no change in IgM. Fears et 
al (1992) found antibody levels to drop, using a streptokinase resistance test.
An immune response in all the patients administered streptokinase was observed 
since all of them had elevated levels of specific antibodies to streptokinase by day 5 
(Figure 3 -10a and b). Similar to the present study after day 4 Fears et al (1992) 
found an elevation in the levels of antibodies corresponding to an immune response 
to the administered streptokinase.
There was no significant difference in reperfusion between patients given 
streptokinase and r-tPA. The patients who reperfused within 2 hours of receiving 
streptokinase, had levels of IgG, IgA and neutralising anti-streptokinase antibodies 
which were within the normal ranges (Table 3-6) and the mean values of anti­
streptokinase antibodies in the patients who reperfused late or did not reperfuse 
were higher than patients who reperfused early (Table 3-6). This implies that 
elevated levels of antibodies prevent the thrombolytic effect of streptokinase.
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reduced efficacy due to elevated antibodies has been reported by other investigators 
(Lew et al 1984, Massel et al 1991 and Bom et al 1993). Lew et al 1984 showed 
that elevated levels of anti-streptokinase antibodies can neutralise 1.5 million units 
administered streptokinase and cause failure of coronary artery reperfusion. 
Furthermore, as described, two of the patients treated with streptokinase had 
elevated levels of anti-streptokinase IgG prior to treatment (patients EM and CD).
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These patients in particular showed a dramatic reduction (50%) in the levels of IgG q
anti-streptokinase antibodies after streptokinase administration (Figure 3-1 la), 
although the levels of IgG anti-streptokinase antibodies in these individuals 
(patients CD and EM) took longer to drop than those with lower levels (Figure 3- 
11a). In individuals with large antibody levels the amount of streptokinase 
administered probably is not sufficient to bind to all available antibodies and as 
described the levels did not fall to undetectable levels as seen in those with low
levels. Although the levels of IgM in group of 10 patients treated with streptokinase 
did not show any significant changes (Figures 3-10b, 3 -12b) one patient in this
group that showed a significant reduction in the levels of IgM (90%) did not 
reperfuse (None reperfusion group, Patient LC, Figure 3 -12b). Patient EM with 
elevated levels of IgG and neutralising anti-streptokinase antibodies, did not 
develop adverse reaction to streptokinase administration but did not reperfuse 
(Table 3-6).
White et al 1990 showed that patients with AMI re-treated with streptokinase 3-5 
days after initial treatment do not exhibit a better response, and immunological 
reactions are more common than after the initial dose. This is not surprising since as 
described at the same period the levels of antibodies are elevated due to immune 
response. It therefore appears that if streptokinase needs to be readministered due to 
failure of the first bolus, it would be advisable to give this therapy shortly after first 
bolus.
In this study three of the patients with normal levels of anti-streptokinase antibodies 
did not respond to streptokinase treatment and should be considered as 25% of
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patients who fail to reperfuse (Anderson 1991, Chouhan 1992). The cause of this 
failure is due to other factors that prevent the thrombolytic effect of streptokinase 
i.e. elevated levels of lipoprotein-A (1-3). These factors have not been clearly 
identified. Lipoprotein-a has extensive homology with plasminogen but lacks the 
critical bond of Arg^^^-Val^^l that is required for the activity of plasminogen 
activators (1-2). Elevated levels of lipoprotein-a have been shown to inhibit the 
thrombolytic effect of streptokinase by competing with plasminogen for binding to 
streptokinase (Edelberg 1989).
Of the 10 patients given streptokinase, one patient (Patient CD, with levels of IgG 
and IgA above the normal range) developed serum sickness. Patient CD with 
elevated levels of IgA (350 units/ml) at 30 minute showed a significant reduction 
(80%) in the levels of IgA (Figure 3-1 lb). The reduction in the levels of IgA in 
patient EM with high levels of IgA (310 units/ml) and other patients was not as 
dramatic (Figure 3-11b). The observed reduction in the levels of IgA in patient CD 
can be explained by the high affinity and specificity of pre-existing IgA in this 
patient for the administered streptokinase. Although we have no clear past history 
of this patient the high specificity of IgG and IgA allows the assumption that this 
patient may have been exposed to a recent streptokinase treatment or group C 
streptococcal infection.
From the present study it is clear that elevated levels of the pre-existing anti- 
streptokinase antibodies are responsible for both failure of repeifusion and initiating 
adverse immunological reactions, and among many types of methodology of 
measuring anti-streptokinase responses, ELISA assays can predict both failure of 
treatment and adverse reactions, by measuring levels of IgG and IgA which seen to 
be important in determining the outcome.
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Chapter 4
The levels of anti-streptokinase antibodies and anti-mycobacterial heat 
shock protein in patients with auto-immune diseases
Introduction
Autoimmune diseases are caused by the breakdown of the immune system which 
results in specific immune reactions to self antigens. There are a wide range of auto­
immune disorders. Auto-immune thyroid disease is organ specific, where auto-immune 
process is confined to an individual organ. In non-organ specific diseases the auto­
immune process is not confined to a specific organ, i.e. systemic lupus erythematosus 
(SLE). Lying between these two kinds of autoimmune disorders there are disorders that 
are localised but their auto-antibodies are not specific for the involved organ (i.e. 
Primary biliary cirrhosis).
Multiple mechanisms may lead to organ specific or systemic auto-immune disorders. It 
is known that multiple genes contribute to the development of auto-immune diseases 
(Argyrios 1995a), however, it is not clear how self tolerance mechanisms are broken 
down and auto-antibodies are formed. One theory is that the release of the hidden 
antigen (i.e. lens, sperm) may provoke auto-antibody formation. Another theory is the 
recognition of self antigens and MHC class II proteins complexes by helper T cells 
triggers immune responses. However, T cells do not usually normally respond to these 
complexes due to the effects of suppression mechanisms caused by T cells and 
macrophages, in addition clonal deletion mechanisms prevent such immune responses. 
The unresponsiveness to self antigen is known as tolerance and is altered by the break 
down of any of the mechanisms described and results in auto-immune diseases (Weir & 
Stewart 1993).
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Many studies have tried to illuminate why self tolerance breaks down. Bacterial and 
viral infections have been suspected as antigens which may alter the immune system 
and produce auto-immune diseases. They may present antigen determinants similar to 
self components and produce cross-reactivity. Group A streptococci have similar 
antigens to human heart and glomeruli antigens and cause rheumatic fever or Henoch 
Schonlein purpura (HSP). Some bacterial endotoxins, lipopolysaccarides of gram 
negative bacteria and infections (Epstein Barr virus) provide a non-specific signal for B 
cells and trigger polyclonal activation of them without the mediation of helper T cells.
Streptococcal infections and the following immune response has been associated with 
auto-immune diseases (rheumatic fever). The presence of anti-streptokinase antibodies 
in sera is a result of previous streptococcal infections (Anderson et al 1948, Flute 1973, 
Buchalteret al 1992). To investigate whether streptococcal infections have any role to 
play in initiating the auto-immune disorders the levels of anti-streptokinase antibodies 
were measured in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
thyroiditis and Henoch Schonlein purpura (HSP) patient groups.
Heat shock proteins (HSPs) were first shown to be released by cells cultured at 
temperatures above 37°C. Heat shock proteins (HSPs) are a ubiquitous and highly 
conserved group of proteins and are a major antigenic component of many bacteria 
(Argyrios 1995a). The structural homology between foreign and self HSPs may lead 
through cross reactivity to an organ specific auto-immune disorder (DeNagel & Pierce 
1993), however, it is not clear how this molecular similarity could lead to auto-immune 
diseases.
IgG anti-mHSP65 (mycobacterial heat shock protein) antibody levels were measured in 
the above mentioned auto-immune patients groups and a group of normal individuals, 
to find if the present of this antibody has any relationship with immune responses to 
streptococcal infections.
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Materials and methods
4-1 Rheumatoid arthritis patients. The levels of isotypes IgG, IgA, IgM, IgE (3- 
5) and neutralising anti-streptokinase (3-1) and IgG anti-mycobacterial heat shock 
protein (anti-mHSP^s, 4-6) in fifteen patients with rheumatoid arthritis (RA) were 
studied.
These patients were selected carefully according to their clinical diagnosis and 
laboratory findings. The levels of rheumatoid factor (RE) and anti-nuclear factor (ANF) 
were determined in the Immunopathology laboratory. Western Infirmary, Glasgow 
University. The levels of RF were measured by ELISA's for IgG, IgA, IgM isotypes 
and by nephelometery. They all had elevated positive RF and a negative ANF.
4-2 Affinity chromatography elution of rheumatoid factor. To find whether 
the presence of rheumatoid factor (RF) has any effect on the levels of detectable anti­
streptokinase antibodies, rheumatoid factor from sera of patients with rheumatoid 
arthritis was eluted by affinity chromatography using Sepharose coupled to human 
IgG.
Buffers
IQ'^M HCl: 43 ml concentrated HCl was added to 800 ml water and final volume was 
made up to 1 litre with water (1.0 M HCl). 1.0 M HCl was then diluted 1/1000 to give 
10-3 M HCl.
O.IM NaHCO^ + 0.15 M NaCl: 8.4g NaHCOg and 5.8g NaCl were dissolved in 800 
ml water and the final volume was made up to 1 litre with water.
O.IM Tris-HCl (pH 8.01: Concentrated HCl was added to 800 ml O.IM Tris till pH 8.0 
was achieved and then the total volume was made up to 1 litre with water.
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0.1 M Acetate buffer (pH 4.0)+ 1.0 M NaCl: O.IM Sodium acetate (8.2g/L) and O.IM 
acetic acid (5.7 ml glacial acetic acid/L) were mixed together till pH 4.0 achieved and 
sodium chloride was then added to give final concentration of 1.0 M (58.8g/L).
O.IM Borate buffer (pH 8.01 + l.OM NaCl: O.IM Boric acid (6.18 g/L) and O.IM 
sodium tetraborate (borax) (9.54 g/L) were mixed together till pH 8.0 and sodium 
chloride was added to give final concentration of 1.0 M (58.8g/L).
0.1 M Glvcine-HCl buffer (pH 2.5) 7.5g glycine was dissolved in 800 ml water and 
pH was made to 2.5 with concentrated HCl, the final volume was made up to 1 litre 
with water.
Method: Sepharose 4B-cyanogen bromide was supplied by Pharmacia in a stable foim 
and reactivated by swelling with lO'^M HCl and washed for 15 minutes in same 
buffer. The coupling material, human IgG, was dialysed into O.IM NaHCOg + 0.15 M 
NaCl at 4°C overnight and 10 mg IgG was added per 1 gram of gel and mixed at 4°C 
overnight. The mixture was then spun at 4°C for 10 minutes. The supernatant was 
removed and the amount of protein was determined (2-4) to estimate the efficiency of 
binding of IgG to Sepharose. The Sepharose was washed once in O.IM 
NaHCO3-i-0.15 M NaCl and then mixed with O.IM Tris-HCl (pH 8.0) for 2 hours at 
room temperature on a Matbuen mixer. This buffer reacts with any remaining active 
sites on the Sepharose and renders then inactive. The Sepharose was washed with 0.1 
M Acetate buffer (pH 4.0)+ 1.0 M NaCl, and then with 0. IM Borate buffer (pH 8.0) + 
l.OM NaCl. After repeating this washing cycle once the Sepharose was ready to use. 
For this experiment sera from 13 patients with rheumatoid arthritis were used. The sera 
were diluted 1/2 in PBS and the levels of RF and anti-streptokinase antibodies prior to 
affinity chromatography were measured. The sera were then added to an equal volume 
of Sepharose-IgG and mixed for one hour at room temperature. The Sepharose-IgG- 
sera suspension were then spun, the supernatants were then removed and the levels of 
anti-streptokinase antibodies and RF were measured (4-1).
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4-3 Systemic lupus erythematosus patients. The levels of isotypes IgG, IgA, 
IgM, IgE (3-5) and neutralising anti-streptokinase (3-1) and IgG anti-mycobacterial 
heat shock protein (anti-mHSPgs, 4-6) were measured in twenty patients with systemic 
lupus erythematosus (SLE). These patients were selected according to their clinical 
diagnosis and laboratory findings. They all had positive ANF, positive Crithidia test 
and negative RF as determined in the Immunopathology laboratory, Western Infirmary, 
Glasgow University.
4-4 Thyroiditis patients. The levels of isotypes IgG, IgA, IgM, IgE (3-5) and 
neutralising anti-streptokinase (3-1) and IgG anti-mycobacterial heat shock protein 
(anti-mHSPô5, 4-6) were determined in twenty patients with thyroiditis. These patients 
were selected according to their clinical diagnosis and laboratory findings. They all had 
a high titre of anti-thyroglobulin and anti-thyroid microsomal antibodies as determined 
in the Immunopathology laboratory, Western Infirmary, Glasgow University.
4-5 Henoch Schonlein Purpora patients. Twelve patients with known Henoch 
Schonlein Purpura (HSP) were studied for the presence o f  anti -streptokinase antibodies 
(IgG, IgA, IgM, IgE and neutralising antibodies) (4-1) and IgG anti-mycobacterial heat 
shock protein (anti-mHSP^^) (4-7). These patients were selected according to their 
clinical diagnosis.
4-6 Measuring IgG anti-heat shock protein (HSP6 51 in patient groups.
This method was developed by Dr. David Bumie, Department of Cardiology, Western 
Infirmary, Glasgow University.
Materials
Sources of materials used here are described in 2-1.
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ELISA plates (Dynatech, Immulon 4)
Recombinant mycobacterial mHSP65 (mycobacterial bovis BCG) 
Horseradish peroxidase (HRP) conjugated goat anti-human IgG 
o-pheny lenedi amine (OPD)
Buffers: Prepared as described in 2-2.
Phosphate buffered saline (PBS)
1% BSA in PBS
ELISA coating buffer pH 9,60
ELISA wash buffer (0.05% Tween in PBS)
0.2M citric acid 
ELISA enzyme substrate 
4N H2SO4
Method. ELISA plates were coated with 100 pL per well of recombinant mycobacterial 
mHSP65 solution containing Ipg/ml in coating buffer overnight at 4°C. The plates 
were washed with PBS-Tween and blocked with 200 pL per well of 1% BSA in PBS 
for one hour at room temperature in a humidified chamber.
To construct a standard curve, a sample contained 6,85 mg/ml of IgG anti-HSP65 was 
double diluted in 1% BSA in PBS from 1/30, and 100 pi per well applied in duplicates 
to the plates. The first dilution was assigned a value of 220 arbitrary units/ml. Serum 
samples, diluted 1/400 in 1% BSA in PBS were applied to the plates (100 pi per well in 
triplicate) and incubated for 2 hours at room temperature. The plates were washed and 
HRP conjugated goat anti-human IgG (1/3000 in 1% BSA in PBS) was added (100 pi 
per well) and incubated at room temperature for 1 hour. The plates were washed and 
the colour developed using o-phenylenediamine (OPD) and the reaction stopped using 
4N H2SO4. Colour reaction was read at 490 nm on a Dynatech ELISA reader. The
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antibody concentrations in unknown serum samples were obtained by interpolation 
from the standard curve and the values expressed in the arbitrary units/ml.
4-7 Statistical analysis. Statistical analysis of data was performed using Spearman 
rank correlation test, Wilcoxon rank test and Student t-test (paired).
Results
The leyels of RF and anti-streptokinase antibodies in Rheum atoid  
Arthritis patients. The levels of IgG, IgA and IgM rheumatoid factor (RF) were 
measured by ELISA's and by nephelometry (Table 4 - la). The levels of RF as 
measured by nephelometry, IgG-RF, IgM-RF as measured by ELISA's were above the 
normal ranges, IgA-RF levels fell within the normal range (Table 4-la). The levels of 
RF measured by nephelometry correlated with the levels of IgM-RF measured by 
ELISA's (r=0.51, p<0.04), but did not correlate with IgG-RF (r=0.25). The levels of 
IgM-RF) and IgG-RF measured by ELISA's did not correlate with one another 
(r=0.28).
The levels of IgG, IgM, IgA and neutralising anti-streptokinase antibodies in these 
patients were measured (4-1) and the values compared to the established normal ranges 
(Table 4-lb  Figures 4-1 and 4-2).
The levels of IgG, IgA and neutralising anti-streptokinase antibodies in this group were 
skewed towards the lower end of the range, on the other hand, the levels of IgM anti­
streptokinase antibodies showed a normal distribution (Figures 4-1 and 4-2).
All the patients in this group had levels of IgG (Patients mean=10.5 units/ml, normals 
mean=5.7 units/ml) and neutralising anti-streptokinase antibodies (Patients mean=28.7 
units/ml, normals mean= 29.2 units/ml) that fell within the normal ranges (Figures 4-1
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Rheumatoid Factor Mean Median Normal range
IgG (ELISA) 201 139 0-20 (u/ml)
IgM (ELISA) 5440 4720 0-800 (u/ml)
IgA (ELISA) 7.5 7.5 0-7.5 (u/ml)
Nephelometry 602 470 0-22 (lU/ml)
Table 4-la: The mean, median and normal ranges of rheumatoid factor (RF) in 15 patients 
with rheumatoid arthritis measured by ELISA's and nephelometry. Values for IgG, IgA, 
IgM rheumatoid factor measured by ELISA are expressed in units/ml and values for 
rheumatoid factor measured by nephelometry are expressed in LU./ml.
Isotype RA SLE Thyroiditis HSP
IgG 10.5 8.8 10.6 27
IgA 157 87 44.2 141
IgM 60.3 14.6 14.8 16.5
ASK 28.7 15.5 6.75 36
Table 4-lb: The mean levels of anti-streptokinase antibodies in 20 patients with Systemic 
Lupus Erythematosus (SLE), 15 patients with rheumatoid arthritis (RA), 20 patients with 
thyroiditis and 12 patients with Henoch Schonlein Purpura (HSP). The values are 
expressed in units/ml, normal ranges for IgG=0-45.8, for IgA=0-324, for IgM=0-10.8 and 
for neutralising anti-streptokinase antibodies=0-166 units/ml.
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Figure 4-1: The levels of IgG (a) and IgA (b) anti-streptokinase in patients with 
rheumatoid arthritis (RA, n=15), systemic lupus erythematosus (SLE, n=20), 
Henoch Schonlein Purpura (HSP, n=12) and thyroiditis (n=20). 126
and 4-2, Table 4-lb). All the patients had detectable levels of IgA anti-streptokinase 
antibodies (Patients mean=:157 units/ml, normals mean= 31.3 units/ml), 13.3% had 
levels which were above the normal range (2.7% normals had elevated levels) (Figure 
4-1, Table 4-lb) and all of the patients had levels of IgM anti-streptokinase antibodies 
(Patients mean= 60.3 units/ml, normals mean= 1.9 units/ml) which were above the 
normal range (9.9% of normals had elevated levels) (Figures 4-2, Table 4-2).IgE anti- 
streptokinase antibodies were detectable in all of the RA patients when the optical 
densities (OD) were compared with the OD of the blank (Figure 4-3), this did not 
follow the finding in normal population studied (Chapter 3).
In this group the levels of anti-streptokinase antibodies correlated significantly with one 
another (Table 4-2) but did not correlate with the levels of RF measured by 
nephelometry or by ELISA's.
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Affinity chrom atography elution o f rheum atoid factor. To determine 
whether the presence of rheumatoid factor (RF) had any effect on the levels of 
detectable anti-streptokinase antibodies, rheumatoid factor from the sera of a second 
group of patients with rheumatoid arthritis (n= 13) was eluted by affinity 
chromatography (4-2). The levels of anti-streptokinase antibodies and RF in the 13 
patients prior to affinity chromatography were measured and compared with the post­
purification values (4-2).
Rheumatoid Factor (RF) was successfully eluted from the sera of patients as measured 
by nephelometry and affinity chromatography with a 73% reduction in the mean value 
of RF (Paired student t-test statistic=6.6, p<0.001) (Table 4-3, Figure 4-4a). However, 
many of the individuals still had RF levels above the normal ranges (Figure 4-4a).
The mean values of IgM, IgG and IgA anti-streptokinase antibodies after affinity 
chromatography were reduced by 66%, 53% and 64% respectively (For IgG, paired 
student t-test statistic=6.6 p<0.001, IgA statistic=3.14 p<0.008 and IgM statistic=4.3 
p<0.001) (Figures 4-4 and 4-5, Table 4-3). The reduction in the levels of RF post­
purification was to higher extent (7-20 %) compared to anti-streptokinase antibodies 
and the levels of IgM anti-streptokinase antibodies in many of the individuals were still 
above the normal range (Figures 4-4 and 4-5, Table 4-3).
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Correlation Statistic (r value) Significance {p value)
IgG/IgA 0.7 0.003
IgG/IgM 0.85 0.001
IgG/ASK 0.86 0.001
IgA/IgM 0.51 0.04
IgA/ASK 0.6 0.01
IgM/ASK 0.8 0.002
IgE/IgG 0.85 0.001
IgE/IgA 0.71 0.003
IgE/IgM 0.86 0.001
IgE/ASK 0.78 0.001
Table 4-2: Correlation between levels of anti-streptokinase antibodies (IgG, IgA, IgM, IgE) 
and streptokinase neutralising antibodies in 15 patients with'rheumatoid arthritis.
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post-affinity chromathography for elution of RF.
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The levels o f  an ti-strep tok in ase  antibodies in System ic L iipas  
Erythematosus patients. The levels of IgG, IgM, IgA and neutralising anti- 
streptokinase antibodies in the Systemic Lupus Erythematosus (SLE) patients were 
measured (4-3) and the values compared to the established normal ranges (Table 4-lb  
Figures 4-1 and 4-2). The individuals in this group had levels of IgG anti-streptokinase 
antibodies which fell within the normal ranges (Table 4 -la, Figure 4 -la), 5% and 85% 
had levels of IgA and IgM anti-streptokinase antibodies respectively above the normal 
ranges (2.7% and 9.9% of normal controls had elevated levels of IgA and IgM) (Table 
4-lb, Figures 4 -lb and 4-2a). The levels of neutralising anti-streptokinase antibodies in 
this group were within the normal ranges (Figure 4-2b). IgE anti-streptokinase 
antibodies were detectable in the majority of individuals in this group (Figure 4-3), this 
did not follow the finding in normal population studied (Chapter 3). The mean value of 
this group (OD49o=0.15) was lower than RA patients group (OD49o=0 .2).
The levels of IgM anti-streptokinase antibodies showed a normal distribution, however, 
the levels of IgG, IgA and neutralising anti-streptokinase antibodies were skewed 
towards the lower end (Figures 4-1 and 4-2). The levels of IgG and neutralising anti- 
streptokinase antibodies in this group correlated significantly (r = 0.7, p < 0.001). The 
levels of IgM, IgA and neutralising antibodies did not correlate with one another.
The levels o f anti-streptokinase antibodies in thyroiditis patients. The
levels of IgG, IgM, IgA and neutralising anti-streptokinase antibodies in the thyroiditis 
patients were measured (4-3) and the values compared to the established normal ranges 
(Table 4-lb Figures 4-1 and 4-2). All the patients in this group had detectable levels of 
IgG anti-streptokinase antibodies, however, only one individual (5%) had an elevated 
value (1.68% of normal controls had elevated levels of IgG) (Figures 4 -la  Table 4-2),
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RF Mean Median Normal Range
Pre 297 250 0-22
Post 79 77 0-22
IgG anti-SK Mean Median Normal Range
Pre 4.9 4.8 0-45.8
Post 2.3 1.9 0-45.8
IgA anti-SK Mean Median Normal Range
Pre 111 52 0-324
Post 52 29 0-324
IgM anti-SK Mean Median Normal Range
Pre 74 100 0- 10.8
Post 25 23.5 0- 10.8
Table 4-3: The levels of rheumatoid factor (RF) measured by nephelometry and IgG, IgA 
and IgM anti-streptokinase antibodies in patients with rheumatoid arthritis (n=13) pre- and 
post-affinity chromatographic elution of RF. The values of anti-streptokinase antibodies are 
expressed in units/ml and the value of RF are expressed in Ï.U.
134
<u«.2445
6  ht
Ga
Oao
12 ■ 
11 ■
10
9
8
7
6
5
4
3
2
1
0
(a)
Normal range=0-45.8 units/ml
Pre Post
%C3.2325g-kl
fies
t
400 
350 
300 
250 
200-j 
150 
100 -  
50 -
(b)
Normal ranee=0-324 units/ml
Pre Post
Figure 4-5: The levels of IgG (a) and IgA (b) anti-streptokinase antibodies in patients with 
rheumatoid arthritis (n=13) pre- and post affinity chromathography for elution of RF.
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most of the patients (90%-95%) had IgA and IgM levels within the normal ranges 
(Table 4-2, Figures 4 -lb  and 4-2a). An IgE anti-streptokinase response was not 
observed in any of the patients (Figure 4-3).
The levels of neutralising anti-streptokinase antibodies detectable in 50% of the patients 
correlated significantly with the levels of IgG and IgA (p < 0.001) but did not correlate 
with the levels of IgM (Table 4-4, Figure 4-2). The levels of IgM showed a negative 
correlation with the levels of IgA (r = -0.6, p <0.002).
The levels of IgM anti-streptokinase antibodies showed a normal distribution and the 
levels of IgG, IgA and neutralising anti-streptokinase antibodies skewed towards the 
lower end of the distributions (Figures 4-1 and 4-2).
The levels of anti-streptokiiiase antibodies in Henoch Schonlein Pupura 
patients. The levels of IgG, IgM, IgA and neutralising anti-streptokinase antibodies 
in the Henoch Schonlein Pupura (HSP) patients were measured (4-3) and the values 
compared to the established normal ranges (Table 4-lb Figures 4-1 and 4-2).
All of the individuals had detectable levels of IgG, IgA and IgM anti-streptokinase 
antibodies, two patients (16.6%) had levels of IgG and IgA above the normal ranges 
( 1.68% and 2.7% of normal controls had elevated levels of IgG and IgA respectively) 
(Figures 4-1 and 4-2, Table 4-2). Eleven patients (92%) had levels of IgM anti- 
streptokinase antibodies which fell above the normal range (9.9% of normal controls 
had elevated levels of IgM anti-streptokinase antibodies) (Figure 4-2a, Table 4-2). Ten 
patients (83.3%) in this group had detectable levels of neutralising anti-streptokinase 
antibodies, only one (8.3%) of them was above the normal range (0.4% of normal 
controls had elevated levels of neutralising anti-streptokinase antibodies) (Figure 4-2b, 
Table 4-2).
Three of the patients in this patient group (25%) had an IgE anti-streptokinase antibody
136
1
I
é
100 
90 
80 
70 i  
60 
50 
40 
30 “i 
20 
10 1
0
e
I
I
#
I
t
I se
e
e
_#
I
I
Control(n=20) RA(n=15) SLE(ii=20) HSP(n=12) Thyroiditis(ii=20)
Figure 4-6: Levels of IgG anti-mHSP65 in RA, SLE, HSP, thyroiditis patients 
and a group of normal individuals.
137
100
11
0»
sIné
%
r=0.57
p<0.05
60 80 
IgG anti-mHSP65 (units/ml)
100
nI
IIB I
I -
I
r=0.52
p<0.07
20 40 60
IgG anti-mHSP65 (units/ml)
80 100
Figure 4-7: Correlation between the levels of IgG (a) , neutralising (b) anti-streptokinase antibidies and IgG anti-mHSP65 in 12 patients with Henoch Shonlein Pupura.
138
response when the optical densities (OD) of samples compared with the OD of blank 
(OD of samples were 0.15, 0.16, 0.21 respectively and OD of blank was 0.004) 
(Figure 4-3).
The levels of IgM anti-streptokinase antibodies showed a normal distribution and the 
levels of IgG, IgA and neutralising anti-streptokinase antibodies skewed towards the 
lower end of the distributions (Figures 4-1 and 4-2).
The levels of neutralising anti-streptokinase antibodies correlated significantly with IgG 
(r = 0.93, p < 0.001) and IgA (r =0.63, p < 0.04). The levels of IgG and IgM 
correlated significantly (r = 0.75, p < 0.1) but did correlate with the levels of 
neutralising antibodies.
The mean value of IgG and neutralising anti-streptokinase antibodies in the HSP 
patients was higher when compared with the mean values in SLE, thyroiditis and RA 
patients (Table 4 -lb, Figures 4-la  and 4-2b). The mean value of IgA anti-streptokinase 
antibodies in these patients was higher than the mean values in SLE and thyroiditis but 
did not differ from the RA patients (Table 4 -la, Figure 4-lb). The mean value of IgM 
anti-streptokinase antibodies in these patients did not differ from the mean values in 
SLE and thyroiditis patients, however it was substantially lower than RA patients 
(Table 4-lb, Figure 4-2a).
The levels of IgG anti-heat shock protein fmHSP65) in auto-immune 
patients. IgG anti-mHSP65 levels were measured in RA (n=15), SLE (n=20). 
Thyroiditis (n=20), HSP (n=12) patients and a group of normal individuals (n=20) (4- 
6 ).
The mean values of IgG anti-mHSP65 levels in the 4 patients groups (RA=35.7 
units/ml, SLE=37.1 units/ml , Thyroiditis= 27.9 units/ml and HSP=30.17 units/ml) 
were higher than the mean value in the normal individuals (18.9 units/ml), although this
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was not statistically significant (Figure 4-6).
The levels of IgG, IgA, IgM, neutralising anti-streptokinase antibodies in RA, SLE and 
thyroiditis patients did not correlate with the levels of IgG anti-mHSP65. The levels of 
IgG anti-mHSP65 in HSP patients (n=12) correlated significantly with the levels of 
IgG anti-streptokinase antibodies (r=0.57, p < 0.05), IgA anti-streptokinase antibodies 
(r=0.58, p < 0.04) and neutralising anti-streptokinase antibodies (r = 0.52 p < 0.07), 
however, the levels of IgG anti-mHSP65 did not correlate with the levels of IgM anti­
streptokinase antibodies (Figures 4-7 and 4-8).
D iscussion
There is abundant evidence to indicate that auto-immune diseases are immunologically 
driven. Certain bacterial and viral infections (i.e. group A streptococci, mycobacteria) 
are suspected agents in the initial aetiology of autoimmune diseases. Among microbial 
antigens, heat shock proteins, have been the focus of attention of many investigators 
(Argyrios 1995a).
In this section the levels of isotype specific antibody responses to streptokinase, the 
antigen released during infection with the common bacterium streptococcus were 
measured in patients with a spectrum of auto-immune diseases (RA, SLE, thyroditis 
and HSP). In addition the specific IgG response to mycobacterium heat shock protein 
65 (mHSP65) a possible superantigen for auto-immune diseases was investigated. 
Rheumatoid arthritis is an auto-immune disease in which IgM antibody to human IgG 
called rheumatoid factor (RF) is present in the serum of the patients. The role of the 
rheumatoid factor in the pathogenesis of this disease is not clear. It has been suggested 
that infections such as mycoplasma or chronic bacterial agents modify the immune 
system which results in failure of normal tolerance. Systemic lupus erythematosus
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(SLE) is a non-organ specific auto-immune disease in which auto-antibodies are not 
confined to a specific organ. In SLE auto-antibodies are against DNA and other cellular 
components of damaged cells, this results in immune complexes formation and 
deposition in various sites that ultimately produces a generalised inflammation. 
Thyroiditis is an organ specific auto-immune disease which includes Grave's disease 
(Hyperthyroidism), Hashimoto's disease (Hypothyroidism) and myxoedema (No 
thyroid function). Henoch Schonlein Purpura (HSP) is an auto-immune disease which 
in small blood vessels in a number of organs are involved (vasculitis). It is usually a 
disease of children age between 4 and 10 years. The biopsy of the affected areas i.e. 
glomeruli, skin shows the deposition of IgA, C3. A variety of infections could be 
associated in the pathogenesis of the diseases.
Since 1940’s the involvement of infectious agents in the pathogenesis of RA has been
the subject of controversial debates. The possibility of heat-shock proteins acting as 
.superantigens and triggering autoimmune disorder, has re-opened these debates.
The general population are commonly exposed to streptokinase as this antigen is 
released during streptococcal infections (throat, skin, nasal, ears, etc.). After analysis 
of a normal population and a group of AMI we were keen to establish what levels were 
like in patients with auto-immune diseases.
The levels of IgG, IgM, IgA and neutralising anti-streptokinase antibodies in the patient 
groups described were measured and the values compared to the established normal 
ranges (Table 4-lb  Figures 4-1, 4-2 and 4-3). Although the levels of anti-streptokinase 
antibodies in these patients were not statistically elevated a significant proportion of the 
patients had elevated levels of the antibodies compared with the normal population. In 
addition the levels of anti-streptokinase antibodies in these patients generally correlated 
with one another.
Patients with RA had significantly elevated levels of specific IgM anti-streptokinase 
antibody levels (Figure 4-2, Table 4-2). The mean value of IgM anti-streptokinase
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antibody in this group (60.3 units/ml) was about 60 fold greater than the mean value of 
normal individuals (1.9 units/ml). The levels of IgM anti-streptokinase did not correlate 
with RF measured by nephelometry or ELISA. However, to determine whether the 
presence of rheumatoid factor (RF) had any effect on the levels of detectable IgM anti­
streptokinase antibodies, rheumatoid factor was removed from the sera by affinity 
chromatography (Sepharose-IgG). The levels of IgM anti-streptokinase post- 
purification were still above the normal range (Figures 4-3 and 4-4, Table 44 ).
The elevated anti-streptokinase antibodies in R.A. patients could be attributable to: a) 
the association of streptococcal infections in the pathogenesis of the R.A similar to 
participation of several infections in induction of auto-immune diseases i.e. carditis 
with group A streptococci, b) the effect of immuno-suppressive therapy on these 
patients making these individuals more susceptible to infectious diseases, c) as 
fibronectin and streptokinase share a similar epitope (Gonzalez-Gronow et al 1993), in 
this chronic inflammatory disease, the presence of autoantibodies against fibronectin (or 
fibronectin combined with other body constituents) may show cross-reactivity with 
streptokinase and d) the presence of excess amounts of rheumatoid factor in the sera of 
theses patients (IgM isotype) enhances the results which are obtained by ELISA's. The 
observed elevation of anti-streptokinase antibodies may renew the idea of the 
streptococcal infections association in the pathogenesis of the Rheumatoid Arthritis, 
however, this infection does not seem to be related to any concomitant rise in the super 
antigen mHSP65.
Heat shock proteins are a ubiquitous, highly conserved group of proteins used in a 
variety of cellular activities. They constitute a major antigenic component of 
mycobacterium and are considered as a major trigger for auto-immunity. Elevated levels 
of anti-mHSP65 have been demonstrated in RA patients (Bahr et al 1988). I could not 
support this observation in the RA patients, or patients with SLE, thyroiditis or HSP as
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the levels of IgG anti-mHSP65 in this group were not statistically elevated compared to 
the normal individuals (Figure 45).
On the other hand, in patients with Henoch Schonlein Purpura there was a correlation 
between IgG anti-mHSP65 levels and IgG, IgA and neutralising anti-streptokinase 
antibodies levels (Figures 4 6  and 4 7 ) . Although this was not highly significant and 
based on a small number of patients, it does however, raise the possibility that 
streptococcal infections and the release of heat shock proteins may play an important 
role in the aetiology of HSP.
From this data it can be concluded that streptococcal infections have an association in 
the pathogenesis of Rheumatoid A rthritis and Henoch Schonlein Purpura.
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Chapter 5 
Streptokinase and Complement System Recruitment 
Introduction
Streptokinase treatment provides a natural model for the study of immune complex 
formation where pre-existing anti-streptokinase antibody levels and complement 
activation products can be monitored serially following administration of the 
thrombolytic agent. The extent of pre-existing antibodies to streptokinase in a normal 
population and patient groups has been examined as well as the changes of these 
antibodies during thrombolytic therapy, to study the important role of pre-existing anti- 
streptokinase antibodies in the poor response to thrombolytic treatment or adverse 
immune response (Chapter 3). This study showed that during streptokinase 
administration, immune complexes appear to be formed and patients with elevated 
levels of pre-existing anti-streptokinase antibodies develop adverse immunological 
reactions, however, elevated levels of anti-streptokinase antibodies do not always 
resulted in such reactions. This in part may be explained bydhe interaction between the 
complement system and the immune complexes (1-8). There are few studies to date 
studying the role of complement in streptokinase therapy (1-10).
There are multiple methods for assessing complement activation, Nephelometry, rocket 
electrophoresis, radial immunodiffusion, enzyme-linked immunosorbent assay 
(ELSIA) and radioimmunoassay (RIA) quantify antigenic levels of complement 
components. Haemolytic assays, the classical pathway CH50, the alternative pathway 
CH50 and specific haemolytic assays are used to determine the functional activities of 
the complement system. More recently, measurement of complement activation 
products has become a popular means of assessing ongoing complement activation, 
particularly in patients with immune complex diseases (Auda et al 1990). Activation of
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classical, alternative and terminal pathways can be assessed by the levels of generated 
C ls:C l-IN H , C3b-P and C5b-9 complexes respectively. C ls:C l-IN H  complex is 
formed during classical pathway activation by covalent binding of C l-IN H  and 
activated C ls, the complexes C3b-P and C5b-9 are formed during alternative and 
terminal pathways activation respectively (1-7) (Figure 5-1). Another product of 
complement activation which is measured in routine measurements is C3d, a product of 
Factor Î mediated cleavage of C3b. The advantages of these assays is their sensitivity 
and specificity for ongoing complement activation.
In this chapter complement system recruitment in AMI patients treated with 
streptokinase and the influence of pre-existing anti-streptokinase antibodies on this 
recruitment is studied. The antigen streptokinase is somewhat unusual in that it may 
trigger complement activation by two mechanisms: 1) Through plasminogen activation 
and generation of plasmin. Plasmin is thought to activate the complement system in two 
ways, firstly, plasmin like trypsin and kallikrein can activate C ls in absence of immune 
complexes and secondly it can activate the alternative pathway by acting as Factor D 
and degrading Factor B (1-0). 2) The more classical mechanism of the complement 
system activation by streptokinase is through immune complex formation and activation 
of the classical pathway (1- 10).
In vitro effects of streptokinase and streptokinase immune complexes, thyroglobulin 
and thyroglobulin immune complexes on complement system were studied by 
measuring the levels of Cls:Cl-INH, C3b-P, C5b-9. Novel ELISA's were developed 
to measure free C3d and erythrocyte bound C3d. The effect of plasmin on this in vitro 
system was also investigated.
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Figure 5-1; Schematic diagram of the formation of, Cls:Cl-INH, C3b-P and 
C5b-9, studied as indicators of complement pathways activation.
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Materials and methods
5-1 Ion exchange chromatography for purification of human anti­
streptokinase IgG. Diethylaminoethyl cellulose (DE52, Whatman) binds to negative 
charged ions and the extent of binding depends on the degree of charge. The serum to 
be used is dialysed into the column buffer (pH 7.6), under those conditions IgG with 
positive charge does not bind to the DE52 but the remaining proteins bind and IgG can 
be eluted. Human sera were screened by ELISA procedure to collect positive samples 
with anti-streptokinase antibody activity (3-3) and IgG was then purified from the 
pooled sera with elevated levels of anti-streptokinase activity.
Materials
Buffer O.OIM sodium phosphate buffer pH 7.6 (Conductivity at 4°C, 0.5- 0.8 mS) (2- 
2 and 2-3).
Column: 1.5 X 9 cm column (60 ml syringe barrel) containing DE52 extensively 
equilibrated with the buffer.
Sample: 20 ml pooled sera with elevated anti-strep to kinase antibodies (protein 
concentration 90 mg/ml) were dialysed into the buffer.
Methods. After dialysis the pooled sera were applied to the column and the column was 
washed with buffer, 3 ml fractions were collected, the protein concentration of fractions 
was measured at 280 nm. Fractions 3 to 10 containing the protein peak were pooled. 
The elution profile of collected fractions by the DE52 columns from pooled sera with 
elevated anti-streptokinase antibodies is shown in Figure 5-2.
The purified IgG was run on a 7.5% SDS-PAGE gel and three bands with molecular 
weights of 150kDa, 105 kDa and 66 kDa were observed. Total concentration of the 
purified IgG was 11.5 mg/ml.
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Figure 5-2: Elution profile of fractions collected by a DE52 column from 
pooled sera with elevated levels of anti-streptokinase antibodies.
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5-2 Preparation of immune complexes. Rabbit anti-streptokinase serum was 
prepared as described before (2-13, 2-14), and double immunodiffusion confirmed 
antiserum specificity to streptokinase (2-7, Figure 2-3). Rabbit anti-streptokinase IgG 
was then purified from this serum by caprylic acid and total concentration of purified 
IgG was 13 mg/ml (2-19). The purified rabbit anti-streptokinase IgG was run on a
5-3 Measurement of complement activation products (C ls:C l-IN H , C3b- 
P and C5b-9). Cls:Cl-INH, C3b-P and C5b-9 were measured by indirect ELISA's 
using a modification of the techniques developed by Auda et al 1990. In this technique 
C ls:C l-IN H , C3b-P and C5b-9 complexes are captured by relevant antibodies and 
using a labelled second antibody which reacts with a different component of the 
complex the bound complex is quantified (Table 5-1). As the antibodies react with 
different components of the complexes, the intact components (Cl-INH, C3 and C5) 
also present in serum samples do not interfere with the assay.
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7.5% SDS-PAGE gel (2-11) and 3 bands with molecular weights of IriOkOa, 94kDa 
and 62 kDa were observed. Rabbit anti-thyroglobulin IgG was purified from the 
immunised serum (a kind gift of Dr.E.Holme) by caprylic acid (2-19) and total 
concentration of purified IgG was 5 mg/ml.
Quantitative precipitin test were performed for both antisera sources (2-18) by adding 
increasing amount of antigens (streptokinase or bovine thyroglobulin) to a constant 
amount of antibody (human anti-streptokinase 11.5 mg/ml, rabbit anti-streptokinase 
IgG 13 mg/ml, rabbit anti-thyroglobulin IgG 5 mg/ml) to determine the equivalence 
points. The equivalence point for rabbit anti-streptokinase IgG was 10 p,g streptokinase 
and 1300 \ig IgG (Figure 5-3a), for human anti-streptokinase IgG was 10 jiig 
streptokinase and 287.5 pig IgG (Figure 5-3b) and for rabbit anti-thyroglobulin IgG '
was at 10 pig thyroglobulin and 100 pig IgG (Figure 2-4).
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Figure 5-3; Quantitative precipitin test for rabbit (a) and human (b) IgG anti-streptokinase.
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Condition Cls:Cl-INH C3b-P C5b-9 C3d
Standard 
curve, coating 
antibody
anti-Cl-INH
(lOpg/ml)
anti-C3
(5pg/ml)
anti-C5
(lOpg/ml)
anti-C3d
(5p,g/ml)
Samples,
coating
antibody
anti-Cls 
(lOpg/ml)
anti-properdin
(10p.g/ml)
anti-C9
(lOpg/ml)
anti-C3d
(5pg/ml)
Blocking
buffer
0.1% Gelatin 
in PBS
0.1% Gelatin 
in PBS
0.1% Gelatin 
in PBS
0.1% BSA in 
PBS
Initial standard 
dilution
1/1000 1/10000 1/1000 1/5000
Initial standard 
concentration
180 ng/ml 130 ng/ml 70 ng/ml 200 units/ml
Sample
dilution
1/10 or 1/80 1/10 or 1/80 1/10 or 1/80 1/80 or 1/600
Biotin-
conjugate
dilution
anti-Cl-INH
(1/6000)
anti-C3
( 1/ 10000)
anti-C5
(1/6000)
anti-C3d
(1/ 10000)
HRP-Avidin
dilution
1/5000 1/5000 1/5000 1/5000
Table 5-1: ELISA conditions for measuring complement activation products. The first 
dilution for samples is the dilution used to dilute patients sera and the second dilution is the 
dilution used for in vitro assays.
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Materials. Sources of materials used here are described in 2-2.
ELISA plates (Immuion 4, Dynatech)
Goat anti-human C3 (IgG fraction)
Goat anti-human Properdin (IgG fraction)
Goat anti-human Cl (esterase) inhibitor (IgG fraction)
Goat anti-human C ls (IgG fraction)
Biotin N-hydroxy-succinimide ester 
Horse radish peroxidase Avidin-D
Buffers were made as described in 2-3. 
Phosphate buffered saline (PBS)
ELISA coating buffer (pH 9.60)
ELISA blocking buffer (0.1% gelatin in PBS) 
ELISA wash buffer (PBS-Tween)
ELISA enzyme substrate 
4N H2SO4
20 mM isotonic EDTA
Method. The ELISA conditions for measuring the complement activation products are 
summarised in Table 5-1.
The first two rows of ELISA plates were coated with goat anti-human Cl-INH, anti-C3 
or anti-C5 to construct standard curves (Table 5-1). The remaining wells were coated 
with goat anti-human Cls, anti-properdin, anti-C9 or rabbit anti-human C3d in ELISA 
coating buffer (Table 5-1). The plates were incubated at 4°C overnight and washed 
extensively with PBS-Tween. Non-specific binding sites were blocked with 0.1%
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gelatin in PBS (200 pi per well) for 1 hour at room temperature in a humidified 
chamber (Table 5-1). The plates were washed and fresh NHS, diluted in 20mM PBS- 
EDTA as described in Table 5-1, was applied in the first two rows to construct the 
standard curves ( 100 pi per well). Diluted samples were applied to remaining wells and 
incubated for 1 hour at room temperature (Table 5-1). After washing 100 pi of the 
relevant biotin-conjugated antibody (2-22) was added to each well and incubated for 
half an hour (Table 5-1). The plates were washed and 100 pi Avidin-horseradish 
peroxidase was applied per well and incubated for 20 minutes at room temperature 
(Table 5-1). The plates was washed and the conjugates were developed using O- 
phenylene diamine as the substrate (2-2). The reaction was stopped with 4N H2SO4 50 
pi per well and the optical densities were measured at 490 nm on a Dynatech ELISA 
reader. Intra-assay and inter-assay variations of complement activation products were 
determined as described before (3-6).
5-4 Measurement of serum C3d levels. Complement activation can also be 
assessed by measuring serum levels of C3d, the degraded fragment of C3b. An indirect 
ELISA's was developed for measuring semm C3d levels asTollows.
Materials. Sources of materials used here are described in 2-2.
ELISA plates (Immuion 4, Dynatech)
Rabbit anti-human C3d
Biotin N-hydroxy-succinimide ester
Horse radish peroxidase Avidin-D
Buffers were made as described in 2-3.
Phosphate buffered saline (PBS)
ELISA coating buffer (pH 9.60)
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ELISA blocking buffer (0.1% BSA in PBS)
ELISA wash buffer (PBS-Tween)
ELISA enzyme substrate 
4N H2SO4
20 mM isotonic EDTA
Method. The ELISA conditions for measuring C3d are summarised in Table 5-1. The 
ELISA plates were coated with rabbit anti-human C3d (Table 5-1). The plates were 
incubated at 4°C overnight and washed extensively with PBS-Tween. Non-specific 
binding sites were blocked with 0.1% BSA in PBS (200 pi per well) for 1 hour at 
room temperature in a humidified chamber (Table 5-1). The plates were washed and 
100 pi per well of an activated serum containing C3d, diluted in 20mM PBS-EDTA as 
described in Table 5-1, was applied in the first two rows to construct the standard 
curve. Diluted samples were applied to remaining wells and incubated for 1 hour at 
room temperature (Table 5-1). After washing 100 pi of biotin-conjugated rabbit anti­
human C3d (2-22) was added to each well and incubated for half an hour (Table 5-1). 
The plates were washed and 100 pi Avidin-horseradish peroxidase was applied per 
well and incubated for 20 minutes at room temperature (Table 5-1). The plates was 
washed and the conjugates were developed and the optical densities were measured at 
490 nm as described (5-3). Intra-assay and inter-assay variations of C3d were 
determined as described before (3-5).
5-5 Validity of ELISA used for measuring serum C3d levels. The presence 
of large amount of intact C3 in serum may interfere with the C3d assay. Therefore this 
cross-reactivity was studied by the following experiments.
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Materials. Sources of materials used here are described in 2-2.
ELISA plates (Immuion 4, Dynatech)
Rabbit anti-human C3d 
Goat anti-human C3 
Biotin N-hydroxy-succinimide ester 
Horse radish peroxidase Avidin-D 
Buffers as described in 5-4.
Methods, a) The effect of changes in antibody conditions on the measurement of free 
C3d: To capture C3d, ELISA plate was coated with rabbit anti-human C3d or goat anti­
human C3 (5pg/ml in coating buffer) at 4°C overnight. The plate was washed and non­
specific binding sites were blocked by 0.1% BSA in PBS for 1 hour. After washing the 
plates, activated NHS (By immune complexes, contained C3d and C3, 5-9) and naive 
NHS (non-activated NHS contained only intact C3) diluted 1/600 in 0.1% BSA-PBS 
were applied to the plates and incubated for 1 hour at room temperature. The plates 
were washed and biotin-conjugated anti-C3d or anti-C3 (2-22, diluted 1/10000) was 
added and incubated for half an hour. The plate was washed and Avidin-horseradish 
peroxidase diluted 1/5000 was added and incubated for 15 minutes. After washing the 
conjugate was developed using OPD and the optical densities measured at 490 nm (5-
4).
b) The effect of dilution on the detectable levels of C3d: Activated NHS (By immune 
complexes, contained C3d and C3) and naive NHS (Contained C3) were diluted 1/50 
or 1/600 and the levels generated C3d were measured (5-4) to determine whether by 
diluting the serum samples the effect of C3 on the assay could be minimised.
c) Kinetics of C3 and C3d during complement activation: The levels of C3d generated 
during complement activation (By immune complexes) was studied over a period of 30
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minutes at 37°C (5-4) and compared with the levels of C3. The levels of C3 was 
measured by modified technique used for measuring C3b-P in which anti-properdin 
was replaced with anti-C3 (5 pg/ml) to capture C3 and the values of C3 were read 
against C3 standard curve (5-3).
5-6 D etection of erythrocytes bound com plem ent com ponents by a 
modified ELISA technique. This assay was developed to evaluate erythrocyte 
bound complement components during complement activation.
Materials. Sources of materials used here are described in 2-2.
Round-bottomed microplates 
Rabbit anti-human C3d 
Goat anti-human C3 
Goat anti-human Properdin 
Goat anti-human Factor B 
Human erythrocytes
Buffers were made as described in 2-3.
Phosphate buffered saline (PBS)
ELISA coating buffer (pH 9.60)
1% and 0.1% BSA in PBS 
ELISA wash buffer (PBS-Tween)
Methods, a) Evaluation of erythrocytes bound C3, properdin and Factor B: To capture 
the bound C3, properdin and Factor B on erythrocytes, an ELISA plate (Immuion 4, 
Dynatech) was coated with goat anti-human C3, anti-human properdin or anti-human
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Factor B (5(xg/ml) in ELISA coating buffer respectively and incubated at 4°C
overnight. The plates were washed with PBS-Tween and non-specific binding sites
were blocked with 0.1 % BSA in PBS for 1 hour at room temperature. Erythrocytes
(E's) from an activated blood sample (By immune complexes, 5-9) or naive blood
sample (unactivated) were washed with 1% BSA and reconstituted to iX 10^ cells/ml
(1-17). The erythrocytes were then added to the plate (100 pi / well, in triplicates) and
incubated at room temperature for 2 hours. To remove the unbound E's the plates were
washed very gently by 1% BSA (200pl/well X3) using a multi-channel pipette. After
washing bound erythrocytes were lysed by adding of 100 pi of water per well and the
optical densities of lysed cells measured at 405 nm on a Dynatech ELISA reader, 
b) Evaluation of erythrocytes bound C3d: To capture the bound C3d on erythrocytes,
ELISA plates were coated with rabbit anti-human C3d (Dakopatt) from 0.625 pg to 
SOpg/ml in ELSA coating buffer and incubated at 4°C overnight. Erythrocytes (E's) 
from an activated blood sample (By immune complexes) or an unactivated blood 
sample were washed with 1% BSA and reconstituted to iX 10^ cells/ml, added to the 
plate as described and the plates incubated at room temperature for 2 hours. To remove 
the unbound E's the plates were washed with 1% BSA as described before and the 
bound erythrocytes were lysed with 100 pi of water per well, the optical densities of 
lysed cells measured at 405 nm on a Dynatech ELISA reader. Intra-assay and inter­
assay variations of erythrocytes bound C3d were determined as described before (3-6).
5-7 The effect of throm bolytic therapy on com plem ent activation in 
patients with AML The levels of complement activation products in these patient 
were studied in conjunction with Dr.E.Holme University Department of Immunology, 
Western Infirmary, Glasgow. Twenty patients with AMI who received thrombolytic 
treatment were studied (3-8). Blood samples were taken prior to administration of 
streptokinase and at timed intervals after treatment and kept at -70°C. The following
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activation products were measured, Cls;Cl-INH, C3-b-P and C5b-9. The fluctuations 
of complement activation products and the relationship of these products with the anti- 
streptokinase antibodies were studied.
5-8 Effects of dose and kinetics of streptokinase on the complement 
activation. Normal human serum (NHS) was prepared from venous blood of 10 
healthy volunteers (2-15). As pre-existing elevated levels of anti-streptokinase 
antibodies in the NHS may interfere with this assay by forming of immune complex 
when streptokinase is added, the levels of anti-streptokinase antibodies in the 10 normal 
individuals were measured (3-1 and 3-5) and only sera with levels of anti-streptokinase 
antibodies within the normal ranges were used.
Materials. Sources of materials used here is described in 2-2.
Streptokinase
NHS
Buffers: prepared as described in 2-3.
Phosphate buffered saline (PBS)
Isotonic 20 mM EDTA
Methods, a) The effect of streptokinase on NHS at the therapeutic concentrations; To 
study the in vitro effects of streptokinase on complement activation, 20 pg, 40pg and 
100 pg streptokinase were added to the 200 pi NHS. The volumes were equalised with 
PBS to 300 pi to give a final concentration of 66 pg/ml, 133 pg/ml and 333 pg/ml 
streptokinase in the mixtures (The dose of streptokinase administered to AMI patients is 
5000-7500 I.U./ml = 66-100 pg/ml). After incubation at 37°C the assays were sampled 
at 0, 5 15 and 30 minutes. Complement activation was stopped by adding an equal
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Materials. Sources of materials used here is described in 2-2.
Human and rabbit anti-streptokinase IgG
Streptokinase
Rabbit anti-thyroglobulin IgG
Thyroglobulin
NHS
Buffers: prepared as described in 2-3.
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volume of ice cold isotonic 20 mM EDTA (2-2) and complement activation products 
were measured as described (5-3).
b) The effect of streptokinase beyond the therapeutic concentrations: The dose response 
of streptokinase in concentrations above the therapeutic concentrations was also 
studjed. The levels of anti-streptokinase antibodies in the NHS used for this experiment 
were within the normal ranges (IgG= 1.7 units/ml, IgA, IgM and neutralising anti­
streptokinase were not detectable).
Streptokinase 20 pg to 6000 pg was added to 500 pi NHS and the volume of the 
mixtures equalised to 800 pi with PBS, to give a final concentration from 25 pg/ml to 
7500 pg/ml of streptokinase in the mixtures. The mixtures were then incubated at 
for 30 minutes and complement activation products were measured as described (5-3),
5-9 The effect of streptokinase and thvroglobuiin immune complexes on 
complement activation. Preformed and nascent immune complexes were prepared 
to study the in vitro effects of immune complexes on complement activation. To prepare 
nascent immune complexes, antigen and antibody were added simultaneously to NHS 
and incubated at 37^C. Preformed immune complexes were prepared by incubating 
antigen and antibody at 37G  for 30 minutes prior to experiment.
Phosphate buffered saline (PBS)
Isotonie 0.086M EDTA 
O .lM M gC hEG TA  
20 mM EDTA
Methods, a) Kinetics and dose response of rabbit streptokinase immune complexes: 
The effect of rabbit streptokinase immune complexes (preformed and nascent, see 
above) on complement activation was studied. Immune complexes at equivalence, 
antigen excess or antibody excess were prepared (5-2) by adding Ipg  to 80 pg 
streptokinase to a constant amount of rabbit anti-streptokinase IgG (1300 pg) and the 
volumes equalised to 380 pi with PBS. The mixtures were then incubated with 200 pi 
NHS at 37®C for 30 minutes. The assay sampled at 0, 5 15 and 30 minutes, 
complement activation was stopped by addition of equal volume ice cold isotonic 20 
mM EDTA to the reaction mixture (2-2) and complement activation products were 
measured as described (5-3).
b) The effect of human streptokinase immune complexes on the complement activation: 
The effect of human streptokinase immune complexes (preformed) on complement 
activation was studied. Immune complexes at equivalence, antigen excess or antibody 
excess were prepared (5-2) by adding 5 pg to 320 pg streptokinase to a constant 
amount of human anti-streptokinase IgG (1150 pg) and the volumes were equalised to 
670 pi with PBS, and then incubated with 250 pi NHS at 37°C for 5 minutes. The 
assay sampled at 5 minutes and complement activation stopped by addition of an equal 
volume of ice cold isotonic 20 mM EDTA to the reaction mixture (2-2) and complement 
activation products were measured as described (5-3).
c) Kinetics and dose response of rabbit thyroglobulin immune complexes: The effect of 
rabbit thyroglobulin immune complexes (preformed and nascent, see above) on 
complement activation was studied. Immune complexes at equivalence, antigen excess 
or antibody excess was prepared (5-2) by adding 3pg to 200 pg thyroglobulin to a
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constant amount of rabbit anti-thyroglobulin IgG (500 pg) and the volumes equalised to 
450 pi with PBS, the mixtures were then incubated with 200 pi NHS at 37^0 for 30 
minutes. The assay sampled at 0, 5 15 and 30 minutes, complement activation was 
stopped by addition of an equal volume of ice cold isotonic 20 mM EDTA to the 
reaction mixture (2-2) and complement activation products were measured as described 
(5-3).
Controls: 1) The levels of complement activation products in NHS (In absence of 
activating factors, antigens, antibodies or ICs) at 37°C was used as control throughout 
the experiments, and control for spontaneous complement activation.
2) To inhibit complement activation, NHS was incubated with isotonic 0.086M EDTA 
to give a final concentration of 10 mM (2-2) and to inhibitalternative pathway 
activation, NHS was incubated with 0.1 M MgCl2 EGTA to give a final concentration 6 
mM (2-2). NHS treated with EDTA or Mg++, EGTA were incubated with immune 
complexes at 37°C and complement activation products were measured as described (5-
3).
5-10 The effect of erythrocytes on complement activation. The effects of 
erythrocytes on complement activation were studied as they may influence the levels of 
generated complement activation products, through either the action of CRl, an 
essential cofactor for Factor I or acting as a surface upon which these products can be 
deposited. The effect of erythrocytes on complement activation products was studied.
Materials. Sources of materials used here is described in 2-2.
Human and rabbit anti-streptokinase IgG
Streptokinase
Rabbit anti-thyroglobulin IgG
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Thyroglobulin
NHS
erythrocytes
Mouse monoclonal anti-CRI
Buffers: prepared as described in 2-3.
Phosphate buffered saline (PBS)
1% BSA in PBS 
20 mM isotonic EDTA
Methods, a) The effect of erythrocytes on the complement activation products: Nascent 
thyroglobulin immune complexes at equivalence (25 pg antigen and 250 pg IgG, 5-2) 
were incubated with 200 pL NHS in the presence or absence of 200 pi packed E's and 
the volumes were equalised to 470 pi with 1% BSA in PBS, the mixtures were then 
incubated at 37°C for 30 minutes. The assay mixture was sampled at 0, 5 15 and 30 
minutes, complement activation was stopped by addition of equal volume of 20 mM 
EDTA to the reaction mixture (2-2) and complement activation products were measured 
(5-3).
Preformed rabbit streptokinase immune complexes at equivalence (10 pg streptokinase 
and 1300 pg IgG, 5-2) were incubated with 500 pL NHS in presence or absence of 
100 pi packed E's and the volumes were equalised to 750 pi with 1% BSA in PBS, the 
mixtures were then incubated at 37°C for 15 minutes. The assay sampled at 0, 5 and 15 
minutes, complement activation was stopped by addition of equal volume of 20 mM 
EDTA to the reaction mixture (2-2) and complement activation products, Cls:Cl-INH, 
C3b-P, free C3d and erythrocytes bound C3d were measured (5-3, 5-4 and 5-6).
A limited study was undertaken with preformed human streptokinase immune 
complexes at equivalence (40 pg antigen and 1150 pg IgG, 5-2) incubated with 250 pL 
NHS in presence or absence of 50 pi packed E's, the volumes were equalised to 440 pi
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with 1% BSA in PBS, the mixtures were then incubated at 37°C for 5 minutes. The 
assay mixture was sampled at 5 minutes and complement activation was stopped by 
addition of equal volume of 20 mM EDTA to the reaction mixture (2-2) and 
complement activation products were measured as described (5-3). 
b) The effect of CRl receptors on the complement activation products: To study the 
effect of the CRl receptors, 150 pL of packed E's were incubated with 75 pi of 
monoclonal anti-CRl (Dakopatt, 135 pg/ml) at 37°C for 30 minutes and the cells were 
washed with 1% BSA in PBS. 100 pi of packed naive (untreated with anti-CRl) E's or 
100 pi of packed E's treated with anti-CRl were added to preformed rabbit 
streptokinase ICs at equivalence (10 pg streptokinase and 1300 pg IgG, 5-2) and 500 
pL NHS, the volumes were equalised to 750 pi by 1% BSA in PBS. The mixtures 
were then incubated at 37°C for 15 minutes. The assay sampled at 0, 5 and 15 minutes, 
complement activation was stopped with 20 mM EDTA as described and the levels of 
C ls:Cl-INH, C3b-P, free C3d and erythrocytes bound C3d were measured (5-3, 5-4 
and 5-6).
5-11 The effect of plasm in on the levels of c o m p le m en t a c tiv a tio n  
p ro d u c ts . As described plasmin can interact with complement system (see 
introduction) these interactions therefore may influence the detectable levels of 
complement activation products.
Materials. Sources of materials used here is described in 2-2.
Plasmin
Streptokinase
Rabbit anti-thyroglobulin IgG 
Thyroglobulin
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NHS
Buffers: prepared as described in 2-3. 
Phosphate buffered saline (PBS)
20 mM isotonic EDTA
Methods, a) The effect of plasmin on the levels of complement activation products: 
Direct effect of plasmin on the generated levels of complement activation products by 
rabbit thyroglobulin immune complexes was studied. Thyroglobulin ICs were used as 
streptokinase may affect the assay. Plasmin from 4pg to 256pg (Total protein) was 
added to a constant amount of nascent thyroglobulin immune complexes at equivalence 
(25 pg antigen and 250 pg IgG, 5-2) and 2(X) pi NHS, the volumes were equalised to 
475 pi with PBS. The mixtures were then incubated at 37°C for 30 minutes. The assay 
mixture was sampled at 30 minutes and complement activation was stopped by addition 
of an equal volume of 20 mM EDTA to the reaction mixture (2-2) and complement 
activation products were measured as described (5-3).
Controls: 256 pg plasmin + 200 pi NHS, 200 pL NHS alone, thyroglobulin ICs + 200 
pi NHS in absence of plasmin (Total volumes were equalised to 475 pi with PBS), at 
37°C for 30 minutes were used as controls.
b) Kinetics of complement activation by rabbit thyroglobulin immune complexes in 
presence of streptokinase: To study the indirect effect of streptokinase through the 
generation of plasmin on the levels of complement activation products generated by 
thyroglobulin immune complexes, serial amount of streptokinase from 50 pg/ml to 400 
pg/ml (Therapeutic dose = 66-100 pg/ml) were added to a constant amount of nascent 
thyroglobulin immune complexes at equivalence (25 pg thyroglobulin and 250 pg IgG, 
5-2) and 200 pi NHS, the volumes were equalised to 475 pi with PBS. The mixtures 
were then incubated at 37°C for 30 minutes. The assay mixture was sampled at 0, 5 15
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and 30 minutes, complement activation was stopped by addition of equal volume of 20 
mM EDTA to the reaction mixture (2-2) and complement activation products were 
measured as described (5-3).
Controls: ICs + NHS, streptokinase + NHS and NHS alone (Total volumes were 
equalised to 475 jxl with PBS) at 37°C for 30 minutes were used as controls.
5-12 Statistical analysis. Statistical analysis of data was perform ed using 
Spearman rank correlation test, Wilcoxon signed rank test and Mann-Whitney test.
Results
M easurement of complement activation products C ls:C l-IN H , C3b-P  
and C5b-9. Cls:Cl-IN H , C3b-P and C5b-9 were measured by indirect ELISA's 
using a modification of the techniques developed by Auda et al 1990. These 
modifications were 1) The time of incubation for the samples, biotin-labelled antibodies 
and Avidin-HRP were reduced (5-3, Table 5-1), 2)Pooled sera from 40 individuals to 
construct standard curves to measure the levels of the complement activation products 
in unknown serum samples (5-3, Table 5-1).
Dilutions of samples (Table 5-1) corresponded to the linear part of the standard curves 
and the optical densities were read off the standard curves and the values expressed in 
ng/ml (Figures 5-4 and 5-5). The intra-assay variations of the Cls:Cl-IN H  and C3b-P 
were 12% and 6% respectively (Table 5-2). C ls:Cl-IN H  assay showed a better 
reproducibility since the inter-assay variations (9%) for this assay was 10% lower than 
C3b-P assay (19%) (Table 5-2), For C5b-9 the intra-assay and inter-assay variations 
were not determined.
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Figure 5-4: Standard curves for measuring ClsiClINH (a) and C3b-P (b).
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M easurem ent of serum  C3d levels. An indirect ELI SA's for measuring serum 
C3d levels was developed to assess complement activation by ascribing levels of C3 
breakdown (5-4, Table 5-1, Figure 5-5). The intra-assay and inter-assay variations for 
this assay were 11% and 20% respectively (Table 5-2).
To evaluate whether the presence of intact C3 in serum samples interferes with the C3d 
assay, the conditions of the antibody for measuring C3d were changed (5-5). A larger 
difference between the optical densities (OD) of activated NHS (Contained C3d and 
C3) and the naive NHS (untreated, contained C3) was observed when both trapping 
and detecting antibodies were anti-human C3d (47.5%) (Figure 5-6) and this difference 
was reduced when either trapping or detecting antibodies were changed to anti-human 
C3 (Figure 5-6).
To further overcome the interference of C3 with the C3d measurement, the samples 
were diluted (5-5) and C3d levels was measured as described (5-4). By diluting the 
samples the OD of activated NHS (Contained C3d and C3) did not change, however, 
the OD of the untreated NHS (Contained C3) at the higher dilution of 1/600 showed a 
48% reduction compared to the dilution 1/50 (Figure 5-7a). When these ODs were read 
off the standard curve and multiplied by the dilution factors,.a significant increase in the 
levels of detectable C3d in the activated NHS at the dilution 1/600 compared to the 
dilution 1/50 was observed (87%). By diluting the untreated NHS (Contained C3) no 
significant change in the levels of detectable C3d was observed (Figure 5-7b).
Kinetics of C3d formation during complement activation (By immune complexes) over 
a period of 30 minutes at 37°C was studied and compared to changes in C3 levels (5-
5). The levels of detectable C3d in NHS that contained ICs increased by 5 minutes and 
at 15 minutes reached levels 90% higher than the time. The levels of C3d in the 
untreated NHS did not significantly change during the incubation at 37°C (Figure 5-
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Figure 5-6: Effects of changes in antibody conditions on measurement of free C3d. Free C3d (closed bars) 
trapped with anti-C3d or anti-C3 and detected with biotin conjugated anti-C3d or anti-C3.
(Horizontal values are percentage of differences between sample and control.)
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Intra-assay
Assay No. Mean Median S.D. C.V.
Cls:Cl-INH 9 129 132 16 12%
C3b-P 9 42 43 2.6 6%
Free C3d 4 13200 13200 1469 11%
Bound C3d 6 0.233 0 .2 2 0.04 17%
Inter-assay
Assay No. Mean Median S.D. C.V.
Cls:Cl-INH 5 144.8 140 13.4 9%
C3b-P 5 75.2 80 15 19%
Free C3d 5 14160 13200 3134 22%
Bound C3d 5 0.234 0.23 0.05 23%
Table 5-2: Intra-assay and inter-assay variations of methods employed for measuring 
complement activation products. Cls:Cl-INH, C3b-P value are expressed in ng/ml, free 
C3d in units/ml and erythrocytes bound C3d values are the OD of lysed cell at 405 nm.
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Figure 5-8: Kinetics of changes in the levels of C3d (Figure 4-8a) and C3 (Figure 4-8b) during 
complement activation. The levels of C3d increased by 90% at 15 minutes (a) and C3 levels did not change significantly (b).
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On the other hand the levels of C3 in activated NHS and untreated NHS did not 
significantly change during the incubation at 37°C (Figure 5-8b). The increase in the 
C3d levels and constant levels of C3 during the period of incubation indicate that the 
ELISA system used (5-4) specifically detected C3d and the interference of intact C3 
was minimised by the assay.
D etection of the bound complement components on Erythrocytes by 
m odified ELISA. As described during complement activation the degradation 
product C3d is deposited on the erythrocytes (E's). To detect complement components, 
C3, properdin. Factor B and C3d, bound to erythrocytes a modified ELISA technique 
was developed (5-6).
Erythrocyte-bound C3, properdin and Factor B were trapped in ELISA plate by goat 
anti-human C3, anti-properdin and anti-Factor B and the bound E's were lysed with 
water. The optical densities of lysed cells were measured at 405 nm. All these 
components were detectable on erythrocytes when the levels were compared to controls 
(Figure 5-9). C3 bound to erythrocyte to higher extent (81% higher than control) 
followed by Factor B (43% higher than control) then properdin (20% higher than 
control) (Figure 5-9). The limited use of these detections systems did not warrant 
determination of intra- and inter-assay variations.
Intra-assay and inter-assay variations of erythrocyte-bound C3d by the modified ELISA 
technique were 17% and 23% respectively (Table 5-2). Erythrocytes bearing C3d 
during complement activation were trapped by different concentrations of rabbit anti­
human C3d (from 0.625 pg to 80pg/ml) and the ODs of bound and lysed E's was 
determined (5-6). E's incubated with naive NHS (Absence of ICs) showed little 
binding to anti-C3d on ELISA plate (Figure 5-10). E's incubated with NHS and ICs 
(Activated NHS) showed significant binding to anti-C3d on ELISA and the ODs of
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Figure 5-9: Erythrocytes bound C3, Properdin and Factor B were detected by the modified ELISA.
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Figure S 10: Detecting of erythrocyte bound C3d*by modified ELISA 
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bound and lysed E's was significantly higher than naive E's (p<0.05) (Figure 5-10). 
This peaked with coating concentration of lOpg/ml of rabbit anti-human C3d (78% of 
higher than control) (Figure 5-10). The OD values of lysed cells (Activated NHS) 
correlated with the concentration of coating anti-C3d antibody (r=0.72, p<0.02) 
(Figure 5-10).
Complement activation products during administration of throm bolytic 
therapy. In the group of the 10 patients administered r-tPA there was no statistically 
significant difference in values of Cls:Cl-INH, C3b-P or C5b-9 between pre- and 
post- r-tPA infusion (Time points 5, 30 minutes, then daily until discharge). One 
patient showed an elevation in C5b-9 only at days 2 and 4. At days 3 and 5 the levels 
dropped back to baseline value. All the ten patients administered streptokinase, showed 
an elevation in levels of C ls;C l-lN H  post-therapy compared with the pre-therapy 
levels (Time points 15, 30 and 60 minutes, days 1 and 2, p<0.01) (Figure 5-11). After 
day 1 the levels of C ls:Cl-lN H  returned to pre-therapy levels and remained low until 
discharged (Figure 5-11). Analysis of the individual responses of the three patients 
F.M., C.D., E.M, with elevated levels of anti - streptokinase antibodies, showed that 
they had particularly high levels of generated C ls-Cl-INH post-administration of 
streptokinase (Figures 5-11).
The levels of C ls:Cl-IN H  in the 10 patients given streptokinase correlated inversely 
with the levels of anti-streptokinase antibodies in particular at 2 hours after thrombolytic 
treatment and the day of discharge from the hospital (Table 5-3, Figure 5-12). 60%, 
20%, 10% and 60% of the patients showed a negative correlation with the levels of 
IgG, IgA, IgM and neutralising anti-streptokinase at 2 hours respectively, this was 
90%, 20%, 30% and 80% at day of discharge (Table 5-3, Figure 5-12).
Only one patient (F.M.) had levels of C3b-P and C5b-9 which increased substantially 
post-administration of streptokinase (Figure 5-13). The pattern of increased followed 
Cls:Cl-lNH and returned to base-line levels at day 1 (Figure 5-13). The other 9
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Figure 5-11: Ructuations of Cls:Cl-INH in 10 patients with AMI treated with streptokinase.
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IgG IgA IgM
Patient 30 min 2 hours 30 min 2 hours 30 min 2 hours 30 min 2 hours
FM -0.7
(p<0.004)
- 0.34 
(N.S)
-0.73
(p<0.002)
- 0.64 
(p<0.04)
-0.08
(K S j
0.35
(N.S.)
-0.88
(txO.OOl)
- 0.7
(p<0.02)
EM -0.5
(îxO.08)
- 0.66 
_(2<a04)
-0.46
(N.S.)
- 0.42 
(NS)
0.12
OKSj
-0.4
(NS)
- 0.65 
(1X0.01)
- 0.50 
(NS)
CD - 0.71
(p<0.02)
- 0.71
(p<0.02)
- 0.77 
(rxO.oi)
- 0.77
(p<0.01)
-0.66
(N.S.)
-0.66
(N.S.)
- 0.80 
(p<0.006)
- 0.80 
(1x 0.006)
M G - 0.79
(p<0.001)
- 0.65 
(p<0.04)
0.28
(N.S.
- 0.35 
(N.S.)
0.001
(N.S.
-0.17
(N.S.)
-0.38
(N.S.)
- 0.52 
(N.S.)
LC - 0.70 
(rxO.oi)
-0.61
(p<0.06)
-0.30 
.. (N.S.)
- 0.1 
(N.S.)
- 0.65 
(lxO.03)
- 0.57 
(txO.08)
- 0.85 
(1x 0.001)
- 0.85 
(1x 0.001)
JM - 0.56 
(txO.03)
-0.12
(N.S.)
0.13
(N.S.)
- 0.01 
(N.S.)
0.53
(N.S.)
0.2
(N.S.)
- 0.24 
(N.S.
- 0.47 
(N.S.)
JS -0.55
(P<0.04)
- 0.52 
(N.S.)
0.001 
_ _(N.S.)
0.06
(N.S.)
- 0.15 
(N.S.)
- 0.14 
(N.S.)
- 0.84 
(ixO.OOl)
- 0.84
(1x 0.001)
AM - 0.6 
(P<0.008)
- 0.40 0.31
(N,S.)
0.33
(N.S.)
0.12
04SJ
- 0.03 
(N.S.)
- 0.48 
(1x 0.06)
- 0.54 
(N.S.)
HM - 0.78 
(p<0.005)
- 0.70
(p<0.02)
0.03
_ O tS j
- 0.18 
_(N.S.)
- 0.11 - 0.18 
(N.S.)
- 0.84 
(ixO.OOl)
- 0.84 
(1x 0.001)
MA - 0.68 
(p<0.02)
- 0.59 
(tx0.07)
- 0.45 - 0.32 
(N.S.)
0.44 
_ (N S .)...
, 0.36 
(N.S.)
- 0.86 
(p<0.001
- 0.86 
(1x 0 .001)
ASK
Table 5-3: Con'elation between, the levels of anti-streptokinase antibodies and generated levels 
of C ls:Cl-IN H  in 10 AMI patients treated with streptokinase (during the first two hours of 
treatment).
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Figure 5-12; Mean values nuctuations of Cls:Cl-INH and anti-streptokinase antibodies in
10 AMI patients treated with streptokinase.
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Figure 5-13; Complement activation products (ng/ml) during streptokinase treatment (Patient P.M.).
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patients had very low or undetectable levels of C3b-P and C5b-9, and these were not 
significantly different from pre-therapy values.
As described of 10 patients treated with streptokinase, 5 had early reperfusion, 3 had 
late reperfusion and 2 did not reperfused (Chapter 3, Table 3-4). The levels of 
generated C3b-P during streptokinase administration in ten patients treated with 
streptokinase did not show any difference in early, late and non reperfusion groups 
(mean values at two hour, 2.2 ng/ml, 2.66 ng/ml and 2 ng/ml respectively). However, 
the levels of generated Cls:Cl-INH were higher in late (mean value=49,66 ng/ml) and 
non-reperfused groups (mean value=28.5 ng/ml) compared with early reperfused group 
(mean value=16.6 ng/ml).
Dose and kinetics of streptokinase on the complement activation. NHS
was prepared from ten normal individuals to study the effect of different doses and the 
kinetics of streptokinase alone on the complement activation (5-8). All of these normal 
individuals had levels of anti-streptokinase antibodies which fell within the normal 
ranges (Table 3-2), the mean values for IgG, IgA, IgM and neutralising anti­
streptokinase antibodies in this group being 8.1 units/ml, 4.5 units/ml, 3.25 units/ml 
and 16,25 units/ml respectively. The effects observed could be considered due only to 
streptokinase and not ICs.
Streptokinase was added at concentrations of 66 (xg/ml, 133 pg/ml and 333 pg/mi to 
NHS and incubated at 37°C (Therapeutic dose = 100 pg/ml). Streptokinase at 
concentration 66 pg/ml did not generate significant levels of CIs:Cl-INH at any time 
points when compared with the controls (Table 5-4, Figure 5 -14a). However, 
streptokinase at concentrations 133 pg/ml and 333 pg/ml generated significant levels of 
C ls:Cl-INH (p<0.05, time points 15 and 30 minutes, Table 5-4, Figure 5 -14a).
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Minutes Cls:Cl-INH C3b-P
0 79 (NS) 67 (NS)
5 51 (NS) 54 (NS)
15 31 (NS) 26 (NS)
30 29 (NS) 8.5 (P<0.05)
Minutes C ls:CM N H C3b-P
0 83 (NS) 64 (NS)
5 59 (NS) 52 (NS)
15 15 (P<0.05) 21 (P<0.05)
30 14 (P<0.05) 8 (P<0.05)
Minutes Cls:Cl-INH C3b~P
0 80 (NS) 60 (NS)
5 29 (NS) 25 (NS)
15 7 (P<0.05) 20 (P<0.05)
30 7,5 (P<0.05) 8 (P<0,05)
Table 5-4: The significance of generated levels of Cls:Cl-INH and C3b-P by 66 pg/ml (a), 
133 fxg/mi (b) and 333 pg/ml (c) streptokinase compared to controls at different time points 
incubation at 37°C in 10 normal individuals (Therapeutic dose =100 fxg/ml). (Mann- 
Whitney test, the first values are U values, tabulated U value for a group of 10 samples for 
the probability of 5% is 3-23),
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Figure 5-14: Study the effects of different doses and the kinetics of streptokinase on 
Cls:Cl-INH (a) and C3b-P (b) in 10 normal individuals. Therapeutic dose= lOOug/ml.
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Streptokinase at concentration 66 pg/ml generate significant levels of C3b-P at 30 
minutes when compared with controls (Table 5-4, Figure 5-14b). Streptokinase at 
concentrations 133 pg/ml and 333 pg/ml generated significant levels of C3b-P 
(p<0.05, time points 15 and 30 minutes. Table 5-4, Figure 5 -14b).
There was no significant difference in the levels of complement activation products 
generated by different concentrations of streptokinase (Figure 5-14). The levels of 
C ls:Cl-IN H  at time points 0 in samples contained streptokinase were lower than the 
control levels (Figure 4-14a).
The extent of Cls:Cl-INH and C3b-P generation in the ten individuals did not correlate 
with the levels of anti-streptokinase antibodies (Table 5-5), however, using 
streptokinase at concentrations below the therapeutic dose (66 pg/mi) generated levels 
of complement activation products showed a weak correlation with the levels of IgG 
anti-streptokinase antibodies (Time points 5, 15 and 30 minutes) but did not correlate 
with the levels of IgA, IgM and neutralising anti-streptokinase antibodies (Table 5-5). 
With streptokinase concentrations beyond the therapeutic levels (25 pg/ml to 7500 
pg/ml streptokinase, therapeutic dose = lOOpg/ml, 5-8) the levels of Cls:Cl-INH were 
maximum with streptokinase at 62.5pg/ml (37% higher than control) and beyond that 
concentration the levels of C ls:Cl-INH did not change significantly (Figure 5-15). 
C3b-P levels were maximum at concentration of 500 pg/ml of streptokinase (58% 
higher than control) and then decrease to values that were 14-35% higher than control 
level (Figure 5-15).
The effect o f streptokinase and thvrogiobulin immune com plexes on 
complement activation. Preformed and nascent immune complexes were prepared 
to study the in vitro effects of immune complexes on the complement activation (5-2 
and 5-9).
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Figure 5-16: Classical pathway activation by preformed and nascent rabbit streptokinase immune complexes at antigen excess, equivalence and antibody excess.
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Figure 5-17; Alternative pathway activation by preformed and nascent rabbit anti-streptokinase
immune complexes at antigen excess, equivalence and antibody excess.
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Figure 5-18: The effect of preformed human streptokinase immune complexes 
on the classical (a) and alternative (b) pathways at 5 minutes incubation at 37oC.
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The effect of rabbit thyrogiobulin immune complexes (preformed and nascent) at 
equivalence, antigen excess or antibody excess on complement activation were studied. 
Rabbit thyrogiobulin (preformed and nascent) immune complexes at equivalence, 
antigen excess and antibody excess caused detectable levels of Cls;Cl-INH and C3b-P 
by 5 minutes when compared to the controls (Figures 5-19 and 5-20).
The levels and the rate of Cls:Cl-INH generation was higher with nascent immune 
complexes than preformed immune complexes (Figures 5-19). On the other hand, the 
levels and the rate of C3b-P generation was higher with preformed immune complexes 
compared to nascent immune complexes (Figures 5-20).
Both preformed and nascent thyrogiobulin immune complexes at antigen excess 
generated higher levels of Cls:Cl-INH and C3b-P than antibody excess (Figures 5-19 
and 5-20).
The levels of complement activation products in absence of activating factors (Antigens, 
antibodies or ICs) at 37 °C were used as control throughout the experiments and did 
not increase significantly during the incubation periods.
NHS treated with EDTA or Mg++, EOT A was incubated with immune complexes at 
37°C and complement activation products were measured (5-9). EDTA caused a 
significant reduction in the levels of generated Cls:Cl-INH and C3b-P by preformed 
human streptokinase ICs at equivalence (Figure 5-21). On the other hand, EOT A which 
also decreased significantly the levels of Cls:Cl-INH, had no significant effect on the 
levels of C3b-P generated by the ICs (Figure 5-21).
The effect of EDTA and EGTA on inhibition of complement activation products
î'
generated by preformed rabbit streptokinase immune complexes and rabbit I
thyrogiobulin at equivalence were comparable with the human streptokinase immune 
complexes (Figure 5-22). EDTA inhibited the generation of Cls:Cl-INH and C3b-P in 
all the immune complexes (Figure 5-22). EGTA inhibited the generation of ClsrCl-
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Figure 5-19: The effect of preformed and nascent thyroglobulin immune complexes on 
the classical pathway activation, at antigen excess, equivalence and antibody excess.
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Figure 5-20; The effect of preformed and nascent thyroglobulin immune complexes on thealternative pathway activation, at antigen excess, equivalence and antibody excess.
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Figure 5-22: The effect of EDTA and EGTA on the complement activation products generated by
streptokinase immune complexes (human and rabbit) and thyroglobulin immune complexes. '  ^gg
INH in all the immune complexes (Figure 5-22a) however, it only inhibited the 
generation of C3b-P by thyroglobulin immune complexes (Figure 5-22b) and had no 
effect on the generated levels of C3b-P by human or rabbit streptokinase immune 
complexes (Figure 5-22b).
The effect of erythrocytes on complement activation. The effects of 
erythrocytes were studied as they may influence the levels of generated complement 
activation products, through the action of CRl or acting as a surface to which these 
products are deposited on them.
a) The effect of erythrocytes: The levels of C ls:Cl-ÎNH and C3b-P generated by 
nascent thyroglobulin immune complexes (ICs) and preformed human streptokinase 
ICs at equivalence, in presence and absence of ei-ythrocytes (E's) were studied (5-10). 
Only preformed streptokinase ICs were used due to limitation of anti-streptokinase anti­
sera from human source. The levels of Cls:Cl-INH, C3b-P and free C3d generated by 
preformed rabbit streptokinase ICs at equivalence were also studied in presence and 
absence of E's (5-10).
In the absence of E's Cls:Cl-INH and C3b-P were generated by all these ICs and free 
C3d by rabbit streptokinase ICs (Figures 5-21, 5-23, 5-24 and 5-25).
Erythrocytes had no significant effect on the levels of Cls:Cl-INH generated by all 
these immune complexes when compared with the levels in absence of E's (Figures 5- 
21a, 5-23a and 5-25a).
Erythrocytes had no significant effect on the levels of free C3d generated by rabbit 
streptokinase immune complexes (Figure 5-24).
In the presence of erythrocytes, there was a substantially reduction in rate and extent of 
C3b-P generation by rabbit streptokinase ICs (79% reduction at 5 minutes compared to 
ICs in absence of E's) (Figure 5-23b). The presence of erythrocytes also caused a
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reduction (48%) in the levels of C3b-P generated by human streptokinase ICs at 5 
minutes (Figure 5-2lb). The levels of C3b-P generated by thyroglobulin ICs in 
presence of E’s was also decreased at all time points of the incubation period (Figure 5- 
25b). When comparing the response of the two types of ICs, thyroglobulin ICs 
showed substantial reduction at all time points (Figure 5-25b), however, when 
streptokinase ICs were studied the reduction of C3b-P in presence of E's was at 5 
minutes after which levels approach those of ICs alone (Figure 5-23b). The lower 
amount of C3b-P generated by nascent thyroglobulin compared to preformed 
streptokinase ICs may account for the observed differences.
b) The effect of CRl receptors: To study the effect of the CRl receptors on the levels of 
complement activation products generated by rabbit streptokinase ICs, levels were 
measured in the presence of erythrocytes treated with monoclonal anti-CRl (5-10).At 5 
minutes there was no different in the levels of C ls:Cl-INH in presence of E's or E's 
treated with anti-CRl (E-CRl) (Figure 5-23a). E-CRl at 15 minutes increased the 
levels of Cls:Cl-INH by 33% compared to the levels in the presence or absence of E's 
(Figure 5-23a).
Use of preformed rabbit streptokinase ICs has already shown that E's reduced 
substantially C3b-P levels at earlier time points compared to the levels in the absence of 
E's (Figure 5-23b). At 5 minutes the effect of E's was reversed by E-CRl and the 
levels of C3b-P increased to the levels equal to the levels of C3b-P observed in absence 
of E's (Figure 5-23b).
The presence of anti-CRl did not influence the levels of free or erythrocyte bound C3d 
(Figure 5-24).
The effect of plasmin on the levels of complement activation products.
Streptokinase can initiate complement activation by two mechanisms, through 
plasminogen activation and generation of plasmin and by immune complexes formation
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(1-10). Plasmin can also interact with complement components (See introduction) and 
therefore may influence the detectable levels of complement activation products. These 
effects were studied (5-11).
The direct effect of plasmin on generated levels of complement activation products was 
studied using nascent rabbit thyroglobulin immune complexes at equivalence (5-11). 
Streptokinase ICs were not used as streptokinase has potential effects on serum. Serial 
amounts of plasmin (from 4pg to 256pg) were added to a constant amount of 
thyroglobulin ICs and NHS, after a 30 minutes incubation at 37°C the complement 
activation products were measured (5-3).
The presence of 4 p,g plasmin increased significantly the levels of C ls:Cl-IN H  and 
C3b-P generated by the ICs. The levels of Cls:Cl-INH and C3b-P in presence of 32 
|xg plasmin were highest, bien g 88% and 45% higher than the levels of ICs alone 
respectively (Figure 5-26).
The levels of Cls:Cl-INH and C3b-P then began to decrease and in the presence of 
128 fig plasmin reached to their lowest levels and did not rise again (Figure 5- 
26).Controls: The mixtures of 256 fig plasmin + NHS, NHS alone and thyroglobulin 
ICs + NHS at 30 minutes in 37°C for were used as controls. The mixture of 256 fig 
plasmin and NHS generated levels of Cls:ClINH that were marginally (19%) greater 
than NHS alone (336 ng/ml generated by plasmin and 272 ng/ml generated by NHS 
alone). The mixture of 256 fig plasmin and NHS did not generate C3b-P when 
compared with the levels of NHS alone (3 ng/ml generated by both mixtures).
To study the indirect effect of streptokinase through generation of plasmin on the levels 
of complement activation products generated by thyroglobulin immune complexes, 
serial amount of streptokinase from 50 jig/ml to 400 fig/ml (Therapeutic dose = 66-100 
fig/ml) were added to a constant amount of the ICs and NHS. The mixtures were 
incubated at 37°C and complement activation products were measured at 0, 5 15 and 30 
minutes.
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The presence of streptokinase decreased the levels of Cls:Cl-INH generated by the ICs 
at 15 and 30 minutes compared with the ICs alone (Figure 5-27a). Streptokinase at 
therapeutic doses (50-100 pg/ml) reduced the levels of Cls:Cl-INH to a greater extent 
at 30 minutes when compared with the ICs alone (Figure 4-27a, 50 p,g/ml streptokinase 
caused 57% reduction, 100 pg/ml =54% reduction, 200 pg/ml= 35% reduction and 
400_pg/ml =30% reduction ). This reduction was optimal with the lowest streptokinase 
concentrations (Figure 5-27a).
The presence of streptokinase had no effect on the levels of C3b-P generated by the ICs 
compared with the ICs alone (Figure 5-27b).
Discussion
In chapter 3, one patient with elevated levels of pre-existing anti-streptokinase 
antibodies who received streptokinase, developed an adverse immunological reaction. 
There was also a relationship between poor reperfusion and elevated levels of anti­
streptokinase antibodies. However, from that study it was not clear why elevated levels 
of anti-streptokinase antibodies was not always accompanied by such difficulties. Since ■'I
4rr':
complement system has a central role in processing immune complexes and preventing 
tissue damage a study of the interactions of the complement system and immune 
complexes was important to approach this question (1-8). The first study to mention the 
effect of streptokinase on the complement system was in the early 1970's (Spottl 7& 
Mosuni 1974), and despite the increasing use of this thrombolytic agent in particular in 
patients with AMI, there are only few studies about complement recruitment in 
streptokinase therapy or r-t-PA
The levels of individual complement components i.e. C3 and C4 may not provide a 
precise evaluation of ongoing complement activation since these components are over­
produced to balance the components used during illness and the levels are often normal
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or even elevated (Auda et al 1990). Measurement of complement activation products 
therefore provides a better judgement of ongoing complement activation and hence the 
technique introduced by Auda et al (1990) with some modifications was used to 
measure the levels of Cls:Cl-INH, C3b-P and C5b-9 complexes. In this technique by 
employing two antibodies that recognise different components of the complexes the 
intact complement components are not recognised in the assays (5-3).
The C3b-P assay used showed a better sensitivity than Cls:Cl-IN H  assay (Table 5-2) 
which was in agreement with the results of Auda et al 1990. On the other hand, 
C ls:Cl-IN H  assay showed a better reproducibility (Table 5-2), there is no report for 
inter-assay variations of Cls:Cl-INH and C3b-P by Auda et al 1990.
Serum C3d levels, the final degradation product of C3b by Factor I, reflects ongoing 
complement activation. Rocket immunoassay and ELISA techniques have been 
employed to measure the serum C3d levels (Mollnes 1985, Freysdottir et al 1993). In 
this chapter an indirect ELI SA'for measuring serum C3d levels was developed (5-4). 
Preliminary laboratory investigations have indicated that ELISA's are more sensitive 
than agar techniques (data not shown).
Intact C3 present in serum samples cross-reacts with the rabbit anti-human C3d (Figure
5-6) used in ELISA system, however, this interference was minimised by diluting the 
samples to 1/600. The kinetics of C3 and C3d during complement activation at this 
dilution showed that the levels of C3d increased significantly during complement 
activation but the levels of C3 did not change (Figure 5-8). The increase of the C3d 
levels and constant levels of C3 in the period of complement activation validated that the 
ELISA system used specifically detects C3d and the interference of intact C3 was 
minimised. The intra-assay and inter-assay variations for this technique were 11% and 
20% respectively (Table 5-2).
206
"I
The levels of complement activation products in 20 patients treated with thrombolytic 
agents were studied in conjunction with Dr.E.Holme University Department of 
Immunology, Western Infirmary, Glasgow. Patients treated with r-tPA did not generate 
C ls;C l-IN H , C3b-P or C5b-9, The activation of complement system after r-tPA 
administration has been previously reported, Agostoni et al 1994, measuring 
anaphylatoxins C4a and C3a by RIA showed that the extent of this activation is 
substantially lower than streptokinase. Complement activation in AMI patients 
following r-tPA administration is thought to be the effect of conversion of plasminogen 
to plasmin (Munkuvad 1993).
All the ten patients administered streptokinase generated C ls;Cl-IN H  within the 2 
hours of treatment (p<0.01) and only one patient (P.M.) had increased levels of C3b-P 
and C5b-9. The significant correlation between C ls:Cl-INH, IgG, IgA levels and 
neutralising antibodies clearly indicates the activation of the classical pathway by
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During complement activation degradation products are deposited on the erythrocytes. 
To detect erythrocyte-bound C3d a modified ELISA technique was developed to 
evaluate the relationship of bound C3d and the levels of free complement components 
(5-6).
The modified ELISA during complement activation by ICs showed that C3, properdin, 
Factor B and C3d were deposited on erythrocytes (Figures 5-9 and 5-10), the 
deposition of these components can be explained by direct binding to the surfaces that 
erythrocytes provide and also by indirect binding through incorporation into the ICs 
which bind to E-CRl via IC bound C3b.
The modified ELISA for detecting the levels of bound C3d on erythrocytes showed a 
high C.V. for intra- and inter-assay variations (Table 5-2). This can be explained by the 
ease, with which erythrocytes easily precipitate in test tubes and therefore the number 
of cells during transferring from test tubes to ELISA plate is not highly reproducible.
streptokinase immune complexes formed during treatment (Figures 5-11 and 5-12), It 
was not surprising that the levels of generated Cls:Cl-INH were higher in the group of 
patients who poorly responded to streptokinase treatment (Late reperfusion or non 
reperfusion, 5-7) since the levels of anti-streptokinase antibodies in these patients were 
higher than patients who reperfused within 2 hours of treatment. In ten patients treated 
with streptokinase, one patient (CD with elevated levels of IgG, IgA and CIs:Cl-INH) 
had an adverse reaction to streptokinase. Patient EM also had both elevated IgG anti- 
streptokinase and C ls:C l-IN H  but did not respond adversely to streptokinase 
administration.
Freydottir et al (1993), analysed the extent of complement activation in patients 
administered streptokinase. As seen in our patients administered streptokinase, highest 
levels of complement activation as assessed by production of C3d occurred in those 
individuals with highest levels of antibodies to the administered streptokinase. The 
results of Freydottir et al (1993) and this study suggest that the presence of pre-existing 
antibodies to streptokinase results in the formation of immune complexes (ICs) and 
significant turnover of the classical pathway occurs. Despite this however, very little if 
any recruitment of alternative pathway (C3bP formation) and membrane attack complex 
(MAC) occurred in vivo. This observation is supported by similar results observed by 
in vitro experiments performed with rabbit streptokinase immune complexes (Figures
5-16, 5-17, 5-18, 5-21, 5-22 and 5-23).
The effects of the antigen alone (Streptokinase) was investigated. In vitro studies with 
streptokinase at a range of concentrations covering the therapeutic dose, showed that 
streptokinase at therapeutic dose (100 M-g/ml) could generate significant levels of 
C ls:C l-IN H  and C3b-P (Figure 5-14). The extent of C ls:C l-IN H  and C3b-P 
generation in all the ten normal individuals studied did not correlate with the levels of 
anti-streptokinase antibodies, indicating that the effect of streptokinase alone was not 
due to immune complex formation (Table 5-5).(l-10).These studies also showed that
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levels of CIs:Cl-INH generated are optimal at therapeutic doses (Figure 5-14), whilst 
C3b-P generation is optimal beyond therapeutic dose (Figures 5-14 and 5-15) as 
beyond the 500 pg/ml streptokinase, the levels of Cls:Cl-INH remained constant but 
C3b-P decreased to levels correspond to control levels (Figure 5-15) this can be 
account for the effect of generation of plasmin and dissociation of C3b-P by proteolytic 
effect of plasmin.
Plasmin is thought to activate the complement system in two ways, firstly, plasmin like 
trypsin and kallikrein can activate C ls in absence of immune complexes and secondly it 
can activate the alternative pathway by acting as Factor D and degrading Factor B (1-0). 
Generation of plasmin therefore may influence the detectable levels of complement 
activation products not only by activation of the pathways (1-0) but also by dissociation 
of complement activation products through the proteolytic effect.
As streptokinase alone does influence Cls:Cl-INH and C3b-P formation in vitro, the 
in vitro effects in the presence of immune complexes was studied. For this study 
thyroglobulin ICs were chosen as thyroglobulin IC does not interfere with clotting 
systems. Streptokinase when added to the ICs reduced C ls:C l-IN H  generation by 
thyroglobulin ICs, optimal reduction observed with the therapeutic dose (50-100 
jLig/ml) (Figure 5-27). Streptokinase had no effect on C3b-P generation by 
thyroglobulin ICs.
On the other hand, the presence of low concentrations of plasmin (From 4fxg to 32|xg) 
increased significantly the levels of complement activation products (Cls:Cl-INH and 
C3b-P) generated by rabbit thyroglobulin ICs (Figure 5-26). However, the larger 
concentrations of plasmin (From 64p,g) reduced the levels of generated complement 
activation products by rabbit thyroglobulin ICs (Figure 5-26). The effects of 256 [ig 
plasmin alone (Used in this experiment as control) confirmed the activation of the 
classical pathway (336 ng/ml generated by plasmin compared to 272 ng/ml generated
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by NHS alone) but not the alternative pathway (5-11), however, a range of plasmin 
concentrations should be examined to evaluate the in vitro effect of plasmin.
Both streptokinase and plasmin influenced the levels of C1:C1-INH and C3b-P 
generated by thyroglobulin ICs, although the pattern of changes did not follow each 
another, this can be explained by the different concentration of plasmin presented in 
these experiments.
In our patients group r-tPA did not activate the complement system in spite of the fact 
that this thrombolytic agent activates plasminogen which results in generation of 
plasmin. However, in patients treated with streptokinase the activation of both 
pathways occurred and in vitro studies showed that complement activation by immune 
complexes is enhanced in the presence of plasmin (Figure 5-26), therefore, formation 
of ICs and generation of plasmin together has amplified the complement response in 
the patients treated with streptokinase.
The in vitro study of rabbit streptokinase ICs on complement activation showed that 
preformed immune complexes generate higher levels of complement activation products 
than nascent ICs (Figures 5-16 and 5-17). Streptokinase immune complexes (Rabbit 
and human) at antigen excess activated the classical pathway to a higher extent than 
antibody excess. This was reversed for the alternative pathway activation as determined 
by the generated levels of C3b-P (Figures 5-16 and 5-18).
In contrast to the streptokinase ICs, nascent thyrogobulin immune complexes generated 
higher levels of C ls:C l-IN H  than preformed immune complexes. This can be 
explained by the huge size of thyroglobulin ICs which precipitated in the test tube 
during the preparation of preformed immune complexes and decrease the immune 
complexes available for classical pathway activation (Figure 5-19 and 5-20). The 
preformed thyroglobulin immune complexes generated higher levels of C3b-P than the 
nascent immune complexes. In contrast to streptokinase ICs there was no difference for 
optimal generation of C ls:C l-IN H  or C3b-P and both preformed and nascent
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thyroglobulin ICs at antigen excess generated higher levels than antibody excess 
(Figures 5-19 and 5-20).
The presence of EGTA had no effect on the levels of C3b-P generated by rabbit and 
human streptokinase ICs although it inhibited alternative pathway activation by rabbit 
thyroglobulin ICs (Figure 5-22).
As described erythrocytes may influence the levels of complement activation products 
(1-7). The presence of erythrocytes did not influence the levels of generated C ls:C l- 
INH and free C3d generated by rabbit streptokinase ICs. In the presence of 
erythrocytes the levels of C3b-P decreased and this effect was reversed by blocking 
C R l, this effect was optimal at 5 minutes, and was only partially reversed at 15 
minutes (Figure 5-23). This is probably due to the increased production of C3b-P at 15 
minutes together with insufficient concentration or specificity of anti-CRl to block 
completely the CRl receptors, as according to the manufacturer anti-CRl antibodies are 
raised against podocytes (Figure 5-23).
The role of CRl (CD35) on E's in the reduction of the levels C3b-P is through two 
mechanisms: 1) The clusters of CRl on E's bind to C3b bound to the ICs and reduce 
the detectable levels. 2) CRl participates in the degradation of C3b by serving as a 
cofactor for factor I, preventing further C3bBbP formation. The role of CRl in the 
reduction of C3b-P may account for the inability to detect elevated levels of C3b-P in 
patients treated with streptokinase.
The presence of E's treated with anti-CRl increased the levels of C ls:Cl-IN H , this 
increase in the level of classical pathway activation reflects the effect of newly formed 
ICs (CRl and anti-CRl) on the complement system.
This study showed that erythrocytes do not modulate significantly free and bound C3d 
or Cls:Cl-INH levels, but exert an influence on C3b-P through the actions of CRl on 
erythrocytes. This data suggest that C3b-P levels may not provide a reliable clinical 
marker of ongoing complement activation.
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Chapter 6 
Immune complexes and erythrocytes interactions 
Introduction
Formation of immune complexes is an important physiological process in humoral 
defence to eliminate foreign materials. Immune complexes deposited outside the 
reticuloendothelial system can initiate adverse inflammatory reactions and tissue 
damage. The destination of immune complexes is determined by several factors such as 
size of immune complexes, the nature and amount of antigen, the ratio of 
antigen/antibody and finally the effect of complement on the immune complexes (1-8).
The complement system has a central role in preventing tissue damage by promoting 
clearance of immune complexes and preventing the precipitation of immune complexes
outside the reticuloendothelial system (1-8). Immune complexes coated with C3b can 
bind to complement receptor CRl, predominant in the circulation, and be cleared from 
circulation and be disposed in the reticuloendothelial system. The binding of immune 
complexes to erythrocytes is influenced by the size and nature of immune complexes 
and the iso type of antibodies which participated in the immune complexes lattice 
(Schifferli & Peters 1986). This binding also correlates with the number of CRl 
present on the erythrocytes which is governed by both environmental and genetic 
factors (Davies & Walport 1989, Holme et al 1986, Fyfe et al 1987).
By studying the levels of anti-streptokinase antibodies (Chapter 3) and the effects of the 
streptokinase immune complexes on the activation of the complement system (Chapter 
5), it has been demonstrated that pre-existing anti-streptokinase antibodies in patients 
given streptokinase results in immune complexes formation and complement activation.
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However, elevated levels of anti-streptokinase antibodies in these patients did not 
always provoke hypersensitivity reactions.
In this chapter the binding of streptokinase immune complexes and complement 
activation products to erythrocytes is investigated. The techniques of flow cytometry 
and development of modified ELISA allowed investigation of such binding. The aim 
was* to analyse whether differential handling of ICs may allow for variable reactions to 
streptokinase. Kinetics and dose response of streptokinase and thyroglobulin immune 
complexes binding to erythrocytes were studied and compared with each other. The 
relationship between free and bound complement activation products with the levels of 
bound immune complexes on erythrocytes was studied.
The binding of streptokinase ICs to erythrocytes during streptokinase administration in 
patients with AMI together with the extent of complement activation and levels of anti- 
streptokinase antibodies in these patients was examined.
■iS
Materials and methods
6-1 Preparation of erythrocytes. Blood was obtained from healthy volunteers in 
heparin or EDTA and was spun at 1200 rpm, at 4°C for 10 minutes (2-16). The buffy 
coat layer was completely removed and the cells were washed three times with 1% BSA 
in PBS and resuspended in the same buffer. The cells were then standardised (2-17).
6-2 Preparation of NHS. Blood was obtained from healthy volunteers. The blood 
was incubated in glass tubes at 37°C for 30 minutes (to allow clot formation) followed 
by 30 minutes incubation at 4°C (to allow clot retraction). Aliquots were stored at 
-7CPC and used within ten days.
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6-4 Flow cytom etry assays (FACscan. fluorescence-activated  cel l  
sorting). Flow cytometry is a technique for rapid analysis of particles or cells using a 
laser source or arc lamp. Using fluorescence and light scatter of the cells that flow 
through a flow stream, multiple cellular parameters i.e. cell markers can be measured
fluorescent dyes excited. The scattered and fluorescent light generated by the cells is 
collected by photodetectors and is converted to electronic signals.
6-3 Preparation of immune complexes. Preformed streptokinase im m une 
complexes (Rabbit and human) and nascent thyroglobulin immune complexes were 
prepared at equivalence (5-2, 5-9). The equivalence point for rabbit streptokinase si
immune complexes was 10 pig streptokinase and 1300 pig IgG, for human «j
streptokinase immune complexes was 10 pig streptokinase and 287.5 pig IgG and for 
rabbit thyroglobulin immune complexes was 10 pig thyroglobulin and 100 pig IgG (5- 
2).
and subpopulations of the cells can be distinguished. The cells that pass through a 
detection point (Illuminating beam) are illuminated by the light source and their
JÎ
A forward lens collects forward scattered light in a forward optical path and conducts it 
towards a forward detector. By using a set of mirrors and absorption filters that are 
placed at 45 degrees to the illuminating beam, different wavelengths are separated. The 
first mirror in the side angle optical path to the laser beam reflects wavelengths shorter 
than 500 nm towards the side angle scatter detector, a second mirror reflects 
wavelengths greater than 560 nm towards a 578nm bandpass filter and phycoerythrin 
(PE) fluorescence detector and finally the wavelengths between 550 and 560 nm, pass 
through a 530 nm filter and fluorescein isothiocyanate (FITC) fluorescence detector. 
This allows the specific measuring of the scattered (Forward and side) and 
fluorescence.
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%These signals (scatter and fluorescence) are processed in the detectors to a voltage 
which is then translated into a discrete scale by the analogue-to-digital converter (ADC). 
Finally the results are presented as graphs and statistical data by computer software 
package (i.e. Lysis II). Scattered light is usually proportional to the size of the cells 
(Ormerod 1994).
The common forms for displaying the results are frequency histograms and dual 
parameter correlated plots (Known as cytograms or dot plots). The frequency 
histogram is a graph that presents the number of events occurring for each channel of 
the ADC and counts intensity of fluorescence, forward light scatter or side angle light 
scatter of the cell population. The dot plot is a two-dimensional display of the frequency 
histogram of one set of ADC channels against the second set (i.e. forward light scatter 
channels against side angle light scatter channels or forward light scatter against 
fluorescence intensity channels, etc.). Using the computer programs, markers and gates 
(windows) can be set at specific channels of the histograms and selected areas of 
interest to obtain percentage of total, mean, median and other statistical data of the 
examined population.
All flow cytometry analyses was performed on a Beckton Dickinson flow cy to meter
'i-that allowed measurement of both scattered light and fluorescence intensity of the 
populations. 5000 erythrocytes were analysed using the Lysis II software package. A 
setting was used to study the homogeneous erythrocyte (E's) population and the 
homogeneity of the E's was checked by the forward scatter against side scatter dot 
plots. By this setting erythrocytes were differentiated from debris (very small particles), 
aggregates (very large particles) and contaminating white cells. As described the 
fluorescent intensity of the cell population under analysis can be expressed by median 
fluorescent channel number (MFCN) or mean fluorescence intensity. However, 
skewed distributions can not to be compared by the parametric values, therefore, an
215
appropriate control for each experiment was used to assess the accuracy and specificity 
of each measurement. Then a gate on the control was set on a log scale fluorescence 
intensity histogram to determine the percentage of erythrocytes in samples bearing 
fluorescence above this value.
To study and analyse the binding of immune complexes to erythrocytes a flow 
cytometric assay was developed to detect bound immune complexes on the 
erythrocytes. Erythrocytes were incubated with normal human serum (NHS) in the 
presence and absence (Control) of immune complexes at 37°C, The reaction was 
stopped at different time points by EDTA. The supernatants were removed and studied 
for the presence free complement activation products and the erythrocytes were studied 
for the bound ICs and complement activation products using FITC conjugated 
antibodies. The antibodies used for detecting erythrocyte bound ICs and complement 
activation products were: FITC conjugated donkey anti-rabbit IgG, FITC conjugated 
rabbit anti-human C3c, FITC conjugated rabbit anti-human C3d, FITC conjugated 
sheep anti-mouse IgG, FITC conjugated sheep anti-human IgG, FITC conjugated 
sheep anti-human IgA, FITC conjugated sheep anti-human IgM.
6-5 Dose response of rabbit streptokinase and thyroglobulin i m m u n e  
complexes binding to erythrocytes. Dose response of rabbit streptokinase and 
thyroglobulin immune complexes binding to erythrocytes was studied. Free 
complement activation products C ls:Cl-INH and C3b-P in the supernatants were 
measured to study the relationship between the ICs binding and the extent of the 
complement activation.
Materials: Sources of materials used here are described in 2-1.
FITC conjugated donkey anti-rabbit IgG 
NHS
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Human Erythrocytes 
Falcon round-bottomed tubes 
Antigens: Streptokinase, bovine thyroglobulin
Antibodies: Rabbit IgG anti-streptokinase, rabbit IgG anti-bovine thyroglobulin (5-2) 
Buffers
Filtered phosphate buffered saline (PBS)
1% BSA in PBS 
20 mM isotonic EDTA (2-2)
ELISA buffers (5-3)
Method. Increasing amount of immune complexes at equivalence (5-2) (for rabbit 
streptokinase preformed ICs from 81.87pg to 1310 fxg ICs and for rabbit 
thyroglobulin nascent ICs from 0.85p,g to 110 fxg ICs) were added to 100 |xl NHS and 
20 p,l of packed erythrocytes, the volumes were equalised by 1% BSA in PBS to 310 
p,L for streptokinase ICs and to 158 \i\ for thyroglobulin. The mixtures were then 
incubated at 37°C for 30 minutes. The reaction was stopped by addition of equal 
volume of ice cold 20 mM isotonic EDTA to the mixtures. The erythrocytes and serum 
suspension was spun at 4°C for 5 minutes and the supernatants removed and kept at 
-70°C for later measurement of complement activation products (5-3). Erythrocytes 
were washed with ice cold 1% BSA in PBS once and resuspended in the same buffer. 
The cells were standardised to IXIO® cells/ml (6- 1) and incubated with an equal volume 
of donkey FITC conjugated anti-rabbit IgG (diluted 1/20 with PBS) for 30 minutes in 
an ice bath. The cells were washed with 1% BSA in PBS twice and analysed by a 
FACscan flowcytometer as described (6-4).
FACscan controls: 1) The binding of ICs to E's in absence of NHS was studied at 
doses equal to the maximum doses used for ICs (for rabbit streptokinase 1310 pg ICs 
and for rabbit thyroglobulin ICs 110 pg ICs).
217
I
2) The binding and complement activation products in the presence of streptokinase and 
thyroglobulin at doses equal to the maximum doses used for ICs (10 p.g) were studied.
3) The binding and complement activation products in the presence of NHS alone was 
studied. A mixture of 100 fxl NHS and 20 p.1 of packed erythrocytes was equalised with 
1% BSA in PBS to 310 jal and to 158 pi (for streptokinase and thyroglobulin controls 
respectively) and incubated at 37°C.
4) The binding and complement activation products by rabbit anti-streptokinase IgG to 
erythrocytes equal to amount used for immune complexes (from 81.25 pg to 1300 pg 
IgG) was also studied.
6-6 K inetics of rabbit streptokinase immune com plexes binding to 
erythrocytes. The kinetics of rabbit streptokinase immune complexes binding to 
erythrocytes was studied at 37°C.
Materials and buffers are described in 6-5.
Method. Increasing amounts of the preformed rabbit streptokinase immune complexes 
at equivalence (5-2) from 131 pg to 2096pg were added to 200 pL NHS and 200 pL of 
packed erythrocytes and the volumes were equalised by 1% BSA in PBS to 620 pL. 
The mixtures were then incubated at 37°C and the assay sampled at 0, 5, 10, 25 and 30 
minutes. The reaction was stopped by addition of an equal volume of ice cold 20 mM 
isotonic EDTA to the mixtures. The erythrocytes were for bound immune complexes 
and the supernatants for free complement activation products, Cls:Cl-INH, C3b-P as 
described (6-5).
Control: The volume of a mixture of 200 pL NHS and 200 pL of packed erythrocytes 
was equalised with 1% BSA in PBS to 620 pL incubated at 37°C and used as negative 
control and the levels of Cls:Cl-INH, C3b-P and E's bound ICs was determined at 30 
minutes.
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6-7 Detecting bound C3c on erythrocytes during complement activation  
by FACscan. The binding of C3c to erythrocytes generated during complement 
activation by rabbit streptokinase and thyroglobulin immune complexes was studied by 
flow cytometry. The relationship between erythrocyte bound C3c and free complement 
activation products was investigated by studying the supernatants for the presence of 
theC ls:C M N H  and C3b-P.
Materials: Sources of materials used here are described in 2-1.
FITC conjugated rabbit anti-human C3c 
NHS
Human erythrocytes 
Falcon round-bottomed tubes 
Streptokinase
Rabbit IgG anti-streptokinase (5-2)
Rabbit IgG anti-thyroglobulin
Streptokinase
Thyroglobulin
Buffers
Filtered phosphate buffered saline (PBS)
1% BSA in PBS
20 mM isotonic EDTA (2-2)
ELISA buffers (5-3)
Method. Preformed rabbit streptokinase ICs at equivalence (2620 pg ICs, 6-3) were 
added to 200 pi NHS and 200 pi of packed erythrocytes, nascent rabbit thyroglobulin 
ICs at equivalence (440 pg ICs, 6-3) were added to 300 pi NHS and 300 pi of packed 
erythrocytes, the volumes were equalised by 1% BSA in PBS to 620 pi and 712 pi for 
the mixtures of streptokinase and thyroglobulin ICs respectively. The mixtures were 
then incubated at 37°C and the assay sampled at 0, 5, 10, 15 and 30 minutes. The
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■reaction was stopped by addition of equal volume of ice cold 20 mM EDTA to the 
mixture. The suspension of erythrocytes and serum were spun at 4°C for 5 minutes and 
the supernatants kept at -70°C for the later measurement of complement activation 
products (5-3). Erythrocytes were washed with ice cold 1% BSA in PBS once and 
resuspended in the same buffer. The cells were standardised to iXlO^ cells/ml (6-1) 
andhncubated with equal volume of rabbit FITC conjugated anti-human C3c (diluted 
1/20 with PBS) for 30 minutes in a ice bath. The cells were washed with the 1% BSA 
in PBS twice and analysed by a FACscan flow cytometer as described (6-4).
FACscan control: The volumes of mixtures of 200 pL NHS and 200 pi of packed 
erythrocytes or 300 pL NHS and 300 pL of packed erythrocytes were equalised with 
1% BSA in PBS to 620 pi and 712 pi, incubated at 37°C and used as negative control 
for the streptokinase and thyroglobulin ICs respectively and the levels of Cls:Cl-INH, 
C3b-P and E's bound ICs was determined at 30 minutes.
6-8 Detecting bound C3d on erythrocytes during complement activation  
by FACscan and modified ELISA. The binding of complement activation product 
C3d to erythrocytes generated during complement activation by rabbit streptokinase 
immune complexes was studied by flow cytometry and modified ELISA (5-5). The
relationship between erythrocyte bound C3d and free complement activation products 
was investigated by studying the supernatants for the presence of the Cls:Cl-INH and 
C3b-P.
Materials: Sources of materials used here are described in 2-1.
Rabbit anti-human C3d
HTC conjugated rabbit anti-human C3d
NHS
Human erythrocytes 
Falcon round-bottomed tubes 
ELISA plate (Immulon 4)
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Streptokinase
Rabbit IgG anti-streptokinase (5-2)
Buffers
Filtered phosphate buffered saline (PBS)
1%BSA in PBS 
20 mM isotonic EDTA (2-2)
Isotonic 0.086 M EDTA (2-2)
ELISA buffers (5-3)
Method. Preformed rabbit streptokinase immune complexes at equivalence (6-3, ICs 
1310 pg ICs) were incubated with 500 pi NHS and 100 pi of packed erythrocytes and 
the volumes were equalised by 1% BSA in PBS to 750 pL. The mixtures were then 
incubated at 37°C and the assay sampled at 0, 5, 15 and 30 minutes. The reaction was 
stopped by addition of equal volume
of ice cold 20 mM isotonic EDTA to the mixture. Erythrocyte bound C3d and free 
complement activation products were measured as described (6-7).
Erythrocyte bound C3d was also detected by the modified ELISA (5-5). Erythrocytes
C ontrols: 1) The volume of a mixture of 500 pL NHS and 100 pL  of packed 
erythrocytes was equalised with 1% BSA in PBS to 750 pL. The mixture was 
incubated at 37°C and sampled at 0, 5, 15 and 30 minutes and used as negative control 
for both the FACscan and modified ELISA assays.
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(100 pL per well from IXIO^ cells/ml) were incubated on a ELISA plate (pre-coated 
with anti-human C3d, 5-5) for 2 hours at room temperature. The plate was washed 
with the 1% BSA in PBS and the bound E's were lysed by water, the optical density of 
lysed cell were read at 405 nm (5-5).
2) The effect of EDTA on erythrocyte bound C3d and free Cls:Cl-ÎNH, C3b-P and 
C3d. Preformed rabbit streptokinase ICs at equivalence (6-7, 1310 pg ICs) were added 
to 500 pi NHS or 500 pi NHS treated with isotonic 0.086M EDTA (End point lOmM 
EDTA) and 100 pi of packed erythrocytes. The volumes of mixtures were equalised by 
1% BSA in PBS to 750 pi. The mixtures were then incubated at 37°C and the assay 
sampled at 10 minutes. The levels of free and bound complement activation products 
were measured as described (See above).
3)The effect of rabbit streptokinase IgG on the erythrocyte bound C3d and free 
Cls:Cl-INH, C3b-P and C3d at concentration equal to concentration used for the ICs 
(1300 pg) and same conditions described (10 minutes) was studied.
6-9 Specificity of monoclonal anti-CRl for human erythrocytes. M ouse 
monoclonal anti-CRl according to manufacturer was raised against podocytes. The 
specificity of the mouse monoclonal anti-CRl antibody for erythrocytes was therefore 
examined.
Materials and Buffer: Sources of materials used here are described in 2-1.
Mouse monoclonal anti-human CRl (IgGl, kappa)
FITC conjugated sheep anti-mouse IgG
Mouse monoclonal anti-human AFP (alpha foetal protein)
Falcon round-bottomed tubes 
Membrane filtered PBS 
Human erythrocytes 
1% BSA in PBS
Method. Erythrocytes were prepared and standardised to 5XlO® cells/ml as described 
(2-17 and 6-1). Increasing amounts of mouse monoclonal anti-human CRl from 0.138 
pg to 4.4 pg was incubated with a constant amount of erythrocytes (2XlO® E's) for half
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an hour at room temperature. The E’s were washed and standardised to iXlO^ cells/ml 
and incubated with an equal volume of FITC conjugated sheep anti-mouse IgG (diluted 
1/20 with PBS) for half an hour at room temperature. The cells were washed with the 
1% BSA in PBS twice and analysed by a FACscan flow cytometer as described (6-4). 
Controls: 1) The above procedure was followed, however, mouse monoclonal anti­
human CRl was replaced with lOpg monoclonal mouse anti-human AFP.
2) Non-specific binding of FITC to E's was analysed by incubating 2XlO^ erythrocytes 
with equal volume of FITC conjugated sheep anti-mouse IgG used for detecting anti- 
C Rl.
6-10 Kinetics of human streptokinase immune com plexes binding to 
erythrocytes and the effect of monoclonal anti-C R l on binding and 
generation of complement actjyation products. Serum from a patient with 
extremely elevated levels of anti-streptokinase antibodies was used to study the kinetics 
of human anti-streptokinase immune complexes binding to erythrocytes. The levels of 
anti-streptokinase antibodies in this serum were as following; IgG > 90 units/ml, IgA> 
1000 units /ml, IgM=34 units/ml, ASK=1280 units/ml and ïgE was not detectable. The 
serum was heat inactivated for half an hour at 56°C to inactivate complement. The 
volume of the serum was not sufficient for purification of individual isotype antibodies. 
Using quantitative precipitin test (2-18) the equivalence point of the serum and 
streptokinase determined which was 50 pg streptokinase and 100 pi serum (Figure 6- 
1).
Flow cytometry was used to detect erythrocyte bound immune complexes (IgG, IgA 
and IgM) and C3d. The relationship between erythrocyte bound immune complexes 
and C3d with the extent of complement activation products was studied by measuring 
the levels of Cls:Cl-INH, C3-b-P and free C3d in the supernatants.
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Materials: Sources of materials used here are described in 2-1. 
FITC conjugated rabbit anti-human C3d 
FITC conjugated sheep anti-human IgG 
FITC conjugated sheep anti-human IgA 
FITC conjugated sheep anti-human IgM 
Mouse monoclonal anti-human CRl (IgGl, kappa)
NHS
Human erythrocytes 
Streptokinase
Falcon round-bottomed tubes 
Buffers
Filtered phosphate buffered saline (PBS)
1%BSA in PBS 
20 isotonic mM EDTA (2-2)
ELISA buffers (5-3)
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Streptokinase (ug)
Figure 6-1: Quantitative percipitin test for streptokinase immune complexes, 
using human anti-streptokinase antibodies derived from positive serum sample. 225
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Method. Prefoimed immune complexes at equivalence (50 pg streptokinase and 100 pL 
serum) were added to 500 pi NHS and 100 pL of packed erythrocytes, the volumes 
were equalised with 1% BSA in PBS to 750 pi and the mixtures incubated at 37°C. 
The assay sampled at 0, 5, 15 minutes and 24 hours. The reaction was stopped by the 
addition of an equal volume of ice cold 20 mM isotonic EDTA to the mixture. The 
mixture was spun at 4°C for 5 minutes and the supernatants removed and kept at -7CPC 
for the later measurement of free complement activation
products, C ls:Cl-INH, C3b-P and C3d (5-3). The erythrocytes were washed once 
with ice cold 1% BSA in PBS and standardised to IXIO® cells/ml (6- 1) and further 
incubated with equal volume of FITC conjugated rabbit anti-human C3d, FITC 
conjugated sheep anti-human IgG, FITC conjugated sheep anti-human IgA and FITC 
conjugated sheep anti-human IgM (All diluted 1/20 with PBS) for 30 minutes in an ice 
bath. After the incubation period the cells were washed twice with the 1% BSA in PBS 
and analysed by a FACscan flow cytometer as described (6-4).
The effect of monoclonal anti-human CRl: The effect of blocking CRl receptors on the 
measurable levels of erythrocyte bound immune complexés, bound C3d and the free 
complement activation products, Cls;Cl-INH, C3b-P and free C3d was studied. The 
above procedure was followed, however, 100 pi of packed naive E's was replaced 
with 100 pi of packed E’s treated with monoclonal mouse anti-human CRl as 
following. Monoclonal mouse anti-human CRl was added at a concentration 13.8 pg 
per 100 pi packed erythrocytes and incubated for half an hour at room temperature. The 
E's were washed and 100 pi of packed E's were incubated with the ICs and NHS as 
described.
Controls: The following controls were used:
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1) The levels of bound immune complexes to erythrocytes in absence of NHS at same 
conditions described above was studied.
2) The levels of free complement activation products (Cls:Cl-INH, C3b-P and free 
C3d) in absence of erythrocytes at same conditions described above was studied.
3) The levels of erythrocyte bound antibodies, C3d and free complement activation 
products (Cls:Cl-INH, C3b-P and free C3d) in the presence of 100 pi of positive 
serum (equal to the volume used for the ICs) and absence of streptokinase at same 
conditions described above was studied.
4) A mixture of 500 pi NHS and 100 pi of packed erythrocytes (Total volume=750 pi) 
at 37°C was used as negative control.
6-11 Effects of antigen and antibody excess on human str ep to k in a se  
im m une com plexes binding to erythrocytes. The binding of human 
streptokinase immune complexes at equivalence, antigen excess and antibody excess to 
erythrocytes was studied. Flow cytometry was used to detect bound immune 
complexes (IgG) and C3d on the erythrocytes. The levels of bound C3d was also 
studied by the modified ELISA (5-5). The relationship between bound immune 
complexes, C3d and free complement activation products was studied by measuring 
C ls:Cl-INH, C3b-P and free C3d in the supernatants (5-3).
Materials: Sources of materials used here are described in 2-1.
Rabbit anti-human C3d 
FITC conjugated rabbit anti-human C3d 
FITC conjugated sheep anti-human IgG 
NHS
Human erythrocytes 
Streptokinase
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Human IgG anti-streptokinase 
Falcon round-bottomed tubes 
Buffers 
Filtered PBS 
1%BSA in PBS 
20 mM EDTA (2-2)
Isotonic 0.086 M EDTA (2-2)
O .IM EGTA, MgCl2(2-2)
ELISA buffers (5-3)
M ethod. Human IgG anti-streptokinase was purified from the sera of patients with 
elevated levels of anti-streptokinase antibodies by ion exchange chromatography (5-1) 
and the equivalence point was determined (5-2). Preformed immune complexes at 
equivalence (1150 pg IgG+40pg streptokinase), 4 times antibody excess (1150 pg 
I g G + l O pg  streptokinase) and 4 times antigen excess (287.5 pg IgG4-40pg 
streptokinase) were added to 250 pi NHS and 50 pi of packed erythrocytes, the volume 
of the mixtures equalised with 1% BSA in PBS to 440 pi. The mixtures were then 
incubated at 37°C for 5 minutes. The reaction was stopped by addition of equal volume 
of ice cold 20 mM isotonic EDTA to the mixtures. The mixture was spun at 4G  for 5 
minutes and the supernatants were removed and kept at -70°C for the later measurement 
of free complement activation products, C ls:C l-IN H , C3b-P and C3d (5-3). 
Erythrocytes were washed once with ice cold 1% BSA in PBS and standardised to 
IXIO^ cells/ml (6-1). The erythrocytes were further incubated with equal volume of 
sheep FITC conjugated anti-human IgG or FITC conjugated rabbit anti-human C3d 
(Both diluted 1/20 with PBS) for 30 minutes in a ice bath. The cells were washed twice 
with the 1% BSA in PBS and analysed by a FACscan flow cytometer (6-4). 
Erythrocytes (100 pi per well from the IXIO^ cells/ml) were also incubated on a ELISA
plate (pre-coated with anti-human C3d, 5-5) for 2 hours at room temperature. The plate
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was washed with the 1% BSA in PBS and the bound E's were lysed by water, the 
optical density of lysed cell were read at 405 nm (5-5).
Controls: The controls for above experiment were: 1) The levels of free complement 
activation products (Cls:Cl-INH, C3b-P and free C3d) in absence of erythrocytes at 
same conditions described above.
2) To inhibit complement activation, NHS was incubated with isotonic 0.086M EDTA 
to give a final concentration of 10 mM (2-2). The levels of bound ICs, C3d and free 
complement activation products (Cls:Cl-INH, C3b-P and free C3d) in presence of the 
NHS treated with EDTA and E's at same conditions described above was studied.
3) To inhibit alternative pathway activation NHS was incubated with 0.1 M MgCl2 
EOT A to give a final concentration 6 mM (2-2). The levels of bound ICs, C3d and free 
complement activation products (Cls:Cl-INH, C3b-P and free C3d) in presence of the 
NHS treated with MgCl2 EGTA and E's at same conditions described above was 
studied.
4) The levels of bound IgG, C3d and free complement activation products (C ls:C l- 
INH, C3b-P and free C3d) in presence of antigen or antibody (streptokinase 40pg, IgG 
1150pg) at same conditions described above was studied. ,
5) A mixture of 250 pi NHS and 50 pL of packed erythrocytes (Total volume=440 pi) 
at 37°C was used as negative control.
6-12 In vivo study of streptokinase immune com plexes binding to 
erythrocytes in patients with AMI. This study was performed in collaboration 
with Department of Cardiology, Western Infirmary, Glasgow (Dr. Stewart Hood and 
Dr. David Bimie). The extent of complement activation products (Cls:Cl-INH, C3b~P 
and C5b-9), and its relationship with the levels of pre-existing anti-streptokinase 
antibodies and the immune complexes clearance in four patients with AMI (2 males, 2 
females) treated with streptokinase were studied.
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Materials; Sources of materials used here are described in 2-1,
:
FITC conjugated rabbit anti-human C3c 
FITC conjugated rabbit anti-human C3d 
FITC conjugated sheep anti-human IgG 
FITC conjugated sheep anti-human IgA
■'iFITC conjugated sheep anti-human IgM 
Falcon round-bottomed tubes
Buffers
Filtered phosphate buffered saline (PBS)
ELISA buffers (5-3) I
5Method. The blood samples from 4 AMI patients were used in this set of experiments.
The patients received 15 00 000 units of streptokinase over a period of 1 hour. Blood 
samples were taken prior to administration of streptokinase and at 5 and 30 minutes 
after treatment.
Blood samples were collected in EDTA at time points 0, 5 and 30 minutes after 
streptokinase administration and spun at 4°C for 5 minutes at 1200 rpm. The plasma 
was then removed and kept at - 7CPC for the later measurement of the levels of IgG,
IgA and IgM anti-streptokinase antibodies (3-3), and complement activation products,
C ls:Cl-IN H , C3b-P and C5b-9 (5-3). After removing the buffy coat the erythrocytes 
were washed once with ice cold PBS and standardised to iXlO^ cells/ml (6-1). 100 pi 
of the erythrocytes were incubated with 100 pi of FITC conjugated rabbit anti-human 
C3c, FITC conjugated rabbit anti-human C3d, FITC conjugated sheep anti-human IgG,
FITC conjugated sheep anti-human IgA and FITC conjugated sheep anti-human IgM 
(All diluted 1/20 with PBS) in an ice bath for 30 minutes. After incubation the cells 
were washed twice with PBS and analysed by a FACscan flow cytometer (6-4).
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6-13 Statistical analysis. Statistical analysis of data was perform ed using 
Spearman rank correlation test, Wilcoxon rank test and Mann-Whitney test.
Results
Dose response of rabbit streptokinase and thyroglobulin im m une 
complexes binding to erythrocytes. A flow cytometric assay was developed 
successfully to detect bound immune complexes on the erythrocytes. The relationship 
of E's bound ICs and complement activation products was studied by measuring 
C ls:Cl-INH and C3b-P in the supernatants (6-5).
Using nascent rabbit thyroglobulin immune complexes at equivalence, as the amount of 
ICs increased (from 0.85 pg to 110 pg) the levels of erythrocyte bound ICs as 
measured by FACscan (Using FITC conjugated anti-rabbit IgG) and increased 
generated complement activation products compared with the controls at 30 minutes 
(Figure 6-2). The levels of Cls:Cl-INH increased over the incubation period compared
:to C3b-P levels which reached to peak of 740 ng/ml at 1.7 pg IC and then reached a 
plateau (Figure 6-2). The levels of erythrocyte bound ICs correlated significantly with 
the levels of generated C ls-Cl-IN H  and C3b-P (r = 0.98 and 0.91 respectively, 
pcO.OOl) (Figure 6-2).
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Figure 6-2: Dose response erythrocytes binding (a) and complement activation (b)by nascent thyroglobulin immune complexes at equivalence.
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Controls: 1) Rabbit streptokinase ICs (1310 fxg ICs) in absence of NHS bound to 
erythrocytes (68 %) which was 49% higher than the presence NHS.
Controls: 1) Rabbit thyroglobulin ICs (110 pg ICs) alone in absence of NHS bound to 
erythrocytes (32 %) which was 14% lower than the presence of the NHS.
2) Thyroglobulin alone (10 pg) showed a similar percentage of positive E's (7%) and 
levels of C ls:Cl-IN H  (140 ng/ml) as the NHS+E's alone (6% positive E's and 112 
ng/ml C ls:Cl-IN H ). However, it generated 39% higher levels of C3b~P than the 
values of NHS+E's alone (330 ng/ml), this was 35% lower than the ICs (840ng/ml).
3) IgG alone (100 pg) in absence of thyroglobulin bound to E's (35%) and generated 
C ls:Cl-IN H  and C3b-P (880 ng/m and 840 ng/ml respectively), this was 6% and 83% 
lower than the ICs for the binding and Cls:Cl-INH respectively and for C3b-P levels 
did not differ from the ICs.
Using preformed rabbit streptokinase immune complexes at equivalence, increasing the
samount of ICs from 81.87pg to 1310 pg resulted in a dose dependent increase in the 4
levels of generated complement activation products compared with the controls at 30 
minutes (Figure 6-3). A striking increase in the levels of C ls:Cl-INH was observed 
compared to the C3b-P levels which rose more slowly with increasing concentrations 
and then reached a plateau as observed with thyroglobulin ICs (Figure 6-3),
The levels of E's bound ICs was detectable at the concentrations of 327.5pg to 1310 
pg ICs when compared with the controls and as demonstrated by FACscan using FITC 
conjugated anti-rabbit IgG at 30 minutes (Figure 6-3). The levels of erythrocyte bound
ICs correlated with the levels of generated Cls-Cl-INH and C3b-P (r= 0.77, p<0.07).
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Figure 6-3; Dose response erythrocytes binding (a) and complement activation (b) by
preformed rabbit streptokinase immune complexes at equivalence.
234
2) Streptokinase alone (10 pg) showed a 4% E's and generated 268 ng/ml Cls:Cl-INH 
and 346 ng/ml C3b~P which did not differ significantly from the values of the 
NHS+E’s alone (4% and 289 ng/ml and 411 ng/ml respectively).
3) Increasing amounts of rabbit anti-streptokinase IgG alone (from 81.25 pg to 1300 
pg IgG) resulted in detectable levels of E's bound IgG and C ls:C l-IN H  and C3b-P 
(Figure 6-4). The concentrations of IgG added correlated with the levels of E's bound 
IgG, C ls:Cl-IN H  and C3b-P (r=0.94 p<0.005, r=0.98 p<0.001 and r=0.98 p<0.01 
respectively). The levels of E's bound IgG correlated with the levels of C ls:C l-IN H  
and C3b-P (r= 0.94 p<0.005 and r=0.75 p<0.08 respectively). The levels of E's 
bound IgG alone (from 81.25 pg to 1300 pg IgG) were higher than the levels of E's 
bound ICs (1.5-12%) (Figures 6-3 and 6-4). However, IgG alone generated lower 
levels of Cls:Cl-INH (79-84%) and C3b~P (3-11%) compared to ICs (Figures 6-3 and 
6-4).
K inetics o f rabbit streptokinase imm une com plexes binding to 
erythrocytes. The kinetics and dose response of preformed rabbit streptokinase at 
equivalence for binding to erythrocytes and its relationship with the complement 
activation products Cls:Cl-INH and C3b-P was studied (6-6).
Increasing amount of the preformed rabbit streptokinase immune complexes at 
equivalence (5-2) from 131 pg to 2096pg were incubated with NHS and erythrocytes 
at 37°C and the assay sampled at 0, 5, 10, 25 and 30 minutes. Over a period of 30 
minutes the immune complexes bound to erythrocytes as demonstrated by FACscan 
using FITC conjugated anti-rabbit IgG (Figure 6-5a). The highest binding was 
observed with greater dose of ICs, peak of the binding was at 5 minutes for doses of 
524 pg, 1024pg and 2096pg ICs and at 15 minutes for 131pg and 262 pg ICs (Figure 
6-5a). The levels of E's bound immune complexes then decreased and reached to 
lowest levels at 30 minutes (Figure 6-5a).
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The levels of generated Cls:Cl-INH again were higher with greater dose of ICs, 1048 
pg and 2096 pg ICs, caused a rapid increase of Cls:Cl-INH peaking by 5 and 10 
minutes respectively then reached a plateau, a peak for the levels of C ls:C l-IN H  
generated by the lower amount of ICs was not observed (Figure 6-5b).
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Figure 6-4: Dose response of erythrocytes binding (a) and complement activation by
rabbit IgG anti-streptokinase at doses equal to doses used for the ICs.
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Figure 6-5: Kinetics and dose response of E's binding (a) and Cls:Cl-INH (b) generation by the 
preformed rabbit streptokinase ICs at equivalence.The levels of E’s bound IgG and Cls:Cl-INH 
in the control (E's-t-NHS) were 0.6% and 196 ng/ml respectively. 238
The levels of generated C3b-P by 1048 |xg and 2096 pg ICs increased and reached a 
peak by 10 minutes, a peak for the levels of C3b~P generated by the lower amount of 
ICs was not observed (Figure 6-6).
C ls;C l-IN H  and C3b-P generation mirrored one another closely. Whilst binding 
peaked at 5 minutes and then dropped quickly for higher IC doses. A lower more
substantial binding and release was observed for lower IC doses.
The levels of E's bound ICs correlated significantly with the levels of generated 
C ls:C l-IN H  and C3b-P at 5 minutes (r=0.97 p<0.001 and r= 0.9 p<0.07 
respectively). The peak of E's bound ICs (5 minutes) occurred earlier than the peak of 
C3b-P (10 minutes) (Figures 6-5 and 6-6).
The levels of E's bound ICs and Cls:Cl-INH, C3-P generated by highest amount of
ICs (2096 pg) at 5 minutes was significantly higher than levels observed for the lowest 
amount of ICs (131 pg) (P< 0.02, 0.01 and 0.02 respectively). ■
Detecting bound C3c on erythrocytes during complement activation by 
FACscan. The binding of complement activation product C3c to erythrocytes 
generated during complement activation by rabbit streptokinase and thyroglobulin ICs 
was studied by flow cytometry, using FITC conjugated rabbit anti-human C3. The 
relationship between erythrocyte bound C3c and free complement activation products 
was investigated by studying the supernatants for the presence of the Cls:Cl-INH and 
C3b-P.
A constant amount of streptokinase or thyroglobulin were incubated with NHS and 
erythrocytes at 37°C and the assay sampled at 0, 5, 10, 15 and 30 minutes. Over a 
period of 30 minutes C3c was detectable on erythrocytes as demonstrated by FACscan 
(Figure 6-7a). Peak binding for both ICs was at 5 minutes after which detectable C3c 
began to decrease and by 30 minutes a 34-36 % reduction in the levels of bound E's 
C3c was observed compared to 5 minutes (Figure 6-7a).
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Figure 6-6; Dose response and kinetics of C3b-P generation by preformed rabbit streptokinase 
immune complexes at equivalence. The levels of C3b-P in the mixture of NHS+E’s (Control) was 32ng/ml at 30 minutes. 240
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thyroglobulin ICs.
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Over the period of 30 minutes the levels of Cls:Cl-INH and C3b-P increased with 
both ICs (Figure 6-7b). The levels of C ls:Cl-INH generated by streptokinase ICs 
reached a peak by 10 minutes and then began to decrease by 30 minutes (34% reduction 
compared to values at 10 minutes). The levels of C ls:C l-IN H  generated by 
thyroglobulin ICs reached a peak by 15 minutes and did not change significantly till 30 
mirlutes (Figure 6-7b).
The levels of C3b-P generated by streptokinase ICs reached a peak by 5 minutes and 
for the thyroglobulin ICs reached to a peak by 15 minutes, the levels of C3b-P did not 
change significantly after their peaks (Figure 6-7b).
The levels of E’s bound C3c correlated with the levels of C3b-P generated by rabbit 
streptokinase ICs (r=0.97, p<0.001) but did not correlate with the levels of C ls:C l- 
INH (r=0.7). The levels of E’s bound C3c did not correlate with the levels of C ls:C l- 
INH and C3b-P generated by thyroglobulin ICs.
Detecting bound C3d on erythrocytes during complement activation by 
FACscan and modified ELISA. The binding of complement activation product 
C3d to erythrocytes generated during complement activation by preformed rabbit 
streptokinase immune complexes at equivalence was studied by flow cytometry using 
FITC conjugated rabbit anti-human C3d and modified ELISA (6-8). The relationship 
between erythrocyte bound C3d and free complement activation products was 
investigated by studying the supernatants for the presence of the Cls:Cl-INH and C3b- 
P.
A constant amount of the ICs (1310 pg) was incubated with NHS and erythrocytes at 
31^C and the assay sampled at 0, 5, 15 and 30 minutes. Over a period of 30 minutes 
C3d was detectable on erythrocytes as demonstrated by both FACscan and modified 
ELISA techniques compared with the controls (E's+NHS at 37°C) (Figure 6-8). Peak
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C3d binding for both methods was at 15 minutes, in contrast to E's bound C3c (Figure 
6-7a) the levels did not change significantly after reaching the peak (Figure 6-8). The 
levels of E bound C3d detected by the two methods correlated with one another 
significantly (r=0.98, p<0.001).Over the period of 30 minutes the levels of C ls:C l- 
INH and C3b-P increased in the presence of ICs compared to the controls (Figure 6-9). 
The levels of C ls:C l-IN H  and C3b-P increased to peak at 5 minutes and did not 
change significantly over the 30 minutes (Figure 6-9). The E's did influence the levels 
of C ls:C l-IN H  (Figure 6-9a). However, in absence of E's the levels of detectable 
C3b-P reached to peak at 5 minutes, this was 60% higher than in the presence of E's 
(Figure 6-9b). Across the time course, levels of C3b-P were greater in absence of E's 
(34% and 40% higher at 15 minutes and 30 minutes respectively) (Figure 6-9b).
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Figure 6-8: Kinetics of erythrocyte bound C3d generated by preformed rabbit streptokinase immune
complexes at equivalence. Detected by flow cytometry (a) and modified ELISA (b).
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The levels of E bound C3d as measured by both techniques did not correlate with the 
levels of Cls:Cl-INH and C3b-P generated by the ICs.
Controls: 1) NHS +E's was (Total volume 750 |xL) at 37°C was used as negative 
control. The low levels of E's bound C3d by both techniques reflected a trace 
spontaneous complement activation (Figure 6-8).
2) The effect of EDTA on erythrocyte bound C3d and free C ls:Cl-INH, C3b-P and 
C3d was studied by incubating 1310 p,g preformed rabbit streptokinase ICs with NHS 
or NHS treated with isotonic 0.086M EDTA and erythrocytes at 37°C for 10 minutes
(6-8). EDTA decreased the levels of E's bound C3d, detected by both techniques, 
C ls:Cl-INH, C3b-P and free C3d (Figures 6-10 and 6-11).
The presence of erythrocytes had no effect on the levels of C ls:Cl-IN H  and free C3d, 
however a 54 % reduction in the levels of C3b-P was observed at 10 minutes (Figure
6- 11).
3) Rabbit IgG anti-streptokinase (1300 p,g) and generated E bound C3d and free 
C ls:C l-IN H , C3b-P and C3d at 10 minutes to a lower extent compared to the ICs 
(Figures 6-10 and 6-11).
Specificity of monoclonal anti-CRl for human erythrocytes. The specificity 
of the mouse monoclonal anti-CRl IgG for erythrocytes was examined by incubating 
increasing amounts of the antibody from 0.138 pg to 4.4 pg with a constant number of 
erythrocytes (2X10  ^E's) (6-9). Non-specific binding was detennined by incubating 
lOpg monoclonal mouse anti-huma AFP IgG with 2XlO^ E's or conjugated sheep anti­
mouse IgG alone. Thr E's were then analysed by FACscan using FITC conjugated 
sheep anti-mouse IgG (6-9).
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immune complexes at 10 minutes at 37oC. Detected by flow cytometry (a) and modified ELISA (b).
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Figure 6-12: Histograms of fluorescence intensity for human erythrocytes incubated with 
monoclonal mouse anti-human CRl (a). Mouse monoclonal anti-human AFP (b) and FITC 
sheep anti-mouse IgG alone (c) were used to analyse non-specific binding. Y axis displays 
the number of erythrocytes for each channel and X axis is a log scale of fluorescence 
intensity.
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K inetics of human streptokinase immune com plexes binding to
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Mouse monoclonal anti-CRl was detectable on 81% of the erythrocytes compared with 
the controls (Figure 6-12). Increasing the concentration of the anti-CRl antibody did ;
not cause any significant change in the levels of detectable anti-CRl antibodies on the 
E’s. Monoclonal mouse anti-human AFP IgG and FITC sheep anti-mouse alone were 
not detectable on the erythrocytes (Figure 6-12).
erythrocytes and the effect of monoclonal anti-C R l on binding and
generation of complement actiyation p rod u cts. Preformed human anti- 
streptokinase immune complexes prepared from the serum of a patient with elevated 
levels of anti-streptokinase antibodies were used in this experiment (6-10). As the 
levels of anti-streptokinase antibodies in this serum were high (IgG > 90 units/ml,
IgA> 1000 units /ml, IgM=34 units/ml, ASK=1280 units/ml), it provides a good model 
of human streptokinase immune complexes when combined with streptokinase. Flow 
cytometry was used to study the kinetics of human immune complexes binding and 4
C3d to erythrocytes over a period of 15 minutes at 37°C and 24 hours at room 
temperature (6-10). The relationship between bound immune complexes, C3d and the 
free generated complement activation products was studied by measuring Cls:Cl-INH,
C3b-P and free C3d in the supernatants. The effects of anti-CRl on the out come of 
this experiment was also studied (6-10).
The levels of bound human streptokinase immune complexes detected by FITC 
conjugated anti-human IgG and FACscan analysis increased and reached a peak at 5 y
minutes, after which the levels began to decrease and at 24 hours were not detectable on 
the erythrocytes (Figure 6 -13a). In the presence anti-CRl the levels of detectable 
surface IgG as detected by FITC conjugated anti-human IgG showed an 36%, 10% and
19% increase at 0, 5 and 15 minutes compared with the absence of anti-CRl (Figures 
6-13a). At 24 hours the binding of IgG was still elevated at 22% (Figure 6-13a).
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incorporated in streptokinase immune complexes (ICs) detected by FACscan.
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complexes (a) and E's bound C3d generated by human streptokinase ICs (b), detected by FACscan.
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Figure 6-15: Kinetics of Cls:Cl-INH (a) and C3b-P (b) generated by human streptokinase immune complexes in presence and absence of naive E's or E's treated with anti-CRI(E-CRl) .
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The levels of bound human streptokinase immune complexes detected by FITC 
conjugated anti-human IgA increased and reached a peak at 5 minutes, after which the 
levels decreased and at 24 hours were not detectable on the erythrocytes (Figures 6-
13b). In contrast to IgG in the presence anti-CRl the levels of detectable surface IgA as 
detected by FITC conjugated anti-human IgA showed 4%, 18% and 3% reduction at 0, 
5 and 15 minutes compared with the absence of anti-CRl (Figure 6-13b). At 24 hours 
the binding of IgA was still detectable at 29 % (Figures 6-13b).
The levels of bound human streptokinase immune complexes detected by FITC 
conjugated anti-human IgM were lower compared to IgG and IgA (Figure 6 -14a), the 
levels increased and reached a peak at 5 minutes, after which they decreased to 
undetectable at 24 hours (Figures 6 -14a). In the presence anti-CRl the levels of 
detectable surface IgM as detected by FITC conjugated anti-human IgM showed a 4% 
reduction at 5 minutes compared to in the absence of anti-CRl (Figures 6-14a). The 
levels of immune complexes (IgM) were not detectable at 24 hours (Figures 6-14a).
The levels of E bound C3d, generated during complement activation by human 
streptokinase immune complexes detected by FITC conjugated anti-human C3d reached 
a peak at 5 minutes, after which the levels decreased slightly and at 24 hours were not 
detectable on the erythrocytes (Figures 6-14b). The presence of anti-CRl did not 
influence the detectable levels of E's bound C3d (Figures 6-14b).
The complement activation products C ls:C l-IN H , C3-b-P and free C3d were 
measured in accompanying supernatants. The levels of C ls:C l-IN H  generated by 
human streptokinase ICs rose up to 15 minutes, 10 minutes later than peak observed 
for erythrocyte binding of C3d, IgG and IgA on E's (Figures 6 -15a). The levels of 
Cls:Cl-IN H  at 24 hours were striking in their degree of elevation (12 pg/ml) (Figures 
6 -15a). The presence of E's did not influence the levels of C ls:Cl-INH significantly 
(Figures 6 -15a). The presence of anti-CRl(E-CRl) increased the levels of C ls:C l- 
INH compared to controls (Figures 6-15a). The levels of Cls:Cl-INH generated by the
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immune complexes in presence of E-CRl and absence of erythrocytes at 24 hours were 
also striking in their degree of elevation (25.6 p-g/ml and 14.4 pg/ml respectively)
(Figures 6 -15a). The presence of anti-CRl generated almost two fold higher levels of 
C ls:Cl-IN H  (25.6 pg/ml) as compared to the ICs in the presence of E's (12 p-g/ml) or 
the absence of E's (14.4 p-g/ml) (Figures 6-15a). The levels of C ls:C l-IN H  in the 
positive serum alone (contained anti-streptokinase antibodies) and NHS+E's (controls) '■c
were increased by 50% at 24 hours (0.720 pg/ml and 0.728 pg/ml respectively) which
::
were still significantly lower than then levels of the ICs in all time points (Figures 6-
15a).
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Figure 6-16: Kinetics of free C3d generated by human streptokinase immune complexes 
in presence and absence of naive E's or E's treated with anti-CRl (E-CRl).
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Bound
C3d
FACscan
Bound
C3d
EUSA
Cls:Cl-
INH
C3b-P Free C3d
Bound IC r=0,94
(p<0.001)
0.62
(p<0.03)
r=0.66
(p<0.01)
r=0.80
(p<0.002)
r=0.67
(p<0.01)
Bound
C3d
FACscan
0.67
(p<0.01)
r=0.68
(p<0.01)
r=0.86
(p<0.001)
r=0.60
(p<0.03)
Bound
C3d
EUSA
r=0.62
(p<0.02)
r=0.67
(p<0.01)
r=0.63
(p<0.02)
Cls:Cl-
INH
r=0.83
(p<0.001)
r=0.83
(p<0.001)
C3b-P
'
r=0.83
(p<0.001)
Table 6-1: Correlation between the levels of erythrocyte (E's) bound immune complexes, 
E's bound C3d and free complement activation products, Cls:Cl-INH,C3b-P, free C3d 
generated by preformed human streptokinase immune complexes at equivalence.
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The levels of CS-b-P generated by human streptokinase immune complexes reached a 
peak at 15 minutes, 10 minutes later than peak binding C3d and ICs on E's (Figures 6- 
15b). In contrast to Cls:Cl-INH, the levels of C3-b-P at 24 hours were not detectable 
(Figures 6-15b). The presence of erythrocytes did not significantly influence the levels 
of C3b-P generated by human streptokinase immune complexes (Figures 6 -15b), this 
was in contrast with the previous experiment (6-8) were a 54 % reduction in the 
detectable levels of C3b-P generated by rabbit streptokinase ICs (Contained only IgG) 
was observed in the presence of erythrocytes (Figure 6-11). The presence of anti-CRl 
increased the levels of C3-b-P by 23% at 15 minutes (Figures 6-15b). The levels of 
C3b-P generated by the immune complexes in presence of E-CRl by 24 hours were 
also not detectable (Figures 6-15b).
I
The levels of free C3d generated by human anti-streptokinase immune complexes 
reached a peak at 15 minutes, 10 minutes later than peak observed for E's binding of 
C3d and ICs (Figures 6-16). The levels of free C3d by 24 hours were detectable and 
only slightly decreased (10%) compared to levels at 15 minutes (Figures 6-16). The 
presence of erythrocytes (Untreated E's and E-CRl) increased the levels of free C3d 
generated by the ICs at 15 minutes (40%) compared with levels in the absence of E's 
(Figure 6-16). The levels of free C3d in positive serum (antibody control) and NHS + 
erythrocytes (controls) were increased by 24 hours and reached to levels of ICs at 24 
hours (Figure 6-16).
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Figure 6-17: The levels of Cls:Cl-INH (a) and C3b-P (b) generated by preformed human 
streptokinase immune complexes at equivalence, 4 times antigen (Ag) excess or 4 times antibody (Ab) excess at 5 minutes incubation at 37oC.
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The levels of erythrocyte bound IgG, IgA, IgM and C3d as measured by FACscan did 
not correlate with the levels of free complement activation products Cls:Cl-INH, C31> 
P and C3d. The levels of E's bound IgG, IgA, IgM and C3d significantly correlated 
with one another (r= 0.99, p<0.001). The levels of free complement activation 
products Cls:Cl-IN H , C3b-P and C3d were also significantly coiTelated with one 
another (r= 0.99, p<0.001).
Effects of antigen and antibody excess on human streptokinase im m une  
complexes binding to erythrocytes. Human anti-streptokinase IgG was purified 
from the sera of patients with elevated levels of anti-streptokinase antibodies by ion 
exchange chromatography (5-1) and preformed immune complexes were prepared (5- 
2). Binding of human streptokinase immune complexes to erythrocytes after 5 minutes 
incubation at 37°C (Time point chosen based on previous experiment), at equivalence, 
antigen excess and antibody excess to erythrocytes was studied by flow cytometry 
using FITC conjugated sheep anti-human IgG to find whether the binding is influenced 
by the antigen/antibody ratio (6-11). The levels of E's bound C3d was studied by flow 
cytometry using FITC conjugated rabbit anti-human C3d and modified ELISA (5-5). 
The relationship between bound immune complexes, bound C3d and free complement 
activation products was studied by measuring Cls:Cl-INH, C3b-P and free C3d in the 
supernatants (5-3). The levels of complement activation products and binding of the 
ICs at equivalence to erythrocytes in presence of NHS treated with EDTA or EGTA 
was used as control (6- 11).
Human streptokinase immune complexes at equivalence generated higher levels of 
C ls:Cl-IN H  (2680 ng/ml) compared to antibody excess (464 ng/ml) and antigen 
excess (920 ng/ml) (Figure 6 -17a). EDTA and EGTA completely inhibited the
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generation of C ls:C l-IN H  and the presence of erythrocytes did not cause any 
significant effect on the levels of Cls:Cl-INH (Figure 6-17a).
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Figure 6-18: The levels of (a) free C3d and (b) erythrocyte (E's) bound C3d (b) generated by preformed
human streptokinase ICs at equivalence, 4 times antibody (Ab)excess and 4 times antigen (Ag) excessby 5 minutes incubation at 37oC.
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The ICs at equivalence generated higher levels of C3b-P (2040 ng/ml)compared to 
antibody excess (920 ng/ml) and antigen excess (432 ng/ml) (Figure 6-17b). EDTA 
completely inhibited the generation of C3b-P, however, EGTA only partially decreased 
the levels of generated C3b-P (Figure 6 -17b). The presence of erythrocytes did not 
cause any significant effect on the levels of C3b-P (Figure 6-17b).
Immune complexes at equivalence generated higher levels of free C3d compared 
(75000 units/ml) to antibody excess (31200 units/ml) and antigen excess (63000 
units/ml) (Figure 6 -18a). Like C ls:Cl-INH, immune complexes at antigen excess 
generated higher levels of C3d than antibody excess (Figure 6-18a). EDTA decreased 
the levels of C3d to the levels of controls, however, EGTA only partially decreased the 
levels of generated C3d (Figure 6-18a). The presence of erythrocytes did not cause any 
significant effect on the levels of C3d (Figure 6-18a).
The levels of bound C3d as measured by modified ELISA supported findings with free 
C3d and were higher at equivalence (ODqp^nm = 0.38) compared to antibody excess 
(OD4osnm = 0.31) and antigen excess (OD4osnm =0.27) (Figure 6 -18b). EDTA 
decreased the levels of C3d, however, EGTA partially decreased the levels of E's 
bound C3d (Figure 6-18b).
The levels of E's bound C3d as determined by FACscan analysis using FITC 
conjugated rabbit anti-human C3d showed higher levels at equivalence (29.92 % 
positive E's) than antibody excess (20.92 % positive E's) and antigen excess (8.44 % 
positive E's) (Figure 6 -19a). At antibody excess the levels of E's bound C3d were 
higher than antigen excess (Figure 6 -19a). EDTA inhibited the detectable levels of E's 
bound C3d by FACscan, however, EGTA only partially decreased the levels of bound 
C3d (Figure 6-19a).
Erythrocyte bound immune complexes as detected by FACscan analysis using FITC 
conjugated anti-human IgG at equivalence also showed a higher binding to erythrocytes 
(22.7% positive E's) than antibody excess (14.1% positive E's) or antigen excess
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(2.8% positive E's) (Figure 6-19b). At antibody excess the levels of bound immune 
complexes were higher than the levels of bound immune complexes at antigen excess 
(49 % higher. Figure 6-20b). EDTA inhibited the binding of immune complexes to ::
erythrocytes, however, EGTA only partially inhibited binding (Figure 6 -19b).
t
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Figure 6-19: The levels of (a) erythrocyte (E's) bound C3d and (b) E's bound preformed
human streptokinase ICs at equivalence, 4 times antibody (Ab) excess and 4 times antigen (Ag)excess after 5 minutes incubation at 37oC. 266
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Figure 6-20: The levels of IgG (a) and IgA (b) anti-streptokinase antibodies in 4 patientswith AMI treated with streptokinase.
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Figure 6-21: The levels of IgM anti-streptokinase antibodies (a) and Cls:Cl-INH (b)
in 4 patients with AMI treated with streptokinase.
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Correlation between the E's bound ICs, C3d and free complement activation products, 
C ls:Cl-IN H , C3b-P and free C3d were analysed. The levels of E's bound immune 
complexes and E's bound C3d (Detected by FACscan and modified ELISA) correlated 
significantly with the levels of free complement activation products (Table 6-1). The 
levels of E's bound C3d detected by FACscan correlated with levels obtained by 
modified ELISA (Table 6-1). Free complement activation products Cls:Cl-INH, C3b- 
P and free C3d also correlated significantly with one another (Table 6-1).
Study the streptokinase immune complexes binding to erythrocytes in 
patients with AML Using flow cytometry binding of human streptokinase immune 
complexes to erythrocytes formed during streptokinase treatment in 4 patients with AMI 
was studied, the levels of pre-existing anti-streptokinase antibodies and the extent of 
complement activation and its relationship with the levels of E's bound immune 
complexes were also studied (6-12). Blood samples were taken prior to administration 
of streptokinase and at 5 and 30 minutes after treatment.
The pre-treatment levels of IgG and IgA anti-streptokinase antibodies in the 4 patients 
were within the normal ranges (Mean value for IgG = 11,1 units/ml, normal ranges
0.24-45.8 units/ml and mean value for IgA = 44.5 units/ml, normal range= 0.37-324 
.units/ml). All the patients had elevated levels of IgM anti-streptokinase antibodies 
(Mean value 15 units, normal range= 0.06-10.8 units/ml).
Administration of streptokinase resulted in an 38% reduction in the levels of IgG anti- 
streptokinase antibodies at 5 minutes (Mean value = 6.9 units/ml) compared with pre- 
treatment levels (Mean value 11.1 units/ml) at 30 minutes the levels were still depressed 
(Mean value = 2.3 units/ml, 84% reduction) (Figure 6-20).
Administration of streptokinase also caused a 20% and 47% reduction in the levels of 
IgA anti-streptokinase antibodies at 5 minutes (Mean value =35.7 units/ml) and 30
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minutes (Mean value 23.7 units/mi) respectively, compared to pre-treatment levels 
(Mean value = 44.5 units/ml) (Figure 6-20).
The levels of IgM did not show any significant changes at 5 (Mean value = 13.9 
units/ml) or 30 minutes (Mean value = 14.5 units/ml) compared to the pre-treatment 
levels (Mean value = 15units/ml) (Figure 6-21).
Administration of streptokinase generated complement activation products C ls:C l- 
INH, C3b-P and free C3d as compared to pre-treatment levels (Figures 6-21 and 6-22). 
This was significant for C3b-P levels at 5 minutes when the levels compared to pre­
treatment levels (Statistic=16, p<0.05). This was however, due to the rapid increase in 
2 patients, in the remaining 2 patients no C3b-P was detectable at 5 minutes.
The levels of generated Cls;Cl-INH correlated with the levels of generated C3b-P
(p=0.95 p<0.005, at 5 minutes) and the levels of free C3d (r=.99 p<0.001, at 30
..i
minutes). The levels of C3b-P correlated with the levels of C3d at 30 minutes (r=0.99,
p<0.001).
The pre-treatment levels of IgG and IgM anti-streptokinase antibodies in the 4 patients 
showed a significant negative correlation with the levels of generated C ls:Cl-IN H  at 
30 minutes (r= - 0.94 p< 0.05) (Table 6-2).
IgA, IgM, C3c and C3d were not detectable on erythrocytes in the 4 patients, however,
IgG was detectable on the erythrocytes of one patient (Patient T.B.) (Figure 6-23). In
this patient the levels of anti-streptokinase IgG antibodies decreased after streptokinase
administration and the levels of E's bound ICs as detected by FITC conjugated sheep
anti-human IgG increased (r=-0.99, p<0.001) (Figure 6-23). This patient (Patient
T.B.) also generated higher levels of Cls:Cl-INH and C3b-P compared with the other 
.3 patients (Figures 6-21 and 6-22) and these levels significantly correlated with the 
levels of E's bound ICs (r=0,99, p<0.001) (Figures 6-21, 6-22 and 6-23 ).
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Figure 6-22: The levels of C3b-P (a) and free C3d (b) in 4 patients withAMI treated with streptokinase.
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Figure 6-23: Fluctuations of IgG anti-streptokinase antibodies and erythrocytes (E's) bound streptokinase 
immune complexes (ICs) during streptokinase administration, in patient T.B. with AMI.
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Table 6-2: Correlation between the pre-treatment levels'of anti-streptokinase antibodies 
(IgG, IgA and IgM) and the levels of complement activation products (Cls:Cl-INH, C3b- 
P, free C3d) generated at 5 and 30 minutes after streptokinase infusion in 4 patients with 
AMI.
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I
Isotype Cls:Cl-INH C3b-P Free C3d 1
IgG -0.7 (NS) 0.38 (NS) -0.2 (NS)
A':1
IgA 0.2 (NS) 0.2 (NS) 0.4 (NS)
;
IgM 0.73 (NS) -0.39 (NS) 0.2 (NS)
i130 minutes
Isotype Cls:Cl-INH C3b-P Free C3d 1
IgG -0.94 (p<0.05) 0.63 (NS) 0.2 (NS) 1
IgA 0.2 (NS) 0.4 (NS) 0.89 (NS) 1
IgM -0.94 (p<0.05) -0.63 (NS) -0.2 (NS)
s
Discussion
Erythrocytes have an important role in clearance of immune complexes from circulation 
and prevention of tissue damage. This is mainly through the action of the complement 
receptor CRl which binds to immune complexes coated with C3b and clears the 
immune complexes from circulation. These important interactions are governed by the 
complement system and the nature of immune complexes. Immune complexes which
are not transported to liver or spleen will eventually be deposited outside the :
reticuloendothelial system and provoke inflammatory response (Schifferli et al 1988). 
The kinetics and dose response of streptokinase immune complexes binding to 
erythrocytes was studied by flow cytometry and its relationship with complement
activation was determined by measuring the Cls:Cl-INH, C3b-P and C3d in the 
accompanying supernatants. This was compared with the thyroglobulin immune 
complexes system as antigens exhibit different molecular weights. Although many 
studies have looked at ICs and E's few models have had the opportunity which is 
given by streptokinase (In vitro or in vivo, rabbit or human systems).
The interactions between rabbit thyroglobulin immune complexes and erythrocytes 
showed that the binding of the ICs not only significantly correlates with the classical 
and alternative pathways activation (r values 0.98 and 0.91 respectively, p<0.001) 
(Figure 6-2) but also is upon the quantity of IC (p<0.001). The binding of rabbit 
streptokinase immune complexes to human ei'ythrocytes also correlated significantly 
with the levels of generated C ls-Cl-INH (Classical pathway activation) and C3b-P 
(Alternative pathway activation) (r= 0.77, p<0.07) (Figure 6-3).This interaction was 
also a dose dependent reaction (r= 0.77, p<0.7) as observed for the rabbit 
thyroglobulin ICs
The relationship of complement activation, the nature of the immune complexes and 
their binding to erythrocytes has been reported by other investigators. Lucisano &
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Lanchmann (1991), using immune complexes consisting of NIP coupled with 
BSA and different antibody isotypes and subclasses to this antigen (IgGl, IgG2, IgG3,
IgG4, IgM and IgA), showed that binding of the immune complexes to erythrocytes
'■>!correlated with the degree of complement consumption (Using haemolytic assays) 7|
which was influenced by the immune complexes nature i.e. antibody isotype or 
subclass and the antibody/antigen ratio.
Rabbit IgG anti-streptokinase generated complement activation products to a lower 
extent compared to the that corresponding immune complexes but bound to human 
erythrocytes to higher extent (Figures 6-3 and 6-4). The generation of complement 
activation products by rabbit anti-streptokinase IgG can be explained by presence of 
aggregated antibodies formed during purification by caprylic precipitation method. The 
higher extent of rabbit IgG binding to the erythrocytes compared to the ICs binding was
:■surprising since the levels of complement activation products generated by the rabbit |
■ )
IgG were substantially lower than the levels generated by the ICs. This may indicate i
that there is a second mechanism involved in the interaction between immune 
complexes or aggregated IgG and erythrocytes. This secondary mechanism will be 
discussed in detail in chapter 7.
The kinetics of ICs binding to E's was studied using 5 doses of rabbit streptokinase 
immune complexes (6-6, Figure 6-5a). Optimal binding was achieved with higher IC 
doses, binding peaked at 5 minutes and then dropped rapidly, this pattern corresponds 
to. binding of ICs to E's followed by release. This pattern is similar to that originally 
described by Medof & Prince (1983) using BSA ICs system, and is explained by 
processing of ICs. The in vitro release of immune complexes from erythrocytes after 5 
minutes can be explained by ongoing complement activation and degradation of C3b 
incorporated in ICs to iC3b, C3c and C3d. These have reduced or no affinity for CRl 
receptors on the erythrocytes and therefore show no binding. During the kinetic study 
of ICs binding to erythrocytes the sampling of E's at 5 minutes (peak of binding),
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followed by complement in^tivation with EOT A showed that after several washing the 
ICs were still detectable on the erythrocytes surface. This supports the hypothesis that 
degradation of C3b by Factor I influences the release of bound ICs from E’s and as 
Yokoyama & Waxman (1994) have shown that Factor I can accelerate the release of 
DNP-BSA ICs from erythrocytes by degradation of C3b to C3dg. Schifferli et al 
(1988), by infusion of preformed radio-labelled tetanus toxoid IC in human showed 
that the ICs bound to E's and transferred from circulation to the reticuloendothelial 
system. The release of ICs from E's due to degradation of C3b is believed to have an 
important effect on the transferring of E bound ICs to spleen and liver.
The levels of erythrocytes bound C3c and C3d generated during complement activation 
by streptokinase and thyroglobulin ICs was studied to find out whether the levels 
bound to E's reflect the extend of complement activation as measured free in serum. 
The levels of E's bound C3c as detected by flow cytometiy using FITC rabbit anti­
human C3c increased during complement activation and reached a peak at 5 minutes. 
After 5 minutes the levels of bound C3c decreased reflecting the degradation of the 
bound C3 (Figure 6-7). The levels of E's bound C3c correlated with the levels of 
generated C3b-P at 5 minutes (r=0.97, p<0.001).
The levels of E bound C3d (as detected by flow cytometry using FITC rabbit anti­
human C3d or modified ELISA) during complement activation reached to a peak 15 
minutes (10 minutes later than C3c) and in contrast to E bound C3c the levels did 
change significantly over the time course (Figures 6-8 and 6-9). This indicates that E 
bound C3d is more resistance to the effects degradation than E's bound C3c, and as 
C3d is covalently bound to E's can not be degraded further. The deposition of C3d on 
erythrocytes is therefore indicates that the complement system is activated (Davies et al 
1990, Freysdottir et al 1993) and may be used in clinical situations.
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The study of the kinetics and dose response of rabbit thyroglobulin and rabbit 
streptokinase immune complexes binding to erythrocytes provided a helpful 
background for the study of human streptokinase immune complexes (6-10).
Preformed human streptokinase immune complexes at equivalence prepared from the 
serum of a patient with elevated levels of anti-streptokinase antibodies and the levels of 
E bound IgG, IgA and IgM incorporated into streptokinase ICs was studied. Similar to 
the results observed with rabbit streptokinase ICs, the levels of bound human 
streptokinase ICs reached a peak at 5 minutes after which levels decreased. This was 
accompanied by generation of bound and free complement activation products, peaking 
10 minutes later than E bound ICs (Figures 6-13, 6-14, 6-15 and 6-16). The presence 
of erythrocytes treated with anti-CRl (E-CRl) did not inhibit the binding of immune 
complexes to erythrocytes as detected by FITC anti-human IgG, however, it decreased 
the levels of E's bound ICs detected by FITC anti-human IgA and IgM (Figures 6-14 
and 6-15). As described the activation of complement is essential for the binding of 
immune complexes to erythrocytes. Although, this experiment showed that even by 
blocking CRl receptor, ICs (Detected by FITC anti-IgG) bound to erythrocytes and 
also are resistance to the complement mediated degradation-and release from the E's, as 
in the presence of anti-CRl E's bound ICs (Detected by FITC anti-IgG) were 
significantly detectable at 24 hours despite of ongoing complement activation. 
Furthermore, immune complexes in absence of NHS bound to erythrocytes (6-5). This 
observation may be as a result of binding of immune complexes containing IgG to 
erythrocytes through a second mechanism, possibly Fey receptor and will be discussed 
in chapter 7 (Hajos et al 1978).
The antigen/antibody ratio influenced the binding of immune complexes to 
erythrocytes. Human streptokinase immune complexes at equivalence bound to 
erythrocytes to higher extent compared to antibody excess and antigen excess (Figure
6-20b) (6-11). At antibody excess the levels of bound immune complexes were 49 %
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higher than the antigen excess (Figure 6-20b). The immune complex size and the nature 
of ICs and ratio of antibody/antigen affect the binding of immune complexes to 
erythrocytes and ultimately determine the fate of the immune complexes. Lucisano et al 
1991 using NIP-BSA ICs showed that nascent ICs bind to E's to a lower extent than 
preformed ICs, the observed difference is thought to depend on the size of the ICs, 
since solubilization of preformed ICs takes time and nascent ICs are smaller than 
preformed ICs.
EDTA inhibited the binding of immune complexes to erythrocytes, however, EOT A 
only partially inhibited the binding (Figure 6-20b). The alternative pathway activation 
and immune complexes binding erythrocytes through this activation was rather 
unusual. This can be explained by insufficient concentration of EOT A for inhibiting the 
activation.
Studying the levels of anti-streptokinase antibodies the 4 patients with AMI treated with 
streptokinase and the extent of complement activation (6- 12) showed similar results 
with the first 10 patients (Chapter 3), this is indicative that administered streptokinase 
caused immune complexes formation and complement activation. Freysdottir et al 1993 
showed that the levels of bound C3d on erythrocytes were detectable at 1 ,2  hours and 
day 7 post-administration of streptokinase, however, E bound streptokinase ICs were 
not detectable at that time points. This is not surprising as shown previously E bound 
ICs are cleared rapidly from circulation (Schifferli et al 1988). In this study although 
the levels of complement activation products were detectable at 5 minutes and 30 
minutes ( Figures 6-2 la  and 6-22) C3d was not detectable on the E's at this time 
points. On the other hand, streptokinase immune complexes were detectable on 
erythrocytes in one patient (Patient T.B.) (Figure 6-23). This patient generated higher 
levels of C ls:Cl-IN H  and C3b-P compared to other 3 patients. The levels of E's 
bound ICs and serum anti-streptokinase IgG inversely correlated with one another
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(r=.99, p<O.CX)i) (Figure 6-23). This clearly showed that streptokinase ICs formed 
during the first 30 minutes of streptokinase infusion bound to erythrocytes.
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Chapter 7
Non-complement dependent binding of immune complexes to
erythrocytes
Introduction
Study of the kinetics and dose response of streptokinase immune complexes (ICs) 
binding to erythrocytes by flow cytometry and its relationship with complement 
activation as was determined by measuring the Cls;Cl-INH, C3b-P and C3d in the 
accompanying supernatants showed that the binding of the ICs significantly correlates 
with complement activation and depends on the nature of the immune complex (Chapter
6).
The experimental protocols utilised however lead to the conclusion that an Fey receptor 
may also be involved as an alternative mechanism of binding of immune complexes to 
erythrocytes. The observation that immune complexes in the absence of NHS 
(Complement) bind to erythrocytes supported this hypothesis. Other supportive 
evidence was enhanced binding of aggregated rabbit IgG anti-streptokinase in the 
absence of NHS compared to in the presence of NHS. This observation indicates that 
the binding is not only a complement mediated interaction. Based on these pieces of 
evidence we decided to further investigate Fey mediated binding, to allow better 
understating of IC clearance mechanisms.
To study this phenomenon an indirect haemagglutinin test for rabbit IgG anti- 
streptokinase was developed to find whether the capacity of erythrocyt binding (in 
absence of complement) varied among the population. As described FcyR is expressed 
in three forms, FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD16) (1-7). Using
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monoclonal anti-FcyR antibodies and flow cytometry technique the presence of these 
receptors on the erythrocytes were investigated. The binding of F(ab')2 fragment to 
erythrocytes was studied and compared with the intact IgG. As described the specificity 
of Fey receptors for binding to the IgG subclasses varied among the three forms of 
receptors (Table 1-2), therefore the interactions of mouse and human IgG subclasses 
with human erythrocytes were studied.
Materials and methods
7-1 Indirect (Passive) haemagglutinin test for rabbit anti-streptokinase 
IgG . As the rabbit IgG binds to human erythrocytes, to find whether the binding 
varied among the population, an indirect (Passive) haemagglutinin test was developed. 
This technique involves passive binding of IgG to erythrocytes (E's) then incubating 
with donkey anti-rabbit IgG to agglutinate E's,
Materials and Buffer: Sources of materials used here were described in 2-1.
Rabbit anti-streptokinase IgG 
Donkey anti-rabbit IgG 
Human erythrocytes 
Phosphate buffered saline (PBS)
Round bottomed microplate
Method. Blood was collected by venesection from healthy volunteers and patients in 
EDTA (2-16). The normal group consisted of 8 individuals and groups of patients were 
as following; 18 patients with rheumatoid arthritis, 9 patients with SEE and 32 patients 
with miscellaneous diseases. The blood was spun at 1200 rpm, at 4°C for 10 minutes.
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the buffy coat layer was completely removed and the cells were washed three times in 
PBS and resuspended in the same buffer. The cells were then standardised to IX 10  ^
cells/ml (2-17).
130 pg rabbit IgG anti-streptokinase (2-13 and 2-19) was incubated with the 5 mi 
erythrocytes ( IX 10  ^cells/ml) at37°C for half an hour with occasionally shaking. After 
incubation the cells were washed once with PBS and standardised to IX 10^ cells/ml 
(2-17).
Donkey anti-rabbit IgG (heat inactivated) diluted 1/5 in PBS was applied to a round- 
bottomed microplate and double diluted across 2 rows of the plate 23 times. The last 
well (number 24) contained only PBS and was used as control. 50 pL of the 
erythrocytes suspension were then applied per well, the plates were gently shaken and 
incubated at room temperature for 2 hours.
The plates were read using an inverted magnifying mirror. The last dilution which 
prevented the sedimentation of erythrocytes was considered as the end point of the 
agglutinin titre and expressed in reciprocal titre (Figure 7-1).
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Figure 7-1: Indirect haemagglutinin test for rabbit IgG anti-streptokinase. Donkey anti- 
rabbit IgG applied to the two rows of microplate for each sample and double diluted from 
well 1 to well 23. The last well (24th well) is control.
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7-2 Preparation of F(ab')2 fragment of IgG. F(ab')2 was prepared by pepsin 
digestion, this digestion results in Fc and F(ab')2 fragments of which the latter contains
23).
Materials: Sources of materials used here were described in 2-1. 
Rabbit IgG anti-streptokinase (2-13 and 2-19)
Pepsin
Protein G Sepharose 4B 
Buffers:
the intact antigen binding site (MW=100kD). Protein G-Sepharose was used to bind the 
Fc portion of IgG and unbound F(ab')2 and bound Fc fractions can be then eluted (2-
Sodium phosphate 0. IM (pH 7.0) (2-23) 
0.1 M sodium acetate (2-23)
O.IM glycine (2-23)
Method. 5 ml of rabbit IgG anti-streptokinase (13 mg/ml) was dialysed extensively 
against 0.1 M sodium acetate for 3 hours at 4°C. The pH of the IgG was adjusted with 
0. IM acetic acid to 4.5 (2-19). 1 mg pepsin (1-2 mg per 100 mg IgG) was added to the |
IgG and incubated at 37°C overnight. The digested sample was then spun and any 
precipitate discarded, the pH was adjusted to 7.4 by addition of solid Tris. The sample
was then dialysed extensively against PBS for 3 hours at 4°C to inactivate the enzyme.
Protein G-Sepharose was pre-washed with 0.02M sodium phosphate buffer and 
resuspended in buffer to give a ratio of 25% 0.02M sodium phosphate buffer and 75%
Sepharose. The digested IgG was then added to the protein G-Sepharose and mixed at 
room temperature for 90 minutes. The Sepharose was then spun and the supernatant 
containing F(ab')2 removed and retained- The Sepharose was recycled by washing 3 |
times in 0. IM glycine and resuspended in 20% ethanol.
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7-3 Binding of rabbit IgG anti-streptokinase and F(ab')2 fragm ent to 
human erythrocytes. Binding of rabbit IgG anti-streptokinase and F(ab')2 fragment
to human erythrocytes(E's) in presence and absence of NHS was studied by flow 
cytometry. In presence of NHS complement activation products Cls:Cl-INH and C3b- 
P were measured in the supernatants (5-3).
Materials: Sources of materials used here aie described in 2-1.
Rabbit IgG anti-streptokinase (2-13 and 2-19)
Rabbit F(ab')2 anti-streptokinase (7-2)
FITC conjugated donkey anti-rabbit IgG 
NHS
Human erythrocytes 
Falcon round-bottomed tubes
Buffers
Phosphate buffered saline (PBS)
1%BSA in PBS
20 mM isotonic EDTA (2-2)
ELISA buffers (5-3)
Method. Erythrocytes (E's) were obtained by venesection from healthy volunteers, 
blood was clotted in EDTA (2-16) and spun at 1200 rpm, at 4°C for 10 minutes. The 
buffy coat layer was completely removed and remaining E's were washed three times in 
PBS. 580 fxg of rabbit IgG anti-streptokinase or 580 pg rabbit F(ab')2 anti- 
streptokinase were added with 50 pi of packed erythrocytes and 500 pi NHS or 50 pi 
of packed erythrocytes and 500 pi PBS. The volume of mixtures were equalised to 700 
pi with PBS and incubated at 37°C for 30 minutes. The assay was sampled at 0, 5, 15 
and 30 minutes by removing 50 pi and adding to equal volume of ice cold 20 mM
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isotonie EDTA. The samples were then spun at 4°C for 5 minutes, the supernatants 
were removed and analysed for the presence of the complement activation products (5- 
3). Erythrocytes were further washed in ice cold 1% BSA in PBS and resuspended in 
the same buffer to IXIO^ cells/ml (6-1). Erythrocytes were then incubated with an equal 
volume of FITC donkey conjugated anti-rabbit IgG (diluted 1/20 in PBS) for 30 
minutes in an ice bath. The cells were washed twice with 1% BSA in PBS and analysed 
by a FACscan flowcytometer (6-4). The negative control contained 500 pi NHS and 50 
pi of packed erythrocytes (Total volume = 700 pi with PBS) at 37°C and incubated 
with FITC conjugated donkey anti-rabbit IgG at above condition.
7-4 Inhibition of binding of rabbit IgG anti-streptokinase to human  
erythrocytes. To investigate whether human Fc fragment can inhibit the binding of 
rabbit IgG to human erythrocytes an inhibition assay was performed as following. 
Materials: Sources of materials used here are described in 2-1.
FITC conjugated donkey anti-rabbit IgG
Human IgG Fc fragment
Rabbit IgG anti-streptokinase (2-13 and 2-19)
FITC conjugated donkey anti-rabbit IgG 
Goat anti-human IgG (Fc fragment specific)
Human erythrocytes 
Falcon round-bottomed tubes 
Buffers
Phosphate buffered saline 
1%BSA in PBS
Method. Erythrocytes (E's) were obtained by venesection from healthy volunteers, 
blood was clotted in EDTA (2-16) and spun at 1200 rpm, at 4°C for 10 minutes. The 
buffy coat layer was completely removed and remaining E's were washed three times in
286
"a
Materials and buffer: Sources of materials used here are described in 2-1 
Human erythrocytes
Mouse monoclonal anti-human CD64 (FcyRI)
Mouse monoclonal anti-human CD32 (FcyRII)
Mouse monoclonal anti-human CD 16 (FcyRIII)
Mouse IgGl monoclonal anti-human AFP
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PBS and standardised to iXlO^ cells/ml (6-1). The purity of human Fc fragment was
checked by lEP using goat anti-human Fc fragment and anti-human IgG.
100 pi (500 pg) of human Fc and 500 pi erythrocytes (0.5X10^ cells) or 100 pi 1%
BSA in PBS per 500 pi erythrocytes (0.5X10^ cells) were incubated at 37°C for 30 
minutes. The mixtures were spun at 1200 rpm, at 4°C for 5 minutes, the supernatants 
were removed and the pellets resuspended with 500 pi 1% BSA in PBS. The 
suspensions of E's were then incubated with 260 pg of rabbit IgG anti-streptokinase at 
37°C for 30 minutes. Erythrocytes were then washed once in ice cold 1% BSA in PBS 
and resuspended with 500 pi 1% BSA in PBS. The E's were then incubated with an 
equal volume of FITC conjugated donkey anti-rabbit IgG (diluted 1/20 in PBS) for 30 
minutes in an ice bath. The cells were further washed in 1% BSA in PBS twice and 
analysed by a flowcytometer (6-4). Negative control consisted of a 500 pi E's 
suspension (0.5X10^ cells) incubated with FITC conjugated donkey anti-rabbit IgG at 
above condition.
7-5 The binding of m onoclonal anti-FcvR antibodies to hum an  
erythrocytes. To study whether monoclonal anti-human FcyR antibodies can 
recognise any epitopes on the human erythrocytes, the binding of a set of these 
antibodies directed against FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD 16) was 
examined by flow cytometry.
FITC conjugated rabbit F(ab')2 anti-mouse immunoglobulin
Falcon round-bottomed tubes
Filtered phosphate buffered saline (PBS)
7-6 Purification of human IgG by Ion exchange chrom atography.
Diethylaminoethyl cellulose (DE52, Whatman) binds to negative charged ions. The 
serum to be used should be dialysed into the column buffer (pH 7.6), under this 
condition IgG with a positive charge does not bind to DE52 and can be eluted, the 
remaining proteins being retained.
Materials: Sources of materials used here are described in 2-1.
Diethylaminoethyl cellulose (DE52, Whatman)
NHS, 30 ml pooled sera from normal individuals (protein concentration 78.6 mg/ml)
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Method. Erythrocytes were prepared and standardised to IX 10® cells/ml as described 
(7-3). 5pg of mouse monoclonal anti-human CD64 (FcyRI), mouse monoclonal anti­
human CD32 (FcyRII), mouse monoclonal anti-human CD 16 (FcyRIII) and mouse 
monoclonal anti-human AFP were incubated with 100 pi erythrocytes (contained 
5XlO^) at room temperature for half an hour. Erythrocytes were washed once in PBS 
and resuspended in lOOpl PBS. The erythrocytes were then incubated with 20pl of 
FITC conjugated rabbit F(ab')2 anti-mouse immunoglobulin (diluted 1/20 in PBS) for 
half an hour at room temperature. The cells were washed in PBS and analysed by a 
flowcytometer as described (6-4). The negative control consisted of 100 pi erythrocytes 
(contained 5XlO^) and 20pl of FITC conjugated rabbit F(ab')2 anti-mouse 
immunoglobulin (diluted 1/20 with PBS).
I
60 ml syringe barrel
Buffer: 0.0IM sodium phosphate buffer pH 7.6 (5-1)
(Conductivity at 4°C, 0.5- 0.8 mS)
Column: 1.5 X 9 cm column (60 ml syringe barrel) 
containing DE52 extensively equilibrated with buffer.
Method. After dialysis the pooled sera was applied and washed through the column 
with buffer and 3 ml fractions were collected, the protein concentration of the collected 
fractions were measured at 280 nm. The factions containing the protein peak were 
pooled (Figure 7-2).
The prepared IgG from pooled NHS was tested for purity by lEP, a single arc against 
anti-human IgG was observed and no precipitation with anti-human IgA and IgM was 
observed (2-9). The prepared sample was run on a 7.5% SDS-PAGE gel one band 
with molecular weight of 150 kDa was observed. Concentration of purified IgG was 
5.1 mg/ml.
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7-7 Binding of hum an ïgG  to ery th rocy tes. To study the binding of human 
IgG to erythrocytes 3 sources of IgG were used, 1) Pooled NHS (5.1 mg/ml IgG, 7-
'"h6), 2) Pooled sera from patients with elevated levels of anti-streptokinase antibodies.
purified by caprylic acid (14 mg/ml IgG, 2-19) 3) The serum from a patient with an 
IgGl myeloma (21.3 mg/ml IgG, 7-6). Human IgG prepared from the sera of patients 
with elevated levels of anti-streptokinase antibodies on a 7.5% SDS-PAGE gel 
presented four bands with molecular weights of 150kD, 97kD, 78kD and 67 kD.
The proportion of IgG subclasses in the 3 IgG sources was determined by the Clinical 
Immunology Laboratory, Department of Immunology, Western Infirmary, Glasgow.
Materials: Sources of materials used here are described in 2-1 
Human erythrocytes 
Human IgG
FITC conjugated sheep anti-human IgG 
Falcon round-bottomed tubes 
Filtered phosphate buffered saline (PBS)
Method. Erythrocytes were prepared and standardised to iX 10^ cells/ml (7-3). 5pg of 
IgG from the 3 IgG sources mentioned above were incubated with 100 pi erythrocytes 
(Contained 0.5Xl0^ cells) at room temperature for 30 minutes. Erythrocytes were 
washed in PBS and resuspended in lOOpI PBS. The erythrocytes were then incubated 
with 20pl of FITC conjugated sheep anti-human IgG (diluted 1/20 in PBS) for half an 
hour at room temperature. The cells were washed twice in PBS and analysed by a 
flowcytometer (6-4). Negative control consisted of 100 pi erythrocytes (Contained 
0.5Xl0^ cells) incubated with 20pi FITC conjugated sheep anti-human IgG (diluted 
1/20 with PBS) at same conditions described.
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7-8 Specificity of human IgG subclasses for human erythrocytes. The
specificity of IgG subclasses for the 3 forms of Fey receptors is different (Table 1-2), 
the binding of human IgG subclasses to human erythrocytes was studied.
Materials: Sources of materials used here are described in 2-1 
Human erythrocytes
Monomeric human IgG subclasses IgGl, IgG2, IgG3 and IgG4 
Aggregated human IgG subclasses IgGl and IgG3 
FITC conjugated sheep anti-human IgG 
Falcon round-bottomed tubes 
Filtered phosphate buffered saline (PBS)
Method. Erythrocytes were prepared and standardised to iX 10® cells/ml (7-3). lOOpg 
of human subclasses IgGl, IgG2, IgG3 and IgG4 or 50pg of aggregated human IgGl 
and IgG3 were incubated with 100 pi erythrocytes (Contained 0.5X10^ cells) at room 
temperature for half an hour. Erythrocytes were washed once in PBS and resuspended 
in 100pi PBS. The erythrocytes were then incubated with 20pl of FITC conjugated 
sheep anti-human IgG (diluted 1/20 with PBS) for half an hour at room temperature. 
The cells were washed twice in PBS and analysed by a flowcytometer (6-4). A mixture 
of 0.5Xl0^ erythrocytes and 20pl FITC conjugated sheep anti-human IgG (diluted 1/20 
with PBS) was used as negative control. Negative control consisted of 100 pi 
erythrocytes (Contained 0.5X10^ cells) incubated with 20pi FITC conjugated sheep 
anti-human IgG (diluted 1/20 with PBS) under the same conditions.
7-9 Specificity of moose IgG subclasses for human erythrocytes. The
specificity of IgG subclasses for the 3 forms of Fey receptors is different (Table 1-2), 
the binding of mouse IgG subclasses to human erythrocytes was studied.
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Materials: Sources of materials used here are described in 2-1 
Human erythrocytes
Mouse IgG subclasses IgGl, IgG2a, IgG2b and lgG3 
Aggregated mouse IgG subclasses IgGl, IgG2a, IgG2b and IgG3 
FITC conjugated rabbit F(ab')2 anti-mouse immunoglobulin 
Falcon round-bottomed tubes 
Filtered phosphate buffered saline (PBS)
Method. Erythrocytes were prepared and standardised to IX 10  ^cells/ml (7-3). 64pg of 
the mouse subclasses IgGl, IgG2a, IgG2b and IgG3 or 16pg of the con es ponding 
aggregated antibodies were incubated with 100 pi erythrocytes (Contained 0.5Xl0^ 
cells) at room temperature for half an hour. The erythrocytes were then washed once in 
PBS and resuspended in lOOpl PBS. The erythrocytes were incubated with 20pl of 
FITC conjugated rabbit F(ab')2 anti-mouse immunoglobulin (diluted 1/20 with PBS) 
for half an hour at room temperature. The cells were washed twice in PBS and analysed 
by a flowcytometer as described (6-4). Negative control consisted of 100 pi 
erythrocytes (Contained 0.5Xl0^ cells) incubated with 20pi FITC conjugated sheep 
anti-human IgG (diluted 1/20 with PBS) at same conditions described.
7 10 Erythrocytes surface biotinylation and purification of putative 
erythrocyte IgG binding protein. The aim of this procedure was to biotin label 
the surface proteins of erythrocytes, lyse the cells and elute specific IgG binding 
proteins from a IgG-Sepharose column.
Materials and buffers 
Human erythrocytes
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Biotin N-hydroxy-succinimide ester (2-1)
Dimethyl Sulphoxide (DMSO)
Phenyl methyl soiphonyl fluoride (PMSF) (Sigma)
Nonidet P40 (NP40)
Affinity chromatography column (Sepharose 4B coupled to human IgG) (4-3) 
SDS-PAGE materials and buffer (2-11)
Western blotting materials and buffers (2-12)
Method. Erythrocytes were prepared and standardised to IX 10  ^ cells/ml in PBS (7-3). 
0.4 mg biotin N-hydroxy-succinimide ester (From stock solution 5mg/ml biotin N- 
hydroxy-succinimide ester in DMSO) was added to 4 ml erythrocytes (Contained 
5XlO^/ml erythrocytes) and the mixture was shaken gently at room temperature for 15 
minutes. The erythrocytes were then washed 3 times in PBS and lysed at a 
concentration of 10  ^cells per ml in PBS containing 2mM PMSF and 1% NP40. The 
erythrocytes were then spun at 18000 rpm for 20 minutes.
Affinity chromatography column contained Sepharose 4B coupled to human IgG was 
prepared as described before (4-3). The supernatant of lysed erythrocytes were applied 
and washed through the column with PBS, 1 ml fractions were collected, the protein 
concentration of fractions were measured at 280 mn.
The specifically bound material was eluted by washing the column with 0.1 M Glycine- 
HCl (pH 2.5) (4-3) and 1 ml fractions were collected, the protein concentration of 
fractions were measured at 280 nm.
The fractions which contained the protein peak were pooled and run on a 7.5% SDS- 
PAGE gel . The gel was then transferred to a nitro-cellulose membrane for Western 
blotting. The blot was blocked with 1% Marvel in TBS (2-12) and after washing 
incubated with alkaline phosphatase Avidin-D. The colour was developed using 
phosphatase substrate (BCIP/NBT) (2-1).
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Results
Indirect (Passive) haemagglutinin test for rabbit anti-streptokinase IgG.
To find whether the binding of rabbit IgG to human erythrocytes varied among the 
population, an indirect (Passive) haemagglutinin test was developed and the binding of 
IgG to erythrocytes from 8 normal individuals, 18 patients with rheumatoid arthritis, 9 
patients with SLE and 32 patients with miscellaneous diseases was studied (7-1). The 
results were expressed as reciprocal of end titre, in the normal group the end point titres 
were all clustered around a value of 32768. Little spread was seen in the levels of 
binding as reflected by the reciprocal titre (Figure 7-3). In rheumatoid arthritis patients 
the mean of reciprocal titre (985560) was greater than other groups (3.5 times greater 
than normals, 5.6 times greater than SLE patients and 2.9 times greater than 
miscellaneous group) (Figure 7-3). In SLE patients the mean of reciprocal titre (17312) 
was lower than other groups (1.5 times lower than normals, 5.6 times lower than RA 
patients and 1.9 times lower than miscellaneous group) (Figure 7-3). The trend was a 
greater spread of values in patients groups (Figure 7-3).
Binding of rabbit IgG anti-streptokinase and F(ab')2 fragment to human 
erythrocytes. The binding of rabbit IgG anti-streptokinase and the F(ab')2 fragment 
to human erythrocytes was studied in presence and absence of NHS together with 
generated levels of complement activation products (7-3). The purity of prepared rabbit 
F(ab')2 (contained 3.9 mg /ml protein, 7-2) was checked by lEP (2-9) which showed a 
different mobility when compared with intact rabbit IgG (Figure 7-4).
IgG and F(ab')2 fragment when incubated with NHS did not result in generation 
C ls:C l-IN H  levels compared to NHS alone (Figure 7-5a). In contrast, IgG and 
F(ab')2 fragment when added to NHS resulted in predominant of C3b-P peaking at 15 
minutes (Figure 7-5b).
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In the presence of NHS the IgG fraction of rabbit anti-streptokinase bound to human 
erythrocytes peaking at 11% at 5 minutes. The levels of bound IgG then began to 
decrease to 5% at 30 minutes (Figure 7-6a), F(ab')2 fragment of rabbit anti­
streptokinase IgG in presence of NHS showed a similar pattern of binding to 
erythrocytes, however the peak binding at 5 minutes was 5% (Figure 7-6a). The levels 
of bound IgG did not significantly correlate with the levels of complement activation 
products.
In the absence of NHS the levels of erythrocyte bound IgG were significantly higher 
than in the presence of NHS (Figure 7-6b). In the presence of NHS peak binding 
occurred at 5 minutes and then declined, however, in the absence of NHS binding of 
IgG steadily increased over the 30 minutes incubation (Figure 7-6). At 30 minutes 80% 
of the E's showed positive for IgG. in sharp contrast F(ab')2 fragment did not show 
high levels of E's binding. However, at 15 minutes the levels of binding were similar 
to those for IgG in the presence of NHS (Figure 7-6a, b). The binding of F(ab')2 
fragment unlike IgG was not stable (Figure 7-6b).
Inhib ition  the binding of rabbit IgG anti-streptokinase to human 
erythrocytes. To investigate whether human Fc fragment can inhibit the binding of 
rabbit IgG to human erythrocytes (E's), erythrocytes (0.5 X 10  ^ E's) were pre-treated 
with Fc or PBS and the incubated with rabbit IgG (7-4). The human Fc fragment used 
here was pure as checked by lEP using goat anti-human Fc fragment and anti-human 
IgG (plate not presented) and was used at a concentration of almost twice (500 p,g) that 
of rabbit IgG (260 pg) to give approximately an equal number of the molecules (500 pg 
Fc = 6X10^^ molecules and 260 pg rabbit IgG = 1.04 X 10^ "^  molecules).
The binding of rabbit IgG was determined using FITC anti-rabbit IgG as the probe. 
The fluorescent probe alone gave 2.6% binding, this considered as background.
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Incubation of E’s with rabbit IgG resulted in 55% positive E's, blocking with Fc ë
reduced this value to 29% (Figure 7-7).
I
Binding of monoclonal anti-FcvR antibodies to human erythrocytes. To Istudy whether monoclonal anti-human FcyR antibodies can recognise any epitopes on 
the surface of human erythrocytes a set of these mouse monoclonal antibodies directed 
against FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD 16) were incubated with
ierythrocytes and probed with FITC anti-mouse detected by flow cytometry (7-5). The |
negative control consisted of replacing the anti FcyR antibodies with mouse monoclonal 
anti-human AFP (IgGl).
Of the three monoclonal anti-FcyR used, only anti-FcyRI (CD64) gave a significant 
positive signal compared to irrelevant mouse monoclonal antibody control (Figure 7-8).
Binding with anti-CD64 was 29% compared to 1.9% with anti-AFP (Figure 7-8).
Binding of human IgG to erythrocytes. The binding of three sources of human 
IgG to erythrocytes. IgG was studied with 3 sources of IgG, prepared by ion exchange 
chromatography (7-7), caprylic acid precipitation method (2-19) and the serum from a
patient with an IgGl myeloma (7-8). The distribution of the subclasses within these 
IgG preparations are shown in table 7-1.
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Figure 7-3: Reciprocal titres of indirect haemagglutinin test for binding of rabbit IgG 
anti-streptokinase to human erythrocytes in different groups.
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Figure 7-4: Immunoelectrophoresis o f rabbit IgG anti-streptokinase and F(ab')2 
fragment prepared by pepsin digestion and protein G coupled to Sepharose (Well 1 IgG 
fraction, well 2 F(ab')2 fragment). After electrophoresis, donkey anti-rabbit IgG was 
applied to the trough a and sheep anti-rabbit F(ab')2 specific was applied to trough b.
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Figure 7-7: Histograms of fluorescence intensity (log scale x axis) of HTC anti-rabbit IgG 
binding to human erythrocytes (E'). a) E's Incubated with rabbit IgG b) E's pre-incubated 
with human Fc then incubated with rabbit IgG c) FITC conjugate alone.
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Figure 7-8: The binding of monoclonal anti-FcyR antibodies, FcyRI (CD64), FcyRII
(CD32) and FcyRIII (CD 16), to human erythrocytes expressed as percentage binding of 
FITC anti-mouse. Mouse IgGl monoclonal anti-human AFP incubated with the 
erythrocytes or erythrocytes alone with FITC anti-mouse IgG were used as
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Figure 7-9; The binding of human IgG prepared by ion exchange chromatography, caprylic acid and 
from myolema patient to erythrocytes (E's), was studied by flow cytometry.
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The IgG obtained by caprylic acid purification contained predominantly IgG l, similarly 
the sample from myeloma patient contained predominantly IgGl. IgG prepared by ion 
exchange chromatography contained 55% IgGl, 34% IgG2, 7.7% IgG3 and 1.3% 
IgG4 (Table 7-1). These values are closer to the values observed in normals (58% 
IgG l, 29.7% IgG2, 6.9 % Ig03 and 4.9 % IgG4).
IgG prepared by ion exchange chromatography bound to a higher extent to E's 
compared to the other two IgG preparation. By flow cytometry IgG purified by DE52 
showed 70% of E's positive, IgG purified by caprylic acid 38%, and myeloma IgG 
showed 45% binding (Figure 7-9). This reduced erythrocyte binding of IgG was 
observed when IgGl concentrations were elevated.
Binding of human IgG subclasses to human erythrocytes. The specificity of 
IgG subclasses for the 3 forms of Fey receptors is well known to differ (Table 1-2), 
and as IgG from different sources bound differential to E's (see above) the binding of 
pure human IgG subclasses to erythrocytes was studied (7-9).
Commercial supplies of human IgG subclasses were used to study their binding to 
human E's. Using the same concentration of each isotype IgG2 showed higher 
percentage binding to E's (81%) as measured by FACscan (Figure 7-10). This was 
followed by IgGl (51%), IgG3 (26%) and IgG4 (5.4%). Little binding of aggregated 
IgG subclasses was observed (Figure 7-10, Table 7-2).
Binding of mouse IgG subclasses to human erythrocytes. The pattern of 
mouse subclasses binding to human FcgR is well investigated (Table 1-2). 
Commercial supplies of the four mouse IgG subclasses were obtained and the binding 
of a constant amount of the four subclasses to human erythrocytes was studied (7-10). 
B inding was detected using FITC conjugated rabbit F(ab')2 anti-m ouse 
immunoglobulin, and FACscan analysis (7-10).
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All four isotypes in their monomeric form showed some binding to human E's 
compared to the control (Figure 7-11). Highest binding was seen with monomeric 
IgG2b (12.44%). Optimal binding however was seen with heat aggregated IgG3 
(Figure 7-11, Table 7-2).
E rythrocytes surface b iotiny lation  and p u rifica tion  o f pu tative  
erythrocyte IgG binding protein. The aim of this procedure was to label the 
surface proteins of erythrocytes with biotin then lyse the cells in NP40 and affinity 
purify the IgG binding protein on IgG-Sepharose (7-11). 4 ml of erythrocytes 
(5XlO^/ml erythrocytes) were labelled and the lysate applied a column containing 
Sepharose 4B coupled to human IgG, 1 ml fractions were collected and the protein 
concentration was measured at 280 nm (Figure 7 -12a).
The bound material was then eluted from the column with Glycine-HCl (pH 2.5) and 1 
ml fractions were collected, the protein concentration measured at 280 nm (Figure 7- 
12b). Application of Glycine-HCl resulted in the elution of a broad protein peak tube 1- 
12, and single tube peak at 24. The peak protein fractions (Fractions 6 and 24, Figure 
7 -12b) were pooled and applied to a 7.5 % SDS-PAGE gel and after electrophoresis 
was transferred to a nitro-cellulose membrane for Western blotting. After blocking and 
incubating with alkaline phosphatase Avidin-D the no colour was developed.
Discussion
Study of interactions between anti-streptokinase immune complexes and erythrocytes 
revealed that the binding of the immune complexes is not only a complement mediated 
interaction but they also can bind to erythrocytes in the absence of complement. Other 
investigators have shown that immune complexes bind to human erythrocytes in the
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absence of complement (Hajos et al 1978, Vireila et al 1983), although the involved 
mechanisms are not clear, and the idea not widely supported.
To study the binding of IgG to erythrocytes two methods were utilised, an indirect 
haemaglutination assay and FACscan analysis. The indirect haemagglutinin test was 
used to assess the levels of IgG binding protein on surface of E's among normal 
individuals and patients groups. This revealed that the binding capacity of human 
erythrocytes for rabbit IgG differs (Figure 7-4). The patients showed a wider spread in 
their ability to bind IgG and erythrocytes of SLE patients trended to have lower binding 
capacity for IgG, the erythrocytes of rheumatoid arthritis patients had a higher binding 
capacity (Figure 7-4). These findings suggest that the capacity of erythrocytes to bind 
IgG varies, and greater variation in binding is observed in patients population (Figure 
7-4). These findings indicated that the binding was not occuning non-specifically.
To further elucidate binding a comparison between rabbit IgG anti-streptokinase and 
F(ab')2 fragment binding to human erythrocytes (7-3) revealed that rabbit anti­
streptokinase IgG bind significantly to human erythrocytes, however, F(ab')2 
fragments do not (Figure 7-6b). These observations implied that specific binding of 
IgG occurs through Fc portion and not F(ab')2 fragment.
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Figure 7-10: The percentage binding of human IgG subclasses to erythrocytes, 
as measured by flow cytometry (Agg.^aggregated, E's=erythrocytes) 308
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Figure 7-11: Percentage binding of mouse IgG subclasses to human erythrocytes (E's). (Mono=monomeric, Agg.=aggregated) 309
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Percentage of subclasses
IgG Source IgGl Ig02 Ig03 IgG4
Chromatography 55% 34% 7.7% 1.3%
Caprylic acid 90% 5.7% 2.4% 1.8%
Myeloma 95% 2.7% 0.8% 1.3%
Table 7-1: The proportion of IgG subclasses in 3 sources of IgG, prepared by ion 
exchange chromatography, by caprylic acid precipitation and the serum of a patient with
myeloma.
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IgG subclass Monomer Aggregated
Mouse IgG2b>IgG3, IgG2a>IgGl I gG3»>IgGl>IgG2a>IgG2b
Human I gG2>I gG 1 >I gG3»>IgG4 IgGl >  IgG3
Table 7-2: Affinity of human and mouse IgG subclasses for binding to human erythrocytes 
using FITC rabbit F(ab')2 anti-mouse immunoglobulin and FACscan analysis.
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Figure 7-12: Elution profile of lysed erythrocytes washed through a Sepharose column coupled 
to IgG (a) and the bound material to the column was then eluted by Glycine-HCl pH 2.5 (b).
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Using flow cytometry human IgG (Fc fragment) was shown to inhibit the binding of 
rabbit IgG to human erythrocytes by 26% (Figure 7-7) indicating that both rabbit IgG 
and Fc fragment of human IgG bind to the same sites on the erythrocytes. This was in 
agreement with Hajos et ai 1978 who using a Coombs test showed that Fey fragment 
and not the Fab fragment inhibits the binding of human IgG and immune complexes to 
erythrocytes.
The presence of Fc R on the red cells in rabbit, guinea pig, sheep, birds, reptiles, 
amphibian has been reported previously (Hajos et al 1978), however, in human the 
presence of FcR on the erythrocytes is still very controversial. Using a set of 
monoclonal anti-human FcyR antibodies [(FcyRI (CD64), FcyRII (CD32) and FcyRIII 
(CD 16)], revealed that anti- FcyRI (CD64) is detectable on human erythrocytes (Figure 
7-8). Fey RI (CD 64) (MW = 72 kD) is a high affinity receptor for monomeric IgG 
although the binding of aggregated IgG to the receptor is reported to have the same 
affinity as monomeric IgG (Hulett & Hogarth 1994). This receptor that it is expressed 
on monocytes and naive macrophages has 3 isoformes (isoforms A, B and C) which 
only the specificity of IgG subclasses for isoform A has been documented (Table 1-2). 
Currently one method of FcyR typing on leukocytes and monocytes is to study the 
binding of human and mouse IgG subclasses, for which their are recognised binding 
patterns (Table 1-2). Studies by other groups confirm that the specificity and affinity of 
IgG subclasses for Fey receptors (CD 16, CD32 and CD64) is different (Hulett & 
Hogarth 1994) (Table 1-2), however, the ligand specificity for many of the Fey 
receptor isoforms is not fully elucidated.
The binding of human subclasses to erythrocytes were studied by FACscan, this 
revealed optimal binding with IgG2, followed by IgGl and IgG3 with little binding of 
IgG4 (Figure 7-10) (Table 7-2). This pattern was not consistent with the patterns of 
IgG subclasses specificity and affinity for binding to any of the recorded Fey receptor 
isoforms.
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The affinity of mouse IgG subclasses for binding to human erythrocytes showed 
optimal binding with aggregated IgG3 (Figure 7-11). All the monomeric and 
aggregated mouse IgG subclasses showed some binding compared to the control. The 
preferential binding of IgG3 (Aggregated), compared to IgG2b and IgG2a (Figure 7- 
11, Table 7-2) is consistent with the binding pattern of CD16 (isoforms A and B) and 
CD64 (isoform A).
These results together would support the presence of CD64 on the surface of 
erythrocytes (Figures 7-8 and 7-11, Table 7-2) or an IgG binding protein with a similar 
specificity as CD64. However, human IgG subclasses binding to erythrocytes did not 
follow a pattern consistent to CD64, in fact the binding pattern was not consistent with 
binding sequences to any known Fey receptor.
Initial attempts to purify the IgG binding protein on erythrocytes were not successful, 
however clarifying the existence of such a protein will have an important physiological 
role in handling immune complexes and IgG.
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Chapter 8 
Final Discussion
Streptokinase is now a commonly administered thrombolytic agent in patients with 
AMI. The administration of streptokinase in patients suffering from AMI results in 
heart muscle reperfusion and reduces the mortality rate in these patients. 
Streptokinase has the same efficacy as alternative thrombolytic agent i.e. r-tPA 
(GISSI-2, 1990, White et al 1990) but is often chosen preferentially as it is about 
ten times cheaper (Sharma & Sasharal982). One of the main disadvantages of the 
streptokinase administration is that as foreign antigen it may provoke 
hypersensitivity reactions due to previous streptococcal infections. In addition pre­
existing antibodies are thought to reduce the lytic effect of streptokinase (Gamer & 
Tillet 1935, Lew et al 1984, Massel et al 1991, Bom et al 1993).
The work carried out in this thesis aimed to address humoral immunity to 
streptokinase. Several areas of research were encompassed. These will be 
discussed and drawn together in this final chapter.
Firstly, ELI SA's were developed to measure the levels ofTgG, IgA, IgM, IgE and 
neutralising anti-streptokinase antibodies in a normal population (246 normal 
individuals), to find out to what extend these antibodies exist in the normal 
population. Serum samples were also analysed for neutralising anti-streptokinase 
antibodies using a commercial ASK-kit (Functional assay). This assay is still 
commonly used and more importantly it has been developed into screening 
microcards by TAS (Thrombolytic assessment system), to enable bed side rapid 
testing of new AMI patients for antibody levels to streptokinase.
The ELI SA's were developed using as antigen the streptokinase used for 
therapeutic use. Molecular weight and purity of the commercial streptokinase used 
in different assays by SDS-PAGE revealed two close bands with molecular weights
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of 47 kD and 50 kD (Figure 3-1). This is in agreement with previous reports on 2 
close band corresponding to streptokinase of molecular weight at approximately of 
47 kD (Lynch et al 1993). The presence of two bands has been observed by other 
investigators and reported to be due to the effect of de-amidation of the 
streptokinase molecule by alkaline buffer (Dillon & Wannamaker 1964, Hugh 
1965, Einarsson et al 1979, Lynch et al 1993).
IgG, IgM, IgA, IgE and neutralising anti-streptokinase antibodies levels were 
measured in the normal group and normal ranges for each antibody isotype were 
established (Table 3-2, Figure 3-8a, b, c and d). Only a small proportion of the 
normal individuals had elevated levels of anti-streptokinase antibodies (IgG 1.68%, 
IgA 2.7%, IgM 9.9% and neutralising anti-streptokinase antibodies 0.4%) (Table 
3-2).
The patients with AMI showed a higher incidence of elevated anti-streptokinase 
antibodies in particular for IgM (80% streptokinase patients group and 50% r-tPA 
group). This observation was confirmed in a further 4 AMI patients (Chapter 6) and 
would suggest that this is not to limited studied sample size of AMI. IgM response 
to streptokinase can be accounted for a recent streptococcal infection in these 
individuals and 2) As fibronectin and streptokinase share a similar epitope 
(Gonzalez-Gronow et al 1993) cross-reactivity of antibodies against fibronectin (or 
fibronectin combined with other body constituents) with streptokinase.
In present study the levels of neutralising anti-streptokinase antibodies which 
measuring the efficiency of anti-streptokinase to prevent clot lysis by streptokinase 
correlated with the levels of IgG anti-streptokinase antibodies (r=0.55 p<0.001), 
this is in agreement with Hoffmann et al 1988 who studied a group of 61 
individuals with AMI, there was a significant correlation between the levels of IgG 
and neutralising anti-streptokinase antibodies (r= 0.43, p<0.001). The group of 
normals that were studied represented a group of Caucasians from limited 
demographic area, therefore the proportion of the population with elevated anti­
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streptokinase antibodies in other normal population groups may vary according to 
their prevalence of streptococcal infections and normal ranges must be established 
based on population being screened.
In vitro and in vivo studies of quantitation of neutralising anti-streptokinase in 
presence of r-tPA, impairs the detection of these antibodies (Chapter 3). This effect 
has not to date been reported and indicates that the neutralising assay is not a 
suitable method for clinical diagnosis of anti-streptokinase antibodies levels in 
patients since any alteration to the coagulation system due to anticoagulant therapy 
(i.e. heparin, r-tPA etc.) may interfere with these assays. :
Administration of streptokinase in 10 patients studied, resulted in an immediate fall 
in level of IgG (at 15 minutes, p<0.01) and neutralising anti-streptokinase 
antibodies (at 30 minutes, p<0.01) (Figure 3-10). The observed reduction in the 
levels of the antibodies could not be accounted for by changes in plasma volume 
during the clinical procedure (Figure 3-13) and is therefore considered to be due to 
sequestering of specific anti-streptokinase antibodies into an immune complex with 
the administered streptokinase. The sequestering of antibodies into an immune 
complex is further supported by Cls:Cl-INH formation occurs in ongoing classical 
pathway activation predominately through ICs. The decrease in levels of specific 
antibodies after streptokinase administration has been observed by other workers 
Lynch et al 1991, Fears et al 1992).
There was no significant difference in rate of reperfusion between patients given 
streptokinase or r-tPA. All the patients when received streptokinase and reprofused 
within 2 hours of streptokinase administration (early reperfusion), had levels anti­
streptokinase antibodies which were within the normal ranges, however, the mean 
values increased in late reperfusion and none reperfusion groups (Table 3-6). To 
ensure that circulating anti-streptokinase antibodies do not prevent the therapeutic 
efficiency of the administered streptokinase, the prescription is generally given as a 
large single dose intravenously (usually 1200000 units) over one hour (Crossland
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1980). Two of patients treated with streptokinase had elevated levels of anti- 
streptokinase IgG prior to treatment (patients EM and CD), the levels of IgG anti­
streptokinase antibodies in these individuals took longer to drop than those with 
lower levels (Figure 3 -lla ), patient CD reperfused late and patient EM did not 
reperfuse. The results from this small patient group study implies that elevated 
levels of antibodies prevent the thrombolytic effects of streptokinase. In individuals 
with large antibody levels the amount of streptokinase administered is probably not 
sufficient to overcome these antibodies therefore a second dose may be necessary. 
An immune response in all the patients administered streptokinase was observed 
since all of them had elevated levels of specific antibodies to streptokinase by day 5 
(Figure 3 -10a and b). This finding would suggest that if further thrombolytic 
therapy is required and streptokinase is the choice, this must be administered with 
hours of first bolus. White et al 1990 showed that patients with AMI re-treated with 
streptokinase 3-5 days after initial treatment do not exhibit a better response, he 
noted that develop immunological reactions were more common than after the initial 
dose. This is not surprising since at this period the levels of antibodies are elevated 
in response to streptokinase administration, this would be amplified of the patients 
already had pre-existing elevated levels.
Patient EM with elevated levels of IgG and neutralising anti-streptokinase 
antibodies, did not develop adverse reaction to streptokinase administration but was 
in the group of non reperfusion patients (Table 3-6). The poor response to 
streptokinase treatment due to elevated anti-streptokinase antibodies has been 
reported by other investigators (Lew et al 1984, White et al 1990, Massel et al 1991 
and Bom étal 1993). In this study three of the patients with normal levels of anti­
streptokinase antibodies did not respond to streptokinase treatment and belong to 
the 25% of patients who fail to reperfuse (Anderson et al 1991, Chouhan et al 
1992) as the antibody levels are low. The cause of this failure must be due to other 
factors that prevent the thrombolytic effect of streptokinase. One candidate is 
elevated levels of lipoprotein-a, this area has not been fully investigated (1-3).
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Of the 10 patients given streptokinase, one patient (Patient CD, with levels of IgG 
and IgA above the normal range) developed serum sickness. In this patient 
significant reduction (80%) in the levels of IgA at 30 minute after streptokinase 
administration was observed (Figure 3-1 lb). This is in contrast to the result of 
patient EM who had elevated IgA, but in this case the levels did not drop as rapidly. 
Stewart et al 1990 using DNP-BSA ICs showed that ICs complexes containing IgA 
isotype precipitate more easily than IgG and IgM isotypes. This may imply a very 
important role for IgA anti-streptokinase isotype in provoking serum sickness in the 
patients treated with streptokinase.
From the present study it is clear that elevated levels of the pre-existing anti­
streptokinase antibodies are responsible for both failure of reperfusion and initiating 
adverse immunological reactions, and among many types of methodology described 
for measuring anti-streptokinase responses, the ELISA assays can predict both 
failure of treatment and adverse reactions. However, a larger sample size of patients 
should be studied to evaluate the role of specific isotype in provoking adverse 
immune reactions to administered streptokinase more clearly.
The general population is commonly exposed to streptokinase as this antigen is 
released during streptococcal infections (throat, skin, nasal, ears, etc.). After 
analysis of a normal population and a group of AMI we were keen to establish what 
levels were like in patients with auto-immune diseases (RA, SLE, thyroditis and 
HSP). The levels of IgG, IgM, IgA and neutralising anti-streptokinase antibodies in 
the patient group described were measured and the values compared to the 
established normal ranges (Table 4 -lb  Figures 4-1, 4-2 and 4-3). Although the 
levels of anti-streptokinase antibodies in these patients were not statistically elevated 
a significant proportion of the patients had elevated levels of the antibodies 
compared with the normal population.
Patients with RA had significantly elevated levels of specific IgM anti-streptokinase 
antibody levels (Figure 4-2, Table 4-2) even when rheumatoid factor was removed.
319
The elevated anti-streptokinase antibodies in R.A. patients could be attributable to: 
a) the association of streptococcal infections b) the effect of immuno-suppressive 
therapy on these patients c) as fibronectin and streptokinase share a similar epitope 
(Gonzalez-Gronow et al 1993). In this chronic inflammatory disease, the presence 
of auto-antibodies against fibronectin (or fibronectin combined with other body 
constituents) may show cross-reactivity with streptokinase and d) the presence of 
excess amounts of rheumatoid factor in the sera of theses patients (IgM isotype) 
enhances the results which are obtained by ELISA's.
Specific anti -streptokinase antibodies were not related to any concomitant rise in the 
super antigen mHSP65 in RA, SLE, thyroiditis and HSP patients. Elevated levels 
of anti-mHSP65 have been demonstrated in RA patients (Bahr et al 1988). We 
could not support this observation in the RA patients, or patients with SLE, 
thyroiditis or HSP as the levels of IgG anti-mHSP65 in this group were not 
statistically elevated compared to the normal individuals (Figure 4-5). On the other 
hand, in patients with Henoch Schonlein Purpura there was a correlation between 
IgG anti-mHSP65 levels and IgG, IgA and neutralising anti-streptokinase 
antibodies levels (Figures 4-6 and 4-7). This although was not highly significant 
based on a small number of patients, it however, dose raise the possibility that 'f
streptococcal infections and the release of heat shock proteins may play an ft
important role in the aetiology of HSP and from this data it can be concluded that 
streptococcal infections have an association in the pathogenesis of Rheumatoid 
Arthritis.
From the study of the anti-streptokinase antibodies levels in AMI patient it was not 
clear why elevated levels of anti-streptokinase antibodies were not always 
accompanied by adverse immunological reactions. The complement system has a 
central role in processing immune complexes and preventing tissue damage, so the 
interactions of complement system and immune complexes was studied (1-8). This 
was performed by measurement of complement activation products C lsiCl-INH, 7
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C3b-P and C5b-9 generated by thyroglobulin and streptokinase ICs in NHS. An 
indirect ELISA's for measuring serum C3d levels and modified ELISA for 
detecting erythrocytes bound C3d were developed to evaluate the relationship of 
bound C3d and the levels of free complement components (5-4).
As mentioned previously in vivo studies in patients administered streptokinase 
showed generation of C ls:Cl-IN H  while if any detectable C3b-P, C5b-9. In 
patients treated with r-tPA no change in the levels of mentioned complement 
activation observed. The activation of complement system after r-tPA administration 
has been reported although the extent of this activation is substantially lower than 
streptokinase (Agostoni et al 1994).
The correlation of C ls:Cl-INH with IgG, IgA levels and neutralising antibodies 
clearly confirmed that the activation of classical pathway was due to formation of 
anti-streptokinase immune complexes during treatment. This is in agreement with 
Freydottir et al (1993), who analysed the extent of complement activation in patients 
administered streptokinase, the levels of complement activation were assessed by 
the extent of C3d production and occurred in those individuals with highest levels 
of anti-streptokinase antibodies.
The antigen streptokinase is somewhat unusual in that it may trigger complement 
activation by two mechanisms, through plasminogen activation and generation of 
plasmin or through immune complexes formation (1-10). Generation of plasmin by 
streptokinase in turn influences the detectable levels of complement activation 
products by activation of the these pathways, by binding to C l inhibitor or by 
proteolytic effects (Levi et al 1993, Cugno et al 1993). In vitro study confirmed this 
and showed that not only streptokinase at therapeutic dose causes detectable levels 
of C ls:C l-IN H  and C3b-P but streptokinase or plasmin can significantly change 
the levels of these complement activation products generated by thyroglobulin ICs 
(Chapter 5).
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In vitro studies of the effect of ICs on complement activation showed that the nature 
of immune complexes and the way they are formed influence the extent and the rate 
of complement activation pathways, i.e. preformed streptokinase ICs (human and 
rabbit) at antigen excess activated the classical pathway to a greater extent than 
antibody excess. This was reversed for the alternative pathway, preformed 
thyroglobulin ICs generated higher levels of C3b-P than the nascent ICs (Chapter 
5). This study clearly illustrated that different ICs activate complement system in 
different ways and results can not be interpreted from model ICs.
I
i':':
Many in vitro systems for studying complement activation do fail to consider the 
effect of erythrocytes. As this mirrors more closely the in vivo situation, the effect 
of E's were examined. The presence of erythrocytes did not modulate significantly 
free and bound C3d or Cls:Cl~INH levels generated by streptokinase and 
thyroglobulin ICs, but exert an influence on C3b~P (Chapter 5).
Erythrocytes have an important role in clearance of immune complexes from the 
circulation and the prevention of tissue damages. This is predominately through the 
action of complement receptor CRl. The interactions between ICs and E's is 
governed by the complement system and the nature of immune complexes, 
ineffective processing may lead to immune complexes deposition in tissues outside 
the liver and spleen (Schifferli et al 1989).
The kinetics and dose response of streptokinase immune complexes binding to 
erythrocytes were studied by flow cytometry and its relationship with complement 
activation was determined by measuring the Cls;Cl-INH, C3b-P and C3d in the 
accompanying supernatants. The study of thyroglobulin immune complexes and 
erythrocytes interaction showed that the binding of the ICs not only significantly 
correlates with the classical and alternative pathways activation (r values 0.98 and 
0.91 respectively, p<0.001) (Figure 6-2) but is dose dependent (p<0.001). The 
kinetics and dose response of rabbit streptokinase ICs binding to erythrocyte gave 
similar result (Figure 6-3). This was in agreement with the results of Lucisano et al
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1991, who showed that binding of immune complexes to erythrocytes correlated 
with the degree of complement consumption and related to ICs nature. Using a 
model of NIP-BSA ICs (IgG, IgM and IgA isotypes) he noticed that optimal 
binding occurred by isotypes that cause significant classical pathway activation 
(IgG l, IgG2 and IgM). In the present study the binding of human streptokinase 
ICs to E's by the classical pathway activation did not significantly differ from the 
alternative pathway activation ( Figure 6-19), however, it is important to study the 
effect of alternative pathway to a greater extent.
The kinetics of E-bound streptokinase ICs (Human and rabbit) during 30 minutes 
incubation at 37°C showed a peak by 5 minutes and after which the levels declined 
corresponding to their release from the erythrocytes surface (Figures 6-5a, Figures
6 -14a, 6 -14b and 6 -15a). The release of ICs has been previously reported by 
Medof & Prince 1983 and can be explained by ongoing complement activation and 
degradation of C3b, incorporated in ICs, to the fragments C3c and C3d which have 
no affinity for CRl receptors on the erythrocytes. This pattern of binding was seen 
with C3c and the results could indicate its corresponding pattern of the ICs, as both 
E bound ICs and C3c followed a similar pattern (Figure 6-7). However, C3d 
remained on erythrocytes surface as detected by FACscan analysis or modified 
ELISA (Figure 6-8). C3d binding is a covalent and these results suggest that the 
binding predominately is not dependent on CRl and is generalised on E’s surface. 
The deposition of C3d on erythrocytes therefore indicates that the complement 
system is activated and may be used in clinical situations. Davies et al 1990 showed 
that C3d was detectable on the surface of E's during serum sickness due to 
streptokinase treatment. Freysdottir et al 1993 by studying 13 AMI patients treated 
with streptokinase reported that C3d is detectable on E's from Ihour to day 7 after 
treatment.
The presence of erythrocytes treated with anti-CRl (E-CRl) did not inhibit the 
binding of human ICs to erythrocytes as detected by FITC anti-human IgG,
: h''
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however, decreased the levels of E’s bound ICs detected by FITC anti-human IgA 
and IgM (Figures 6-14 and 6-15). Immune complexes in absence of NHS bound to
erythrocytes (6-5). This observation may account for binding of ICs containing IgG 
to erythrocytes through a second mechanism, possibly Fey receptor (Hajos et al 
1978).
■By studying the levels of anti-streptokinase antibodies the 4 patients with AMI 
treated with streptokinase and the extent of complement activation similar results 
were obtained to those obtained for the first 10 patients studied in chapter 3 which 
were indicative of immune complex formation and complement activation during 
streptokinase treatment (6-12). The levels of bound IgA, IgM, C3c and C3d were 
not detectable on erythrocytes in the 4 patients. Freysdottir et al 1993 showed that 
the levels of bound C3d on erythrocytes are detectable from the first hour of 
administration of streptokinase, however I could not detect E-bound C3d from 5 
minutes to 30 minutes. In contrast to Freysdottir et al 1993 streptokinase immune 
complexes as detected by FITC anti-human IgG were detectable on erythrocytes in 
one of the patients (Patient T.B.) (Figure 6-23). In this patient the levels of serum
I
%
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anti-streptokinase IgG were not significantly higher than other patients however this
-patient generated higher levels of Cls:Cl-INH and C3b-P and the levels of both E-
bound ICs and serum anti-streptokinase IgG inversely correlated with one another 
(r=.99, p<0.001) (Figure 6-23). This observation confirmed the in vitro studies 
that the clearance of streptokinase ICs was dependent on the extend of complement 
activation. Furthermore, as IgA is a poor activator of the classical pathway (Law et 
al 1988, Holme et al 1989, Lucisano et al 1991). Patients with elevated levels of 
IgA anti-streptokinase are at potential risk of developing serum sickness and this 
may account for adverse reactions seen in patient CD who had elevated levels of 
anti-streptokinase IgA with high affinity (Chapters).
The study of streptokinase immune complexes interaction and erythrocytes has 
revealed that the binding of the immune complexes is not only a complement
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mediated interaction but they can also bind to erythrocytes in absence of 
complement, this is in agreement with other investigators (Hajos et al 1978, Virella 
et al 1983), although the involved mechanisms are not clear, and not generally 
considered
The presence of erythrocyte surface IgG binding was studied (Chapter 7). An 
*indirect haemagglutinin test among normal individuals and patients groups revealed 
that the capacity of human erythrocytes to bind rabbit IgG is different (Figure 7-4) 
indicating that the binding is not non-specific adsorption phenomena. This binding 
is Fc specific as, F(ab')2 fragment do not bind to the erythrocytes (Figure 7-6b). 
Furthermore, using flow cytometry human IgG (Fc fragment) inhibited the binding 
of rabbit IgG to human erythrocytes (Figure 7-7) indicating that both rabbit IgG and 
Fc fragment of human IgG bind to the same sites on the erythrocytes. This is in 
agreement with Hajos et al 1978 who using a Coombs test showed that Fey 
fragment and not Fab inhibits the binding of human IgG and ICs to erythrocytes.
Using a set of monoclonal anti-human FcyR antibodies revealed that anti- FcyRI 
(CD64) is detectable on human erythrocytes (Figure 7-8). It is known that the 
specificity and affinity of IgG subclasses for binding -to the Fey receptors is 
different (Table 1-2). The binding of human IgG subclasses to erythrocytes (Figure
7-10) (Table 7-2) was not consistent with the patterns of IgG subclasses specificity 
and affinity for binding to any of the recorded Fey receptors isoforms. However, 
the affinity of mouse IgG subclasses for binding to human erythrocytes (Figure 7- 
11) (Table 7-2) followed the pattern of CD16 (isoforms A and B) and CD64 
(isoform A).
These results together would support the presence of CD64 on the surface of 
erythrocytes or an IgG binding protein with a similar specificity as CD64. 
However, human IgG subclasses binding to erythrocytes did not follow a pattern 
consistent to CD64, in fact the binding pattern was not consistent with binding 
sequences to any known Fey receptor.
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